|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/4/2 ¤W¤È 09:36:27
|
¯E¹©°O¡G 1¡n¯E¹©2015¦~3¤ë¥¿¦¡±q¿³ÂdÂà¤WÂd,«o±q400¤¸¶^¨ì250¤¸ 2¡nÀHµÛ¸Ñª¼®É¶¡±µªñ,¥«³õ¤W°ª«×ªºÃöª`»P°l±·,¿v©³Ãk¤É¨ì750¤¸ªº¤Ñ»ù 3¡n2016/2/21¸Ñª¼«á, ¥Ñ©ó¸Ñª¼¥¼¹F¹w¥ý³]©wªº¥Ø¼Ð, ¦A¥[¤W¦W¼L¥ß©e´CÅé½Ñ¦h¥H³_¶Ç³_,¥H°¾·§¥þ, ¥B¥¼¸gÃҹꪺ«ü±± ÁöµM¤½¥q»¡¯à°÷²£¥Í§ÜÅ骺±Ú¸s´N¯à°÷²£¥ÍÁ{§É¤WªºÀø®Ä,©ó¬O¦³©Ò¿×ªº"¤@ӸѪ¼,¨âºØ¸ÑŪ,¦U¦Ûªíz" ¤@¸ô¤U¶^¨ì350¤¸¥ª¥k 4¡n¦ý¦b2016/3/31²×©óªï¨ÓÀò±oASCO Oral presentationªº®¶¾Ä®ø®§,4¤ë1¤é·M¤H¸`·í¤Ñ,ªï¨Ó¤F¤[¹Hªº¤@¸ôº¦°±ªO 5¡n6¤ëªìªºASCO, ÁÞ¤k§Y±N´¦¶}¦oªº¯«¯µ±¯½ ¨Ì¾Ú²Î¤@§ëÅU±i¥ß¸s¤ÀªR®v¬ã¨s¡G https://www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0ahUKEwins9egnPzLAhVikIMKHcc1DN8QFgggMAE&url=http%3A%2F%2Fpcmc.uni-psg.com%2Fvip%2F20160226-01.pdf&usg=AFQjCNHCCWDKl493HzcquFVIcJoolRPgnQ »PµL±¡¤jªº¤ÀªR¡G http://tsjh301.blogspot.tw/2014/08/obipharma.html ¥»µÛªø´Á§ë¸ê, °l®Ú¨s©³ªººë¯«¨Ó±´¯Á¯E¹©ªº§ë¸ê»ùÈ, ¤£¦]µu´ÁªÑ»ùªi°Ê°_¥ñ¦Ó¼vÅT¹ï "¥þ²y²Ä¤@ÁûFirst in class, Best in classªº§ÜÀùÁÞ¤À¤l¥þ·sÃĪ«"§ë¸êªº¼ö±¡ ¨ÃÅé²{¤½¥qÄ@´º: "³Ð³y¥xÆW¥Í§Þ«~µP,¦¨¬°Àù¯gÀøªkªº¥þ²y»â¯èªÌ" "2025¦~¦¨¬°¥xÆW¥Í§Þ²Ä¤@«~µP, 2035¦~¦¨¬°¥þ²yÀù¯gªvÀø»â¾É¤½¥q" Åwªï¤À¨É¥ô¦ó¹ï¯E¹©Ä@´º»P»ùȵû¦ôªº¬Ýªk»P°ª¨£~~ |
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/17 ¤U¤È 02:20:32²Ä 2100 ½g¦^À³
|
¥¤ß¤j ¶qÁY¤jº¦ µu½u«È·mµu ªø½u¥~¸êÄ~Äò¦Y³f |
|
|
·|û¡G¥¤ß¦Ó½×10139639 µoªí®É¶¡:2015/10/17 ¤W¤È 11:57:30²Ä 2099 ½g¦^À³
|
¥¤ß¦Ó½×¡A¬Q¤Ñº¦ªº«Ü©Ç¡A¥~¸ê½æ¶W¡Aµ²ªG¦ÛÀç°Ó¶R±o§ó¦h¡A¤jº¦17¤¸¡A¬ð¯}¤WÂd·s°ª¡A§Ú¤]¦³¦n´X±i400¦h¶Rªº¡A¤]ÁÙ¨S¸Ñ®M¡A¦ý¬O·Q¨ì¤Ñ¤U²Ä¤@ÃÄ¡A°µ¹Ú¤]·|¯º¡A®M¨c¤£·Ð´o¡A±þ§C¤~ÁV¿|¡AÀR«Ý¦nÀø®Ä¡AÁȹ¡¦A¨Ó¶]¡A¯E¹©¤@©w¦n¡A©È§A¤£ª¾¹D¡A¤]©È¤£¤[©ê¡A¤U¨®¤K¨§§¯¡A¦nªÑ¤£¦n§ä¡A±æ§g¯àª¾¾å |
|
|
·|û¡GJ·Ý10140867 µoªí®É¶¡:2015/10/16 ¤U¤È 11:32:21²Ä 2098 ½g¦^À³
|
»¡¯uªº¡I³oÓª©´£¨Ñµ¹«Ü¦h¤£ºÞ¬O¤ä«ù¯E¹©»P·Qn»{ÃѯE¹©«Ü¦nªº¥¥x §Æ±æ¤£n³o¼Ë»Ä¨Ó»Ä¥h³o¼Ë¤@ÂI«Ø³]©Ê³£¨S¦³¡A¬O§_¸Û¼°ªº§Æ±æ³o¼ËªºµL²á¹ï¸Ü¨ì¦¹¬°¤î ¬O§_¥i¥H¦^¨ì³Ìªì°J³Ì³æ¯Âªº¹ï¸Ü»P¸ê°Tªº¥æ¬y |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2015/10/16 ¤U¤È 11:12:32²Ä 2097 ½g¦^À³
|
¦³¤°»ò¦n»Äªº¤S¤£¬O¬ð¯}455¤¸ªº·s°ª»ù¡AªÑ»ùÁÙ®M¨c¤@°ï¤H §Ú¤w¶R6238³ÓÄR¤ÎF-±d¤Í¡A¦Ü©ó§ÚªºÁp¨È¨S¦³´X±i §Ú¥´ºâ©ñªø´Á¡C ¯E¹©¶Ü¡H§ÚÓ¤H·Pı½æÀ£ÁÙ«Ü«¡A¨C¦¸¤@º¦½æÀ£´N¥X¨Ó ¤£¹³§Ú¶Rªº³ÓÄR¤ÎF-±d¤Í¨º»ò±j±jºu´X¥G¨C¤Ñ¶}°ª¦¬³Ì°ª¡C |
|
|
·|û¡G¤p³ì10135960 µoªí®É¶¡:2015/10/16 ¤U¤È 10:35:17²Ä 2096 ½g¦^À³
|
¨C¦¸ªÑ²¼¤@º¦ ¤S¦³¤H¶}©l»Ä°_¨Ó¤F¡C |
|
|
·|û¡G¥¤ß¦Ó½×10139639 µoªí®É¶¡:2015/10/16 ¤U¤È 09:59:49²Ä 2095 ½g¦^À³
|
¥¤ß¦Ó½×¡A¤p¶§¬I¥D¡A ªÑ®üµLÃä¡A¦^ÀY¬O©¤ ¯E¹©¦¬°ª¡A¤£¶RÁV¿| Áp¨È¦¬§C¡A¤£½æ¥i±¤ ´«ªÑ¾Þ§@¡AÀ³¸Ó¤£¿ù |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2015/10/16 ¤U¤È 04:27:29²Ä 2094 ½g¦^À³
|
¨C¦¸ªÑ²¼¤@º¦ ¤S¦³¤H¶}©l¼ÖÆ[°_¨Ó¤F¡C |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2015/10/16 ¤U¤È 01:53:38²Ä 2093 ½g¦^À³
|
ÀRÀRªºªY½à¡AªGµM®¡ºAÀu¬ü... |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2015/10/15 ¤U¤È 05:55:28²Ä 2092 ½g¦^À³
|
¹L«×¨ë¿EªÅÀY¡A¤£¤@©w¬O¥ó¦n¨Æò¡IÀRÀRªY½à®¡ºA¤§¬ü... |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/10/15 ¤U¤È 01:44:16²Ä 2091 ½g¦^À³
|
¤w¸g¦³¤H°½°½¦b¶R¤W¨Ó¡A¨C¤Ñ½L¤¤³£¦³§CÂI¡AµM«á§À½L¼Æ¤ñ¤j³æ¤S¤U¨Ó±½³f ¤p¤ß¦~©³ªÑ»ùª½±µ¬D¾Ô455¡A¬Æ¦Ü520 ¹q¼v¬P»Ú®ÄÀ³¦³´£¨ì²ö«D©w«ß¡Aºû°ò¦³»¡: ²ö«D©w«ß¡]^»y¡GMurphy¡¦s Law¡^¡A¤SĶ¬°¼¯µá©w²z¡B²ö«D©w²z¡A¨ãÅ餺®e¬O¡u¤Z¬O¥i¯à¥X¿ùªº¨Æ¥²©w·|¥X¿ù¡v¡A «üªº¬O¥ô¦ó¤@Өƥó¡A¥un¨ã¦³¤j©ó¹sªº¾÷²v¡A´N¤£¯à°÷°²³]¥¦¤£·|µo¥Í¡C µL±¡¤j²q·Qªº5112¤¸¥Ø«e¾÷²v¬O1%,¥un¨ã¦³¤j©ó¹sªº¾÷²v¡A´N¤£¯à°÷°²³]¥¦¤£·|µo¥Í¡C µ¥µÛ¬Ý¯E¹©¦¨¬°ªÑ¥«ªºÊ¤Ñ¼C±OÀs¤MÅý§ë¸ê¬É¦U¤è·m¶RªÑ²¼ªº¦nÀ¸§a |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/14 ¤W¤È 07:49:57²Ä 2090 ½g¦^À³
|
¥xÁÞ¤j ·PÁ±zªº´£¿ô |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/14 ¤W¤È 12:31:28²Ä 2089 ½g¦^À³
|
¯E§J¤j 1n¥ÑÂå®vµû¦ô¤~¯à¨Ï¥Îªü´µ¤ÇÆF 2·j´M:¾é¸Ñ¹w¨¾¤ß¦åºÞ¯e¯fÀ³ª`·N¨Æ¶µ «ô¦Õªü´µ¤ÇÆF¥é³æ¤U¸ü 3°|ªøÀ³¦³µû¦ô¹L¤~·|ªA¥Î¡A¤£¬O¨CÓ¤H³£¾A¦X¡A ¦³¾÷·|¹J¨ì°|ªø¥i½Ð±Ð¥L n¹w¨¾Àù¯gÀ³¾÷·³¶}©lªA¥Î¡AªA¦h¤[¤~¯àµo´§®ÄªG? ³Ì¯à¹w¨¾¦óºØÀù¯g?ªA¥Î§Þ¥©¥H°§C¥X¦å·ÀI? ¬°¦ó¨ÅÀù¤ÆÀø´Á¤£¯à¨Ï¥Îªü´µ¤ÇÆF? |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/13 ¤U¤È 09:44:43²Ä 2088 ½g¦^À³
|
¥xÁÞ¤j ±zªº«Øij §Æ±æ¤½¥qÅ¥¨ì §ÚÓ¤H¤]·Q¹Á¸Õ¬Ý¬Ý ¨C¤Ñ¦YÂIASPIRIN |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/13 ¤U¤È 06:51:57²Ä 2087 ½g¦^À³
|
OBI822 OBI833Áp¦X³oÁû¼w°êªº¦Ê¦~¦ÑÃÄAspirin ·|¤£·|¨Ï¯E¹©¦b¥¼¨Ó©º¾ÔÀù¯gÃĪ«¥«³õ®É¾Ö¦³²Ä¤T§â©|¤èÄ_¼C ÁȨú¥iÆ[ªº§Q¼í? ȱoÁ{§É¸ÕÅç¬Ý¬Ý (»P¼w°êAspirin¥ý¥Íµ²±B¤£¥²¶ù§©,Á{§É¸ÕÅ禨¥\¤S¥i¥H¥¨ÃB°]´I¦^³øOBI¤p©j) |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/13 ¤U¤È 06:05:44²Ä 2086 ½g¦^À³
|
¦U¦ì¤j¤j ¦Ê¦~«Ã½t¤@½u²o ·íÁÞ¤À¤l·sÃÄ¥¼¨Ó¹J¨ì¦Ê¦~¦ÑÃÄ---¦Ñ¤Ö°t¬O§_·|À¿¥X·Rªº¤õªá? A³o¹ï¦Ñ¤Ö°t¥¼¨Ó¬O§_·|À¿¥X·Rªº¤õªá¤£±o¦Óª¾ ,Aspirin ±q¥H©¹ªºÂíµh¸Ñ¼ö§@¥Î¨ì¹w¨¾¤ß¦åºÞ¯e¯f, ªñ¤Q´X¦~ÁÙµo²{Aspirin Á٨㦳°§C¸~½Fµo¥Í²v»P¨¾¤î¸~½F´_µoÂಾªº¥\®Ä¬Ý¨Ó,¼w°ê«ô¦ÕªºAspirin ¦]·sªºÀø®Äµo²{¦Ó¤£Â_©µªø¨ä¥Í©R»ùÈ B¥¼¨Ó¯E¹©¬ãµoªºÃĦpªGnÁp¦X¥ÎÃĤ]¥i¦Ò¼{»Pªü´µ¤ÇÆFÁp¦X¥ÎÃĶi¦æÁ{§É¸ÕÅç¬Ý¬Ý¡A¤@¦~baby Aspirin ÃĶO¤£¨ì600¤¸¥x¹ô¡A¦p»P¶PÀù¥¡A¶P¯e§´¡APD1Áp¦X¥ÎÃÄ,,ÃÄ»ù±N°ªªºÀ~¤H¡A¤Ó°ªªºÃÄ»ù¤£§Q822 833 ¥¼¨Ó¦æ¾P¡A°²³]»Pªü´µ¤ÇÆFÁp¦X¥ÎÃĶi¦æÁ{§É¸ÕÅçÃĮħó¦n¡A°Æ§@¥Î§ó§C,ÃĶO¤S¯à§ó«K©y À³¸Ó«Ü¦³Ävª§¤O, C Aspirin¬O§_¨ã¦³°§C¸~½Fµo¥Í²v»P¨¾¤î¸~½F´_µoÂಾ,±q¬ÛÃö¬ã¨s¨Ó¬Ý¬O¦³¨ä¼ç¤O, ¤@±±q§K¬Ì¾÷¨î¤U¤â ,¥t¤@¤è±±q§Üµoª¢¤U¤â , ÂùºÞ»ô¤U,¹êÅç¬Ý¬Ý¬O§_¯à¦A´£°ªÁ`¦s¬¡´Á»PµL¯e¯f´c¤Æ¦s¬¡´Á D ¥»½g¶K¤å¥Øªº¦b°ò©ó¬ì¾Ç¹ïAspirinªº§ÜÀùµo²{´£¨Ñ°Ñ¦Ò¤À¨É,¨Ã«Øij¥xÆW¯E¹©¥Í§Þ¥¼¨ÓÃĪ«¤W¥««á°£¤F ³æÃĪvÀø¥~ ¦pnÁp¦X¥ÎÃÄ(»ÝÁ{§É¸ÕÅç) ¤£n©¿²¤³oÁû¼w°êªº¦Ê¦~¦ÑÃÄAspirin E Aspirin ·|´£°ª¥X¦å·ÀI »Ý¨Ì¦~ÄÖ ,Åé½è ,¯f±¡,¥¿¨Ï¥ÎÃĪ«,¥ÑÂå®v¬ã§P¬O§_¾A¦X¨Ï¥Î ½Ð¤Å¦Û¦æªA¥Î Fªü´µ¤ÇÆF(aspirin) «DÃþ©T¾J§Üµoª¢ÃĪ«¡]non steroid anti-inflammatory drugs¡A NSAIDs¡^¬°¤@¸s¤Æ¾Çµ²ºc¤£¦P¡A ¦ý§@¥Î¾÷Âৡ¬°§í¨î«e¦C¸¢¯À¥Í¦¨ªº§Üµoª¢ÃĪ«¡A¨ä¤¤ªü´µ¤ÇÆF¡]aspirin¡^³Ì¦³¦W ¬°¦óAspirin¯à°§C¸~½Fµo¥Í²v»P¨¾¤î¸~½F´_µoÂಾªº¥i¯àì¦] 1ºC©Êµoª¢»s³y¤@ÓÅý¸~½F¥Íªøªº¨}¾÷ (Àù¯g¹³¤õ]½¯©µÂX´² ºC©Êµoª¢¦p¦P¤õ¤W¥[ªo) Aspirin §Üµoª¢ªº¥\®Äªý¤îÀù²ÓM¥Íªø (·j´M3) 2¤HÅ餤¦³¨âºØÀô®ñ¤Æ»Ã¯ÀºÙ¬°COX-1»PCOX-2¡A ¦ÓNSAIDs·|¦P®É§í¨îCOX-1©MCOX-2, (cox-2»PÀù¯g²£¥Í¦³Ãö) (·j´M5) 3ªü´µ¤ÇÆF¯à§í¨î¦å¤pªO§@¥Î (Àù²ÓMÂಾ»P¦å¤pªO¬¡©Ê¸û°ª¦³Ãö) (·j´M2) 4¦bÀù²ÓM©P³ò³Ð³y¤@ÓÀô¹Ò¨Óªý¾×¨ä¦¨ªø ( ·j´M3) 5ªü¥q¤ÇÆF¬O¨¾¤î¯×½è¹L®ñ¤Æªº§Ü®ñ¤Æ¾¯¡A¯à¨ë¿E½u²ÉÅé©I§l¡C¥¦¥i¥H§í¨î¤£¥¿±`²ÓM²§±`¤Àµõ¡A «P¶i¥¿±`²ÓM¤Àµõ¡C http://raypeat.com/articles/aging/aspirin-brain-cancer.shtml ·j´M1: ¯Î±Ò´f¨¾Àù ¨C¤Ñ¦Y§C¾¯¶qªü´µ¤ÇÆF ·j´M2: http://www.nature.com/nrc/journal/v11/n2/full/nrc3004.html Àù¯g»P¦å¤pªO¬¡©Ê ·j´M3: ¹ï¤j¸zÀù ªÍÀù GÀù ¨ÅÀù ªA¥Î¦~¼Æ»P°§C±oÀù·ÀI ¥i¯àªº·ÀI§iª¾ Can a daily aspirin lower your cancer risk? ·j´M4:ªü´µ¤ÇÆF¥i°§C¨ÅÀù·F²ÓM¥Íªø»P¦Û§Ú§ó·sªº¯à¤O Aspirin reduces the growth and self-renewal capacity of breast cancer stem cells ·j´M5 http://www.ncbi.nlm.nih.gov/pubmed/26124697 ·j´M6: An aspirin a day could keep breast cancer at bay ·j´M7 ªü´µ¤ÇÆF·s¥Î³~©Î¥i¨¾Àù ·j´M8 ¬ÛÃö¬ã¨s³ø§i¬Û·í¦h ¦³¿³½ì¥igoogle ·j´MAspirin XX cancer Aspirin breast cancer Aspirin lung cancer Aspirin colorectal cancer Aspirin prostate cancer Aspirin liver cancer Aspirin ovarian cancer Aspirin esophageal cancer Aspirin pancreatic cancer Aspirin gastric cancer ¥H¤W«D±M·~¤À¨É¶È´£¨Ñ·s·Qªk»P«Øij ¦p¦³¿ù»~½Ð§ó¥¿ |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/10/11 ¤U¤È 06:28:18²Ä 2085 ½g¦^À³
|
¤µ¤Ñ¤u°Ó®É³ø¦³´£¨ìn§ë¸ê¯E¹©~~ Æg°Õ ®Ú¾Ú¤¤°ê¤H¥Á»È¦æ¤½¥¬¼Æ¾Ú¡A2015¦~«e9Ӥ뤤°ê¥~¶×¦s©³¦@´î¤Ö3,289»õ¬ü¤¸¡A°£³¡¤ÀÄݼڤ¸¡B¤é¶êµ¥¸ê²£¦]¶×²vÅܰʼvÅT±b±»ùÈ¥~¡A¶i¤J¤U¥b¦~«á¡A³æ´N²Ä3©u§Y´î¤Ö¹O¥b¼Æ¤§1,797»õ¬ü¤¸¡A¤Ï¬M¤H¦æ¬°¹ï§Ü¥«³õ¶Sȹw´Á¡A¤£±¤¦å¥»¤j¶q©ß°â¥~¶×¦s©³¡A¦b¶×¥«±j¤OÅ@½L¤H¥Á¹ôªºµ²ªG¡C ªñ´Á¥«³õ¹ï¤H¥Á¹ô³vº¥§Î¦¨¶Sȹw´Á¡A±q°ò¥»±Æ[¹î¥Dn¨ü¡G¡]1¡^¶T©ö¶i¥X¤f¡B¥H¤ÎªA°È¶µ¥Ø¡]¥]§t®È¹C»P¸ó¹Ò¹B¿é¡^ºc¦¨ªº¸g±`±bÅܤơA¡]2¡^¸ó¹Ò§ë¸ê¡BɶU¤§ª÷¿Ä±b¥X²{¥~¬y¡A¡]3¡^¸ó°ê§Q®tÁY¯¶¡A¥H¤Î¡]4¡^³f¹ô¬Fµ¦ºû«ù¼eÃP´XÓ¦]¯À¼vÅT¡C¤¤°ê¥Ø«e°Ó«~¶T©öÁö¤´ºû«ù¹dÃB¥X¶W¡A²Öp2015«e8Ó¤ë¥X¶W3,655»õ¬ü¤¸¡A¦ý¨Ã«D¥Ñ¥X¤f¦¨ªø±a°Ê¡A¦Ó¬O¨ü¨î©ó¤º»Ý¡B¥[¤u¥X¤f»Ý¨D§¡¯h®z¡A¾ÉP¶i¤f°I°h´T«×¤j©ó¥X¤f°I°h§Î¦¨ªº¡u°I°h«¬¥X¶W¡C¡vÀH¥X¤fÄvª§¤O¤U·Æ¡A»s³y·~¥~²¾³]¼t¡A¥¼¨Ó¥X¶W³W¼ÒÁY´îªº¥i¯à©Ê¶V¨Ó¶V°ª¡C¦P®ÉÀH°ê¥Á©Ò±o´£¤É¡A¥H¤Î¥~°ê³f¹ô¶SÈ®ÄÀ³¡A²Öp2015¤W¥b¦~©~¥Á¥X°êÆ[¥ú¤w³y¦¨1,122»õ¬ü¤¸¸êª÷²b¬y¥X¡A¬Û·íµ{«×©è¾P¶T©ö¥X¶Wªº®ÄªG¡C ¦b¸ê¥»¬y°Ê¤è±¡A¬ü°ê¤É®§¹w´ÁÁö©µ«á¦ý¥¼®ø´²¡A¦P®É¤¤°ê¶i¤J°®§´`Àô¡A¤¤¬ü§Q®tÁY¯¶¥ç±À°ª¸ê¥»¥~¬yªºÀ£¤O¡C¦¹¥~¡A¥Ø«e¤¤°êª÷¿Ä¥«³õ°ÊÀú¡A¤£¦ý¥~¸êºMÂ÷¡A¥ç«P¨Ï³\¦h¤¤°ê§ë¸ê¤H´£°ª¥~¹ô¸ê²£¤ñ«¡C¤Wz¦]¯À§¡¾ÉP¤¤°ê¸ê¥»¥~¬y³t«×¦³¥[§Öªº¸ñ¶H¡A²Öp2015¤W¥b¦~¡A¤¤°êª÷¿Ä±b¥X²{1,619»õ¬ü¤¸°f®t¡C¦Ó¦b¸gÀÙ©ñ½wªº®æ§½¤U¡A¥¼¨Ó©x¤è±À°Ê³f¹ô¼eÃPªº¤j¤è¦V¤£ÅÜ¡A¥ç¼W±j¤H¥Á¹ôªº¶Sȹw´Á¡C ¥Ñ©ó¥@¬É¸gÀÙ«e´º¤£©ú¡A¤¤°ê©ó8¤ë¤@«×¹Á¸Õ±À°Ê¤H¥Á¹ô¥«³õ¤Æ§ï²¡A¦ýµo²{¤H¥Á¹ô¶Sȹï¥þ²y¥«³õªº¼vÅT¶W¥G·Q¹³¡A¦¹«á¤¤°ê©x¤è«K¤£´±¦A©ñÃP¶×¥«ªº¤z¹w¤O«×¡CY¥H3¥ü¬ü¤¸¬°«O¦u¼Ð·Ç¤U²z·Qªº¥~¶×Àx³Æ¤ô¥¡A¥H¥Ø«e¨C¤ë¥§¡400»õ¬ü¤¸ªº®ø¯Ó³t«×¦ôºâ¡A¤H¦æ©|¥i¤ä¼µ¤H¥Á¹ô§I¬ü¤¸¶×²v©ó3¢Hªº°Ï¶¡¡]6.35¡ã6.50¡^¤º¯B°Ê¬ù12Ó¤ë¡A¨¬¥HÅ@°e¤H¥Á¹ô¯Ç¤JIMFªº¯S§O´£´ÚÅv¡]SDR¡^³f¹ô¡C ¦]¦¹¹w´Á¤j³°¬F©²¦b¸gÀÙ±¡¶Õµy¨£½w©M¡A±N¶}©l¥X¥x¬ÛÃöªº°]¬F¬Fµ¦¡A¥H¨ú¥N®e©ö¤Þµo¤H¥Á¹ô¶×²vÁp·Qªº³f¹ô¬Fµ¦¡A¦¨¬°²Ä4©u¤j³°Ã¼Wªøªº¥D¶b¡C¥[¤W¤Q¤T¤³W¹º¦b§Y¡A¹w´Á¤j³°ªÑ¥«±N¦³¸û©úÅ㪺¤Ï¼u»P¤Wº¦¡C ¦^¨ì¥xÆW¡A¥xÆW¤µ¦~¤@¨Ó¸ò©Ò¦³·s¿³¥«³õ¤@¼Ë¡A±Á{¤j³°¸gÀÙ¼ö«×°½w¡A¬ü°ê¤É®§®É¶¡¤£½T©wªº¼vÅT¡A¦AªÌ±Á{¤¤°ê¬F©²±j¤O§ß«ù¬õ¦â¥b¾ÉÅé»P¹q¤l¨ÑÀ³Ã쪺²£·~½ÄÀ»¡A¥xªÑ¦b¦~¤¤¤§«á¶}©l¤j´T«××¥¿¡A³Ì§C´¿¸g¨Ó¨ì7,203ÂI¡C¦Ó¸gÀÙ¦¨ªø²Ä2©u¤§«á©úÅã©ñ½w¡A¹w´Á¤µ¦~¥xÆWGDP±N¦u¦b1¢H¤W¤U¡C³Ì®tªºÀ³ÄݲÄ3©u¡A¬Æ¦Ü¦³¥X²{¬õ¦rªº¾÷·|¡A¦ý¹w´Á²Ä4©u¤§«á±N·|ºCºC´_µd¡A°t¦X¤j³°¤Þ»âªº¨ÈªÑ¤Ï¼u¡A¥xªÑ²Ä4©uªí²{¹w´Á·|¤ñ²Ä3©u¦n¡C¥u¬O¥»ªi´º®ð´`Àô¬O¥xÆW³Ì®zªº´º®ð´`Àô¶g´Á¡A¦]¦¹¹w´Á²Ä4©u¨ì©ú¦~²Ä1©u¤´¥H¤Ï¼uµø¤§¡C¤Ï¦Ó¬O©ú¦~¤U¥b¦~¡A¦]¬°°ò´Á¦]¯À¡A¥xÆW¸gÀÙ¤~¦³¾÷·|ºCºC¨«¥X¨¦©³¡C¦]¦¹µu½u¥xªÑ¤´¥HÅvȤñ«§Cªº§Q°ò«¬²£·~ÀsÀY¡A¦p¯è¤Ó²£·~¡]º~µ¾¡^¡A¥Í§Þ²£·~¡]¯E¹©¡^¡A¨®¥Î¹q¤l²£·~¡]¦PP¡^¡A¬°¥Dn§ë¸ê¦Ò¶q¼Ðªº¡C(¤u°Ó®É³ø) |
|
|
·|û¡G¥¤ß¦Ó½×10139639 µoªí®É¶¡:2015/10/9 ¤U¤È 05:18:37²Ä 2084 ½g¦^À³
|
¥Í§ÞªÑ¤Ï§ð ¤p¤ß¶Â¤ÑÃZÅͶæÀ¤ô ¨ä¤¤¡A»âÀY«ü¼ÐªÑ¨Õ¬ã(3205)¡B¯E¹©(4174)¡B¨¹¯S(4107)¡A³£³Ð¤U¤W¥«¥H¨Ó·s°ª¡A¤×¨ä¨Õ¬ã¤µ¦~º¦´T¨Ó¨ì615.2¢H¡Aªñ´Áè¤W¥«ªº®i©ô(4167)¤]¸òµÛötº¦¤@¿¡CˬO2013¦~±j¶Õªº°ò¨È(3176)¡B¥x·LÅé(4152)¡B´¼Àº(4162)¡B¦w¦¨ÃÄ(4180)µ¥µ¥°ª»ùªÑ¡A³oªi¨«¶Õ¨Ã¨S¦³©úÅã¸ò¤W¡A·¥¤jªºì¦]¦b©ó·~ÁZ¤Wªºªí²{®t²§¡F¤£¹L¡A±q¨Ó¨SÁÈ¿úªº¯E¹©¤´¦³385¤¸ªº°ª»ù¡A»á¦³·í¦~°ò¨Èªwªj°ªÂI486¤¸¥»¹Ú¤ñª£§@ªº®ð¶Õ¡C http://www.ettoday.net/news/20151008/576796.htm |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/7 ¤U¤È 06:54:41²Ä 2083 ½g¦^À³
|
·j´M1: ·sÃĤ½¥q°ªºq¡A¾Ç¦WÃÄ©M¥Íª«¬Û¦üÃļtÍñ«¨µ¥ªº§x¹Ò ·j´M2: ±iµ½¬Fªí¥Ü¡A¥xY¥[¤JTPP¡BRCEP¡A«h¦³§U¥~¾P¤O¹D´£¤É ¥H¤W¨â«h¸ê°T¨Ó¬Ý¦³³Ð·sªº¥Í§Þ·sÃĤ½¥q¬O¦n®ø®§ |
|
|
·|û¡GKent10139281 µoªí®É¶¡:2015/10/7 ¤U¤È 03:47:09²Ä 2082 ½g¦^À³
|
¹ï, ¥xÆWªº°OªÌdiscipline«Ü®t, ¦³«Ý¥[±j! |
|
|
·|û¡G»¨¥J10136712 µoªí®É¶¡:2015/10/7 ¤U¤È 02:34:32²Ä 2081 ½g¦^À³
|
TPP ¹ï·sÃij¡¤À;;´CÅé¼g±M§QÅv¬ü°ê¬O12¦~;¤é¥»¬O8¦~;;¿D¬w¬O5¦~;;³Ì«á§é°J¬O8¦~ ¦ýÄY®æ¨Ó»¡¤£¬O«ü±M§QÅv;;ºë·Çªº»¡¬O"¸ê®Æ±MÄÝÅv" (Data Exclusivity) ©Ò¥H¾Ç¦WÃļtÃÄnµo®i¸Ó¾Ç¦WÃĬOn±M§Q´Á+¸ê®Æ±MÄÝ´Á«á¤~¥iµo®i |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/10/7 ¤U¤È 01:58:40²Ä 2080 ½g¦^À³
|
9/18 S¤p©j¦^¥hÂå°|°µ¥¿¤l±½´y¡A 9/23 »¡«D±`´Îªº³ø§i¡A¤ù¤l¨S¦³«GÂI(§¹³Ó) S¤p©j«D±`¿³¾Äªº»¡¦o«D±`°í«H¤w¸g§JªA¤F³oÓÂಾ©Ê¯e¯f ¬Û«H¦³³\¦hS¤p©jªº¦¨¥\±d´_¤]·N¨ýµÛ¤j®a¤£Â÷¤£±óªº§ë¸ê¯E¹©¬O³Ì¤F¤£°_ªº¨M©w¡A ¦@«j¤§ ~~ |
|
|
·|û¡G·Q·Q10140340 µoªí®É¶¡:2015/10/7 ¤W¤È 11:36:29²Ä 2079 ½g¦^À³
|
Áa¨Ï±M§Q´ÁÁYµu¬°8¦~, ¤§«á¶}©ñ, ¦ý¥H¥Ø«e¥H¯Eôªº»sµ{³¡¤À,¨ä¥L®ancopy¦ü¥G¦³Ãø«×§a ?! ¦ý¤´¤£¥i¤£¤p¤ß´N¬O... |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/7 ¤W¤È 11:02:58²Ä 2078 ½g¦^À³
|
SAM¤j ·PÁ¤À¨É |
|
|
·|û¡GSAM196910138913 µoªí®É¶¡:2015/10/7 ¤W¤È 10:31:07²Ä 2077 ½g¦^À³
|
¬Q¤Ñ¹Ú¨ì¤Ñ¤W¦³¤j¥ú µo¥XÁnÅT ¡u«Ä¤l§A·R§Ú¶Ü?¡v ¡u¦A¼µ¤@·|,´£«e¨ì1¤ë¤F³á!¡v ¤@ª½·Q±i¤j²´¬Ý²M¥LªºÁy ¤@Án¥¨ÅT~~~´N¿ô¤F!! |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/10/6 ¤U¤È 02:28:39²Ä 2076 ½g¦^À³
|
¬Ý¨Ó¤WÂd27,000±i½æÀ£¤´´N¦s¦b¡A380¤S³y¦¨¤@¦¸ªº®M¨c°Ï¡AÄw½X¦ü¥G¤S¨£ÃP°Ê ¥~¸ê¶R½L¤]¼È®É·²¤â¡A©Ò¥H×¥¿¤@¤U¡A¶¶«K´ú¸Õ¤@¤U«ùªÑ«H¤ß¡A»°¨«µu½u«È TPP·sÃıM§Q´Á³Ì«á¬ü°ê»P¿D¬w§´¨ó¬°8¦~(¬ü°ê12-->8,¿D¬w5-->8)¡A ¦ýY¥i¥´¤J¦U°ê°·«OÅé¨t¡A¤]ºâ®t±j¤H·N ¹ï¯E¹©¦Ó¨¥822«áÁÙ¦³833¥i¥H±µ´Î¡A¤£¦Ü©óÂ_ª¤¡A¦ý°È¨D¤@À»§Y¤¤¡A§¹¬ü±µÁ_¤W³õ ¯E¹©¥ý«eÁö±j¡A¦ýªñ¨ÓÁÙ¬O¸òÀH¥Í§ÞªÑ°_¥ñ¡A©|¥¼¨«¥X¦Û¤vªº¸ô ´¼ÀºFDA¼f¬d§Y±N¤½§G¡AÀ³¸Ó¬O¥ª¥k10¤ë¥Í§ÞªÑ¨«¶Õªº«nÃöÁä ¬Ý¬Ý¬O§_¯à¦³®¶¾Ä¤H¤ßªºµ²ªGÀA¤W²Kªá¼y¯¬¦æ±¡¤F ²¦³ºÂ÷©ú¦~3¤ëÁÙ¦³¥b¦~¡A1¤ë¤S¦³Á`²Î¤Î¥ß©e¿ïÁ|ÅܼơA¤£¸g¾ã²z¤@µfµL¥H¬°Ä~ |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2015/10/5 ¤U¤È 06:14:24²Ä 2075 ½g¦^À³
|
³o´N¬O°ê¤º§ë¸êªÌ»P°ê¥~§ë¸ê¤H©úÅ㤣¦P¤§³B °ê¥~§ë¸ê¤H«i©ó§ë¸ê¥»¹Ú¤ñªº¤½¥q¡A°ê¤º§ë¸ê ¤H¥u«µøEPS...EPS...EPS ...«¢«¢¡I |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2015/10/5 ¤U¤È 05:36:36²Ä 2074 ½g¦^À³
|
¸ÜÁö¦p¦¹¡A¦ý¬Û¤Ïªº¡A¦pªG·íªì»{½ß±þ¥X¯E¹© ¦ÓÂà¶RÁp¨È©ÎªÌ¬O¨Õ¬ã³oºØ±j¶ÕªÑªº¤H·|¤ñ¸û®t¶Ü¡H ¯E¹©¥u¤£¹L¬O³Ð¤F¤WÂdªº°ª»ù¡A¤S¤£¬O³Ð·s°ª ¤W¥«¤WÂdùØÀY¦³¤@¤j°ï³Ð·s°ªªºÓªÑ¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/5 ¤U¤È 05:09:29²Ä 2073 ½g¦^À³
|
Äw½X¬y¦V¥~¸ê¸ò¤j¤á ªÑ»ù¦^¨ì¤WÂd«e°ªÂI¡C³o¬O´²¤áªº©R¹B¡C¤]¬Oªø´Á§ë¸êªÌªº¥²³Ó¤§¹D¡CÅó±ø±ø¡C´N¹ï°Õ |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/10/5 ¤U¤È 04:06:09²Ä 2072 ½g¦^À³
|
µL±¡¤j¤S¦³³Ì·sªº§ó·s¤F http://tsjh301.blogspot.tw/2014/08/obipharma.html 1.2016¦~3¤ëªÑ»ù>520±q56%¨ì67%, 2/3ªº¾÷²v¼Ú 2.10¤ë«ùªÑ¤H¼Æ50±i¥H¤Uªº¤H¼ÆÆJ´î1800¤H¡A50±i¥H¤Wªº¤H¼Æ¼W¥[15¤H ´²¤áÀò§Q¤Fµ²¡A³£³Q¤j¤áµ¹¦¬¨«¤F¡A³o¨â¤Ñ¬~Äw½X¡A¬~§¹´N·Ç³ÆÄ~Äò§ð°í |
|
|
·|û¡GKent10139281 µoªí®É¶¡:2015/10/5 ¤U¤È 03:40:57²Ä 2071 ½g¦^À³
|
¦Ò¼{4162ªº´¼Àº, §Ö®³ÃÄÃÒ¤F, ±j±jºu, Merrimack ¤jº¦17%, ·Ç³Æ®³ÃÄÃÒ¤F... |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/10/5 ¤U¤È 12:05:24²Ä 2070 ½g¦^À³
|
¤p¶§¤j,¥»ª©ªÑ¯««D±z²öÄݤF.´Á«Ý±z¤U¤@¤äªº³øµP. |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2015/10/5 ¤W¤È 11:47:15²Ä 2069 ½g¦^À³
|
³o¤äªÑ²¼Äw½Xâ¶Ã¶R¦b400¦h¤¸®M¨cªº¤H«Ü¦h ÁÙ¬O§ÚªºÁp¨È±j |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/10/5 ¤W¤È 11:35:19²Ä 2068 ½g¦^À³
|
MSD¥»¨Ó´N¤£¬O¶¤¤Í¡A¦b°Ó¨¥°Ó¡A¦pªG§Ú¨S°O¿ù822¨ì®ÉÔÁÙ¦³±M§QÁÙ¬OÅv§Qª÷¤§Ãþªºnµ¹OPT(MSD)§a OPT(MSD)¤]¤£·|»´©ö´N¿ù¥¢822³oÓ¤jª÷Âû¥À¡AY822¤W¥«MSD·Q¥²¤]·|¨Ón¼Ú¬w¤é¥»¯Ã¿Dªº¾P°âÅv§a ¯E¹©¬O°µªø½uªº¡Aµu½uÁȪi¬q«ÜÃø§ì¨ì¦n¶R½æÂI¡A¤@ª½³£¦³¤H·|¶i¥X¨Ó¶ÃµL¥iÁקK ª©¤W¤]¦³¤H³ßÅwª±µu½u¡A¦ý¤p¤ß³Q¬½¬½×²z¡A¨Ò¦p¬Q¤ÑDificid 300¸U¬üª÷¨£³ø¡A¤~¤@»õ¤J³U©Ò¥HªÑ»ù¤£¬°©Ò°Ê ¦ýY¬Y¤Ñ822°²³]¬O3»õ¬üª÷±ÂÅvª÷ªº¸Ü¡A¬Û«Hµ¥¨ìº¦°±¥´¶}¥i¯à·|"¤ÖÁȫܦh«Ü¦h·|·Q¥´¤H" ³o¤]´N¬O¬°¦ó¿³ÂdÂà¤WÂd·í¤Ñ·|Ãz27,000±i¤j¶qªº¤@ӫܤjì¦] ³\¦h¯E¤ÍÁ׶}ÃÒ©Òµ|¡A¹ç¥i·l¥¢³¡¤ÀA¤áÂàB¤áªº¥æ©ö¦¨¥»¡A¤]¤£´±¶TµM±N¤â¤¤«ùªÑ²MªÅ ³\¦h¤H¤â¤¤Y¨S¦³³oÀɪѲ¼·|¹ì¹Ãø¦w¡A¦]¬°¦h¦~¥HÁÙ«ÜÃø§ä¨ì³oºØ¶°·ÀI»PÀò§Q¦b¤@¨ªºªÑ²¼ ¥H«eºô¸ôªÑEPS¬O¥Î·Q¹³ªº¡A²{¦b822 EPS¬O¥Î¹êÅ禨ªG¥i¥H±Àºâ¥X¨Óªº¡Aµ´«D«H¤f¶}ªe ¿ù¹L¤F´N¬O¿ù¹L¡A®M¥y¦W¨¥©Ò»¡¡A§ë¸ê¯E¹©¦³¦p: ®}§Ó¼¯¡G ¦pªG¯u¬Û¬O¤@ºØ¶Ë®`¡A½Ð¿ï¾ÜÁÀ¨¥¡C ¦pªGÁÀ¨¥¬O¤@ºØ¶Ë®`¡A½Ð¿ï¾Ü¨IÀq¡C ¦pªG¨IÀq¬O¤@ºØ¶Ë®`¡A½Ð¿ï¾ÜÂ÷¶}¡C (¯E¹©822¦¨¥\¯u¬Û¬O§_¬OÁÀ¨¥©O?µª®×¦Û¦b¯E¤Í¤ß¤¤) µØ²Q±Ó¡G Àuµ¥ªº¤ß¡A¤£¥²µØÄR¡A¦ý¥²¶·°í©T¡C(§ë¸ê·N§Ó¬O§_°í©w¤£²¾?) ®}§Ó¼¯¡G ¤@¥Í¦Ü¤Ö¸Ó¦³¤@¦¸¡A¬°¤F¬YÓ¤H¦Ó§Ñ¤F¦Û¤v¡B¤£¨D¦³结ªG¡B¤£¨D¦P¦æ¡B¤£¨D´¿¸g¾Ö¦³¡A¬Æ¦Ü¤£¨D§A·R§Ú¡A ¥u¨D¦b§Ú³Ì¬üªº¦~µØùØ¡A¹J¨ì§A¡C(¦U¦ì³£¹J¨ì¯E¹©¤F) §E¬î«B¡G §Aªº¹L¥h§Ú¨Ó¤£¤Î参»P¡A §Aªº¥¼¨Ó§Ú©^³¨ì©³¡C (¹Ç§AÅó±ø±ø§a) |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2015/10/5 ¤W¤È 10:21:54²Ä 2067 ½g¦^À³
|
¯E¹©¤j´T¤Ï¼u«á¡Aªñ´Á§e²{°ªÀɾã²z¥ð§Lª¬ºA¡A¸Ñª¼ÁÙn¥b¦~®É¶¡¡Anº¦n¶^³£¦³¹D²z¡A¨ä¹ê§ÚÌ»Ýnªº¬O¦w©wªø´ÁªºÄw½X¶i³õ¡A¦b³o¸Ìµoªí·¥¬°¼ÖÆ[ªº¨¥½×¡A§l¤Þ¨ìªº¤]¥u¤£¹L¬O·Qª£µu½u¯B°Ê¤£¦wªº´²¤á¡A¤@¨£·¶Õ¤£¹ï°¨¤W´N«æµÛ¤UÃâ¤F¡A¦ó¥²©O? ¬Ý¨£§Ú̦ۻ{¬°¤â¤¤ªºÄ_«o¾D´²¤áÌ¥ô·N¥á±ó¡A¤ß¤¤Ãø§K¤£±Ë¡A§Ú·Q¤£¥²¦A¹ª°Ê¤H¤ß¥h«ù¦³¯E¹©¡Aªø´Áéwªº¶R½L(³sÄò¤j¶q©Îªk¤H«ùÄò¶i³õ)¤~¬O§Ú̸Ӫ`·Nªº¤è¦V¡A¦Óªø½uªk¤H©Î§ë¸ê¤H¬O±Äº¥¦¸©Ó±µ¤âªk¡A§Ṳ́Ŷ·Á¿¤°»ò¡A¥L̤ߤ¤¦¤w¦³©w¨£¡A©Ò¥H«O«ù¼ÖÆ[ªººA«×±¹ï§a!¤£®É°Ý°Ý¦Û¤v¡Aªø´Á«ù¦³ªº¤ßºA·Ç³Æ¦n¤F¶Ü?ÁÙ·|ÀHªÑ»ù¤j´T¤U·Æ¦Ó¼vÅT«ùªÑ¤ßºA¶Ü? |
|
|
·|û¡GD§b10139065 µoªí®É¶¡:2015/10/5 ¤W¤È 10:12:16²Ä 2066 ½g¦^À³
|
¹©¸¡ªYÁöµM½æ¤£¨ì¤°»ò¿ú¦ý´N¬O¤£Åý§A¦Û¤v½æ¡A³s¦b¥xÆW¦Û¤vªº¥D³õ³£¤@¼Ë¡A¬Ý¨ÓÀq¨FªFÃļt¡]MSD¡^ªø´Á¬O¨Ó¶Ãªº¡A¦³³o½Þ¤@¼Ëªº¶¤¤Í¯u¤£¥²¯«¤@¼Ëªº¹ï¤â¡I |
|
|
·|û¡G¦n¤ßªº¯Q¾~10137878 µoªí®É¶¡:2015/10/5 ¤W¤È 09:28:03²Ä 2065 ½g¦^À³
|
¦A¸ò¤j®a¤À¨É¤@Ó·s»D,À³¸Ó¬ONBIªñ´Á¼É¶^ªº¯u¥¿ì¦],¹ï·sÃĶ}µo°Ó¥´À»¤£¤p. Ãļt±M§Q¶ÇÀò¬ð¯} TPP¹F¦¨¨óij¦b±æ ¡]¤¤¥¡ªÀ¨È¯SÄõ¤j4¤éºî¦X¥~¹q³ø¾É¡^¸s¶°¨È¯SÄõ¤j¨ó°Ó¦h¤éªº12Ó¤Ó¥¬v°ê®a¥Nªí¡A¦b´N·s¥Í§ÞÃĪ«À³µ¹¤©Ãļt¦h¤[±M½æ¿W¦ûÅv°ÝÃDÀòP¬ð¯}«á¡A¤µ¤Ñ±µªñ´N¥þ±¦Û¥Ñ¶T©ö¨ó©w¹F¦¨¨óij¡C Ãļt·s¥Í§ÞÃĪ«±M§QÅv°ÝÃD¡AÅý¬ü°ê»P¿D¬wº[¥t5°ê¥Nªí°w¾W¬Û¹ï¡A¬ü°ê¥D±iµ¹¤©¸ûªøªº±M§Q«OÅ@¡A¿D¬w¤Î¥t5°ê«h»{¬°¡A¹Lªø±M§Q«OÅ@±N¨Ï°ê®a°·«O¹wºâ¦Yºò¡A¥BÅýt¾á¤£°_ªº¯f±wµLªkÀò±o³o¨Ç±Ï©RÃĪ«¡C ±µªñ½Í§Pªº®ø®§¤H¤h³zÅS¡A¿D¬w¹ï©ó¯à¹F¦¨§´¨ó·P¨ì°ª¿³¡A¦]¬°§´¨ó¤º®e¥i«O¦³¬J¦³ªº5¦~´Á±M§Q«OÅ@¡A¤S·f°t¥HÃB¥~´Áªº½w½Ä´Á¡F¤£¹L³o¦ì®ø®§¤H¤hĵ§i¡A³o¤´¶·Àò±o¨ä¥L°ê®aªº¦P·N¡C ¥L»¡¡A¡u¦³8¨ì9¦¨ªº¾÷·|¡v¹F¦¨³Ì«á¨óij¡C ²Ä2¦W®ø®§¤H«ü¥X¡A´¼§Q©M¯µ¾|¹ï³o¶µ§´¨óªº¥ß³õ¤´¤£²M·¡¡F¦ý³o¦W®ø®§¤H¤h¹ï§´¨ó¦¨¥\ªº¾÷·|¡A¼ÖÆ[¥H¹ï¡C ¬ü°ê¹ï¥Î¥H¬ãµo¹³¬OÀù«ä°±¡]Avastin¡^µ¥ªvÀùÀøªkªºÁ{§É¸ê®Æ¡A´£¨Ñ12¦~ªº¿W¦ûÅv¡A¥H¹ªÀy³Ð·s¡C¿D¬w«h°í«ùµ¹¤©5¦~ªº«OÅ@¡A¥H¨D¯à¸û§Ö©Ô¤UÃÄ»ù¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/5 ¤W¤È 09:18:10²Ä 2064 ½g¦^À³
|
¯Q¾~¤j BINGO!!±z¯uÁo©ú!! ¤]¹ï,¥¢À£Äò¶]L¤]¬O·|¨ü¶Ëªº,«¢«¢«¢(«ç»ò¦n¹³¨Ó¨ìmobil..) ¨¥Âk¥¿¶Ç ±zªº´£¿ô,Åý¤j®a¯à«O¦u.ÂÔ·V,¨ä¹ê¬O«Ü«nªº ²¦³º¦b»sÃĪº¹Lµ{¤W,³£¥²¶·¾Ô¾Ô¹¸¹¸,¦p¼iÁ¡¦B§r |
|
|
·|û¡G¦n¤ßªº¯Q¾~10137878 µoªí®É¶¡:2015/10/5 ¤W¤È 09:05:40²Ä 2063 ½g¦^À³
|
³Í¤l¤j ¤§«eÀ³¸Ó¬O¥d¦bÃÄ»ù¤Ó§C,°·«O¥uµ¹1404¤¸;³Ì«á½Í¨ì3138¤¸¤~¨M©w¥i¥H½æ.(¦ýÁÙ¬O¥@¬É¦U°ê¤¤ÃÄ»ù³Ì§Cªº) Faith¤j ±zÀ³¸Ó¬O¶}BMW?¥¢À£Äò¶]L¤]¬O·|Ãzªº,ÁöµM¤ñ¸û¥i¥H¸ÉL,¦ýÄY«ÁÙ¬On¥h´«¤@±øªº. |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2015/10/5 ¤W¤È 08:49:18²Ä 2062 ½g¦^À³
|
¦^¥xÁÞ¥Sªº¸Ü §Ú6/19ªº¤å¦r«ÂI¬O¦bµû¦ôBLA®É¶¡ PFS°ª§C¥u¬O¤ñ³ë PFS°ª¥NªíPD¤H¼Æ¤Ö¡A¼Æ¦r¥¼¦¨¼ô¡ABLA®É¶¡·|¸û±ß PFS§C¥NªíPD¤H¼Æ¦h¡A¼Æ¦r·í¤w¦¨¼ô¡ABLA®É¶¡·|¸û¦ «Ü©êºp§Ú¨Sªí¹F²M·¡ |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/10/5 ¤W¤È 07:27:16²Ä 2061 ½g¦^À³
|
¬Q¤Ñ±ß¤W¬Ý¨ì¤F¼ÖÆ[¼¥H100¿ªº¸ÑŪ,°¨¤WÁÙ¦³¬O¦³ºô¤Í¨Ó§ó¥¿.¤Ñ¦ö¯E¹©. |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/5 ¤W¤È 06:34:47²Ä 2060 ½g¦^À³
|
¯Q¾~¤j ¤p§ÌÓ¤H¤]»{¬°¹©¸¡ªY¦b»OÆW½æ¤£¨ì¤°»ò¿ú ¦ý¤p§Ì¤]n§i¶D±z¡A¤p§Ìªº¨®¬O¨¾ÃzL¡A¦´N©ñ¤U³ÆL¤F ÁÂÁ±z´£¿ô¤j®a ¼f·V¡B«O¦u |
|
|
·|û¡G³Í¤l³Í10140178 µoªí®É¶¡:2015/10/5 ¤W¤È 06:22:19²Ä 2059 ½g¦^À³
|
¦^¯Q¾~¤j¤j: ¤£¬O¯E¹©¤£·QÁÈ,¬OÀq¨FªF¥dµÛ¦X¬ù 5¤ë·í®É§Ú¦³¥´¥h°Ý¬°¤°»ò³£¨S¦³À禬¶i±b(¶ÀÁ`¤£¬O»¡·|¦³¾P°â) ¯E¹©¦^µª¬O:12¤ëÀq¨FªF¦Y¤U¤F¡u¹©¸¡ªY¡vªº¦X¬ù,¦ý¬O´N¬O¤£µ¹¥xÆWÃÄ,n«·s©w»ù ±i¦Ñ¤j¥L̬O§Æ±æÅýÃįà¶i¨Ó¥xÆW°µ¥XÅý¨B(¥h¦~9¤ë°·«O§½´N®Öã,¤@¦~¥xÆW³£®³¤£¨ìÃÄ) |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2015/10/5 ¤W¤È 06:05:38²Ä 2058 ½g¦^À³
|
https://tw.news.yahoo.com/%E6%B5%A9%E9%BC%8E%E6%8E%88%E6%AC%8Amsd-%E8%BF%91%E5%84%84%E5%85%83%E7%B0%BD%E7%B4%84%E9%87%91%E5%85%A5%E8%A2%8B-215005472--finance.html ¯E¹©±ÂÅvMSD ªñ»õ¤¸Ã±¬ùª÷¤J³U -A +A ¤¤®É¹q¤l³ø§@ªÌ°OªÌ§ù¿·»T/¥x¥_³ø¾É | ¤¤®É¹q¤l³ø ¡V 2015¦~10¤ë5¤é ¤W¤È5:50 ¤u°Ó®É³ø¡i°OªÌ§ù¿·»T/¥x¥_³ø¾É¡j ¯E¹©¥Í§Þ¡]4174¡^¬Q¡]4¡^¤é«Å¥¬¡AºX¤U·s«¬§Ü¥Í¯À¡u¹©¸¡ªY¡vDIFICIDR¡]°Ó«~¦WFidaxomicin¡^¦b¥x²£«~¶}µo¤Î¾P°âÅv§Q¡A¿W®a±ÂÅvµ¹¬ü°ÓÀq¨FªFÃļt¡]MSD¡^¡Añ¬ùª÷300¸U¬ü¤¸¡]¬ù¦X¥x¹ôªñ1»õ¤¸¡^¡A¹wp¥¼¨Ó²Öp¾P°â²bÃB¤Î·s¾AÀ³¯g¨½µ{ª÷¡A³Ì¦h¥i¹F525¸U¬ü¤¸¡C ¡u¹©¸¡ªY¡v¬OªvÀø°°½¤©Êµ²¸zª¢ªº·s«¬§Ü¥Í¯À¡A¸Ó·sÃĬO¥Ñ¬ü°êOptimer¡A§Y¥xÆW¯E¹©«e¥À¤½¥q¬ãµo¡A2011¦~4¤ëÀò¬ü°êFDA®Öã¤W¥«ªº·sÃÄ¡A2012¦~8¤ë¤]¨ú±o¥xÆWTFDAÃÄÃÒ¡A¨Ã¥Ñ¥xÆW¯E¹©¾P°â¡A2014¦~³q¹L°·«O¸p®Ö»ùµ¹¥I¡C ¯E¹©Á`¸g²z¶À¨q¬ü»¡¡A¹©¸¡ªY±ÂÅvMSD¾P°â«á¡A¦³§U©ó¯E¹©±Mª`Àù¯g¬Ì]µ¥·sÃĶ}µo¡C ¨Ì·Ó¦X¬ù¨óij¡AMSDªì´Á±N¤ä¥I300¸U¬ü¤¸Ã±¬ùª÷¡A¥¼¨Ó¯E¹©ÁÙ¥i¦¬¨ú¾P°âÅv§Qª÷¤Î¼ÆÓ¥¼´¦ÅS¨Æ¶µ¹F¦¨«áªº¨½µ{ª÷¡A²Öp¾P°â²bÃB¤Î·s¾AÀ³¯g¤§¨½µ{ª÷¡A³Ì¦h¥i¹F525¸U¬ü¤¸¡CMSD±Nt³d¹©¸¡ªY¦b¥x©Ò¦³¸g¾P¡B¬ãµo¤Î¥Í²£¸g¶O¨Æ©y¡C ¡u¹©¸¡ªY¡v¬O¥Î¨Ó¥Î¨ÓªvÀø§xÃø±ôµß¡]Clostridium difficile¡^·P¬V©Ò¤Þ°_ªº¡u§xÃø±ôµß¸¡Âm¡v¡]CDAD¡^¡C§xÃø±ôµß©ó¯f¤H¤j¸z¤º¾À¼W¥Í¡B²£¥Í¬r¯À¡Aªì´Á·|³y¦¨°°½¤©Êµ²¸zª¢»PÄY«¸¡Âm¡B¹q¸Ñ½è¥¢¿Å¡Aªø´Á¥i¯à¾ÉP¸z¬ï¤Õ¡B¥¨¸zµ²¸z¯g¦Ó»Ý¤â³N¤Á°£ªvÀø¡F¤×¨ä¤ÏÂзP¬V¤U¡A¹ï¯f¤H¥Í¬¡«~½è»PÅé¤O¼vÅT¬Æ¹d¡AÄY«ªÌ¬Æ¦Ü¥iP¦º¤`¡C ³Qµø¬°¬O·sÃĪѫü¼Ðªº¯E¹©¡A³Ì¨üÃöª`ªº¨ÅÀù·sÃÄOBI-822²ÄII/III´ÁÁ{§É¸ÕÅç¡A¤w³Wµe±N©ó©ú¦~3¤ë«e¸Ñª¼¡A§¹¦¨¨Ã¤½¶}¼Æ¾Ú¤ÀªRµ²ªG¡C ªk¤H»{¬° ¡A¥Ñ©ó¥Ø«e¨C¤ë´_µo¤H¼Æ·¥§C¡AÁô§tOBI-822¦³¤£¿ùÀø®Ä¡A¦³¾÷·|©ú¦~¥Ó½Ð¥xÆWÃÄÃÒ¡A¤]¿EÀy¯E¹©³o¤@ªiªÑ»ù±j¶Õ¤Ï¼u¡A±q8¤ë¤U¦¯³Ì§Cªº250¤¸¤Wº¦¦Ü¤é«e½L¤¤°ª»ù388¤¸¡Aº¦´T°ª¹F55.2¢H¡C |
|
|
·|û¡G¤po10135877 µoªí®É¶¡:2015/10/5 ¤W¤È 12:14:48²Ä 2057 ½g¦^À³
|
ncover¹©¸¡ªY,»Ýn¤£¤Ö¤H¤O©M¤ß¤O,³o¨Ç¤HÂk8xxªº¹Î¶¤§ó¥i¶°¤¤¤õ¤O |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/5 ¤W¤È 12:13:56²Ä 2056 ½g¦^À³
|
°e³ø¤j »{¦P§Aªº±À½×>>>>©Î³\©MÀq¨FªF¦X§@ªº¶}©l§óȱoª`·N. Âù¤è¥ý¾Ç²ß¦X§@ ¦X§@¾Ç²ß ¦A¦æ¾P¦X§@±ÂÅv Àq¨FªF¦V¯E¹©¥Ü¦n ³g¹ÏÀ³¤£¬O¹©¸¡ªY³oÁû¤pÃÄ Àq¨FªF·Qn¤jÁûªº |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/4 ¤U¤È 11:54:44²Ä 2055 ½g¦^À³
|
BRN¤j §Ú¿ù«Ü¤j ÁÂÁ§Aªº´£¿ô ±ÂÅvª÷ÃBÁö¤£¤j ¦ý¤£µL¤p¸É ¨¬¥H¨ÑÀ³822¯Ø¸¢Àù¤G´Á»P833¤@´ÁÁ{§É¶O¥Î ¦ý¤]Åý§Ṳ́ϦV«ä¦Ò¤p¤pªº¥xÆW,¤p¤pªºÃÄ´N¦³¦p¦¹±ÂÅvª÷ÃB ³o¤]¼W¤j¨ÅÀù¤jÃļڤéÁú±ÂÅvª÷ÃBªº¬Û·Q¹³ªÅ¶¡ |
|
|
·|û¡G¦n¤ßªº¯Q¾~10137878 µoªí®É¶¡:2015/10/4 ¤U¤È 11:49:51²Ä 2054 ½g¦^À³
|
¤Ó¹L¼ÖÆ[ªº¨¥½×¤S¥X²{¤F ¥xÆW¯E¹©¥u¬O§â¥xÆWªºdificidªº±M§Q¨Ï¥ÎÅv¤Î¥N²z¾P°âÅv"ÁÙ¦^¥h"µ¹¬ü°êOptimer¦Ó¤w, ©Ò¥H¤£·|¦A¦³§Oªº°ê®aªº¾P°âÅv§Qª÷¦¬¤J¤F,§ó§O¦k·Q¬O¥þ²yªºÀ禬,¨ºÓ³£¬O¬ü°êOptimer¦Û¤v¦Y¤U¨Óªº, ´N§Úªº¬Ýªk,³oÓ®ø®§¬O¤@¦n¤@Ãaªº±Ò¥Ü: 1. ²×©ó¦³¤@µ§¤ñ¸û¥i¥HºÙ±o¤W¦¬¤Jªºª÷ÃB¥X²{¤F: ñ¬ùª÷300w USD. ¦ý¤§«áªº¾P°âÅv§Qª÷¥u·|¦¬¨ì¥xÆWªº. 2. ³o®a¤½¥qªº¾P°â¹Î¶¤ÁÙ¥¼«Ø¸m§¹¦¨(¤£ª¾ì¦]¬°¦ó),¥»¨Ón¦Û¤vÁȪº®³µ¹§O¤HÁÈ,µLªk¹F¨ì³Ì¤j¼ç¦bÀ禬.(·íµMn¸ÑÄÀ¬°©ñ±¼³ÆL¤]ok,¦ýÓ¤Hµø¬°°¾¦V¼ÖÆ[ªº±À½×,§Ú¶}¨®ÁÙ¬O·|±aµÛ³ÆL¤W¸ôªº.) |
|
|
·|û¡GBRN10139393 µoªí®É¶¡:2015/10/4 ¤U¤È 11:37:20²Ä 2053 ½g¦^À³
|
¥xÁÞ¤j: ±zªº»{ª¾¥i¯à¦³¸¨®t¡I ¹©¸¡ªY·íªì¬O¥Ñ¯E¹©¥À¤½¥qOPTIMER¶È±N¥xÆW¦a°Ï±ÂÅvµ¹¯E¹©¡A¥u¬O¥Ø«e¯E¹©¬°±Mª`©óÀù¯g¬Ì]ªº¶}µo¡A§â¥xÆW¦a°Ïªº¿W½æÅv¦AÂà±ÂÅvµ¹OPTIMER¤½¥q¦b¥x¤§Ãö«Y¥ø·~MERCK SHARP&DOHME(I.A.)LLC.-TAIWAN BRANCH ©Ò¥H¯E¹©³o¦¸±ÂÅv¶È¬O¥xÆW¦a°Ï¡A¯E¹©¬O§¹¥þ¤£¨ã¦³¹©¸¡ªY¦b¥xÆW¥H¥~¨ä¥L¦a°ÏªºÅv§Q¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/4 ¤U¤È 10:14:08²Ä 2052 ½g¦^À³
|
¥xÁÞ¤j ³o¦¸±ÂÅv¶È¬O¥xÆW¦a°Ï ÁÙ¦³¨ä¥L¦a°Ïµ¥«Ý±ÂÅv ¾P°â±¡ªp·|ÀHµÛ±ÂÅv¦Ó¥[¤j ±zªº¹w¦ô «ü¤é¥i«Ý ¹©¸¡ªYªº±ÂÅv ¶H¼x»²§U¤õ½b¤w¸g¶}©l¹B§@ ¯u¥¿ªº¬ð¯}¦a²y¤Þ¤O°é ¶i¤J¥~¤ÓªÅ ´N¥ý¬Ý822¿U®ÆÄ鹡¤F¨S |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/4 ¤U¤È 09:15:50²Ä 2051 ½g¦^À³
|
½÷·ç«Å§G¥¿±ªºÁ{§Éªì¨Bµ²ªGtop-lin(2014 02) ¨ìÀò¬ü°êFDAÃÄÃҮɶ¡¬O¤@¦~(2015 02) ³o¤]²Å¦X¦Ñ¥v¤j6¤ë19¤é ¶K¤å: FDA¦¬¨ìNDA©ÎBLA«á¡A¦pªG¬Oµ¹¤©¥Ó½ÐªÌpriority review¸ê®æ¡A·|¦b60¤Ñ¤º¦^ÂЧiª¾¡A ¦^ÂЫáFDA«ö³W©w·|¦b6Ӥ뤺¼f®Ö§¹²¦¡A¦pªG¬Oµ¹¤©¥Ó½ÐªÌstandard review¸ê®æ¡A·| ¦b74¤Ñ¤º¦^ÂЧiª¾¡A¦^ÂЫáFDA«ö³W©w·|¦b10Ӥ뤺¼f®Ö·sÃħ¹²¦¡C¤]´N¬O»¡¡A¼Ð·Ç¬yµ{ ¤§¤Upriority review·|¤ñstandard review§Ö4.5Ó¤ë¡C FDA¼f®Ö¶i«×ªº·ÇÂI²v±µªñ90% http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/ucm209398.htm ¦Ñ¥v¤j ½Ð°Ý§A6¤ë19¤é¶K¤å´£¨ì: ¦pªGPFS¸¨¦b2x Ó¤ë¡AK-M¦±½uªº¼Æ¦rÀ³¤w¦¨¼ô¡A¤K¤ë±M®a·|ij«á¡A§Ú»{¬°Q4´N·|¸Ñª¼ ¥Ø«e¬O3¤ë¸Ñª¼ ³o¹ïPFSªº¼vÅT¦p¦ó? ÁÂÁ 1 FEBRUARY: Pfizer announces positive top-line results from PALOMA-1, which demonstrate that adding palbociclib to letrozole significantly prolongs PFS over letrozole alone. 2014¦~2¤ë½÷·ç«Å§G¥¿±ªºÁ{§Éªì¨Bµ²ªGtop-lin 2 APRIL: Dr. Richard Finn presents detailed results from PALOMA-1 at the American Association of Cancer Research (AACR) Annual Meeting 2014 in San Diego. 2014¦~4¤ë½÷·ç°Ñ¥[¸t¦a¤úôAACR¦~·|§eÄm¸Ô²ÓÁ{§Éµ²ªG 3 AUGUST: Pfizer announces it has completed the submission of a New Drug Application (NDA) to the FDA for palbociclib. 2014¦~8¤ë½÷·ç¦VFDA ´£¥X·sÃĥӽРNDA ( 60¤Ñ¤º¦^ÂЧiª¾) 4 OCTOBER: On October 13, which is Metastatic Breast Cancer Awareness Day, Pfizer announces that its NDA for palbociclib has been accepted for filing and granted Priority Review by the FDA. 2014¦~10¤ë½÷·ç«Å§GÀòFDAÀu¥ý¼f¬d¸ê®æ 5 FDA approves Ibrance for postmenopausal women with advanced breast cancer 2015 02 03 palbociclib ÀòFDA ÃÄÃÒ¼f¬d³q¹L |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/4 ¤U¤È 08:59:17²Ä 2050 ½g¦^À³
|
·PÁÂCliff¤jªº»¡©ú ¤p§Ì»â¨ü¤F 300+525¸U¬üª÷ªº¦¬¤J ±µªñ1.58¤¸ªºEPS ¤£µL¤p¸É |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/10/4 ¤U¤È 08:48:17²Ä 2049 ½g¦^À³
|
«ù¤[ªº¯E§J¤j¡G ¡u³¥¤HÄmÃn¡v+¡uè¤H»¡¹Ú¡v ¨C¦~¥iÀò±oªº¾P°âÅv§Qª÷¬°·í¦~¾P°âÃBªºA%¡A¤§«á¨C¦~¾P°âÃBÀ³·|³v¦~¼W¥[¡Aª½¨ì¬Y¦~¾P°âÃB¹F¨ìB¬ü¤¸®É¡A°£ÃÄ«~¾P°âÅv§Qª÷¡]·í¦~¾P°âÃBªºA%¡^¥~¡A¯E¹©¡]¥i¯à¡^¥i¦A¨ú±oC¬ü¤¸ªº¤@¦¸©Ê¨½µ{ª÷¦¬¤J¡C¡]¯E¹©¤½§G«¤j°T®§¤¤¨Ã¨S¦³´£¨ìªºC¸U¬ü¤¸ªº¤@¦¸©Ê¨½µ{ª÷¦¬¤J¡A¯Â²q´ú¡^ ©Ò¥H¤½¥q¤£·Q¤½§G²Ó¸`«o¤S·Qµ¹ªÑªF¤@Ó¤j¬ùªº¼Æ¦r·§©À¡A³q±`´N·|»¡¡A¡u²Öp¡v¦U¦¸¡]¦~¡^¾P°âÅv§Qª÷¦Ü±M§Q¨ì´Á¬°¤î¡A³Ì¦h¥i¹FXXX¸U¬ü¤¸¡K¡K ´£¨Ñ2006¦~¤¤¾ó¤l¤½¥qSynpacªº©t¨àÃÄMyozymeªº¾P°âÅv§Qª÷¤À°t¤ñ¨Ò°µ°Ñ¦Ò¡G ¡u®Ú¾Ú¤¤¾ó (2104) »PGenzyme¦X¬ù¤º®e¡ASynpac°£¨C¦~¨ÌGenzyme¾P°âMyozymeª÷ÃBªº13.5%¦¬¨úÅv§Qª÷¡AY¾P°âª÷ÃB¶W¹L2»õ¬ü¤¸®É¡A§ó¥i¦¬¨ú1000¸U¬ü¤¸¤§¨½µ{ª÷¡AY¤µ¦~¡]2009¡^Myozyme¾P°âª÷ÃB¹F4.4»õ¬ü¤¸¡A°£ÃÄ«~¾P°âªºÅv§Qª÷¥~¡A¤¤¾ó¥i¦A¨ú±o2,000¸U¬ü¤¸ªº¤@¦¸©Ê¨½µ{ª÷¦¬¤J¡C¡v ¡u±q2006¦~10/1¨ì2013¦~ªº3/29¡A¤¤¾ó¤l¤½¥qSynpac¥iÀò±oªºÅv§Qª÷¬°¦b¬ü°ê¾P°âÃBªº13.5%¡F2013¦~¨ì2023¦~³o¬q´Á¶¡¡AÅv§Qª÷¬°¾P°âÃBªº15%¡C¡v ¦^¨ì¹©¸¡ªY¡A¤ñ¸û¥O¤H¦n©_ªº¬O¡A¡u·s¾AÀ³¯g¤§¨½µ{ª÷¡K¡v¡A¤°»ò¬O¹©¸¡ªYªº¡u·s¾AÀ³¯g¡v¡H ¬d¨ì¤F³o»ò¤@«h®ø®§¡ACubist¦b2014¦~ªºID¶g¡]µù¡GIDWeek 2014¡^ªº¾Ç³N³õ¦X¤Wµoªí¤F¹©¸¡ªY¥Î©óªvÀø¤p«Ä·P¬VC.difficile ¸zª¢ªºPhase I¼Æ¾Ú¡G¡uCubist to Present New Data from Study of fidaxomicin in Children with Clostridium Difficile-Associated Diarrhea at IDWeek 2014¡v¡]http://www.businesswire.com/news/home/20141008005083/en/Cubist-Present-Data-Study-fidaxomicin-Children-Clostridium ¡^¡A¥»¨Ó¹©¸¡ªY¦b2011¦~5¤ë¥u³QFDA®Öã¥Î©ó¦¨¦~¤HªºC. difficile·P¬V¡A¥¼¨Ó¥i¯à·|³v¨B¨«§¹¤p«ÄÁ{§É¤T´Á«á¡AÂX¥R¾AÀ³¯g¦Ü18·³¥H¤U¦~ÄÖ¼h±wªÌ¡C¨º®ÉÔ¯E¹©¤´¥i«ö¤ñ¨Ò¤À±o¾P°âÅv§Qª÷¡C¥H¤W¬O§Úªº²q´ú¡C µù¡GIDWeek 2014 ID¡×Infectious Disease¶Ç¬V¯f¡C ¨C¦~¦³¤@¶g¶°µ²¤F¥|ӶǬV¯fªºÂå¾Ç·|±M®a¡A¤@°_¶}·|°Q½×¶Ç¬V¯f¨¾ªv»P¬ã¨s¡A2015¦~¬O10¤ë7-11¤é¦b¥[¦{San DiegoÁ|¦æ¡C þ¥|ÓÂå¾Ç·|¡H IDSA¡GInfectious Diseases Society of America¬ü°ê¶Ç¬V¯f¾Ç·| SHEA¡GSociety for Healthcare Epidemiology of America¬ü°ê°·±d·ÓÅ@¬y¦æ¯f¾Ç·| HIVMA¡GThe HIV Medicine Association·R´þ¯f¨ó·| PIDS¡GPediatric Infectious Diseases Society¤p¨à¶Ç¬V¯f¾Ç·| ¡uIDWeek is the combined annual meeting of the IDSA, SHEA, HIVMA, and PIDS, where infectious diseases professionals can meet, share experiences, and develop collaborations. With so many common issues and challenges cutting across four disciplines, IDWeek provides an opportunity to learn from each other¡¦s knowledge, experience and expertise, for the improvement of patient care and public health.¡v¡]https://www.idweekinternational.com/Home.aspx ¡^ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/4 ¤U¤È 08:28:45²Ä 2048 ½g¦^À³
|
¼¤j¡AÁÂÁ±zªº§Ö°T ¯E¤ÍÌ¡A¬Ý¥X¤°»òºÝÙ¤F¶Ü¡H ªí±¤W¦n¹³¨S¦³¡A¦ýªiÀܬ¤´é¥i¯à¤w¸g¶}©l¤F¡A«¢«¢«¢ ¤p§Ì³Ì·R¶Ã²q¤F¡A¥H¤U¬O¤p§Ìªº²q´ú 1.¹©¸¡ªY·íªì¬O¯E¹©ªº³ÆL¡A³ÆL½æ±¼¤F¡A¥Nªí¤°»ò¡H 2.¹©¸¡ªY»¡¹ê¦bªº¡AÁȤ£¤F¿ú¡AOPTIMER¤½¥q¦b¥x¤§Ãö«Y¥ø·~MERCK SHARP&DOHME(I.A.)LLC.-TAIWAN BRANCH ±Nt³d¹© ¸¡ªY¡AÃø¹D¥L̬O²Â³J¶Ü¡H«¢«¢«¢ 3.¤W¦¸³õ¥~¥æ©öªº¨â¤d¦h±i¡A¥Î414Âà¡AÅý¤HµL·å·Q§r¡I 4.¤£¥Îµ¥±M®a·|ijªºµ²ªG¤]ª¾¹D¡A¥Ø¼Ð¬O9Ó¤ë¡A²{¦b³Ì¤Ö¤]13Ó¤ë¤F Áo©úªº¯E¤ÍÌ¡A±z¯uªºnµ¥¬ü°êªº¤T´Á°µ§¹¶Ü¡H«¢«¢«¢ ¥H¤W¤p§Ì¦Û¤vªº²q´ú¡AÁٽЯE¤Í̤]¤À¨É¬Ý¬Ý±zªº·Qªk¡I |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/4 ¤U¤È 05:08:12²Ä 2047 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j ²Öp¾P°â²bÃB¤Î·s¾AÀ³¯g¤§¨½µ{ª÷¡G³Ì¦h¥i¹F525¸U¬ü¤¸ ¬O¨C¦~pºâ¶Ü? ÁÙ¬O¥þ³¡ºâ¨ìñ¬ù¨ì´Á¤é¬°¤î? |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2015/10/2 ¤U¤È 09:54:59²Ä 2046 ½g¦^À³
|
Please keep in mind.... ¥¼¨ÓÁÙ¬On°µ¬ü°ê¤T´Á ¥¼¨ÓÁÙ¬On°µ¬ü°ê¤T´Á ¥¼¨ÓÁÙ¬On°µ¬ü°ê¤T´Á µ¥¤£¤U¥h or ¨S«H¤ßªº»°§Ö½æ¤@½æ¡A¤£¹L«áªG¦Û¦æt³d |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/10/2 ¤U¤È 05:34:21²Ä 2045 ½g¦^À³
|
°ò¥»±:«ù¥¤£ÅÜ(©ú¦~3¤ë¸Ñª¼) ®ø®§±:¨S¦³·s»D Äw½X±:¥~¸ê½æ¶W ¥Í§ÞªÑº¦¦h¥ð®§¡A³¡¤À¥~¸ê½æ¥X¡A©Ò¥HªÑ»ù¦^¶^¡A¦p¦¹¦Ó¤w µ¥½L¦n«á¦A¤W¡C¥un¦b350¤¸¥H¤W¾ã²z¤£¯}¡A¬Û«H¦h¤è´Nnª½±´400 |
|
|
·|û¡G¦sªÑP´I10136213 µoªí®É¶¡:2015/10/2 ¤W¤È 12:46:09²Ä 2044 ½g¦^À³
|
¦pªG¨S°O¿ù¥Ã©ý¥u¦Y¨ì¥xÆW³¡¥÷ ¦Ó¥B¬OÃij̫ᶥÂ_ªº¥N¤u ¬ü°ê¤T´Á¦³³W©wÁ{§É¥ÎÃÄ »P±N¨Ó¶q²£ÃĪ«¥²¶·¦P¼Ë¨Ó·½ ªÎ¤ô¤£¸¨¥~¤H¥Ð ¼í¶®¤£¬O»\¤ß»Äªº |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/2 ¤W¤È 12:35:22²Ä 2043 ½g¦^À³
|
¨ÅÀùOBI822¤W¥««áÀ³·|¥Ñ¥ÃÏç¥N¤u¡A ³o®a¤w²Å¦X¼Ú·ù»P¬ü°êªº»sµ{¼Ð·Ç¡A ¼í¶®¬O³Æ¦ì¥N¤u¼t¡A»Ý´ú¸Õ»P¬d¼t ²Å¦X¼Ð·Ç¤~¯à¥N¤u¥Í²£ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/2 ¤W¤È 12:16:21²Ä 2042 ½g¦^À³
|
¯E§J¤j §A²q´ú¨S¿ù¡A¤A¥¼¦~¬î«á®üÂAn¾iªÎ¤@ÂI¡A ¾i¦h¤@ÂI¡A¤þ¥Ó¦~¥Î¶q±À´úÀ³¸Ó«Ü¤j¡A ³o®a¤½¥q¦ÑÁóÀ³¸Ó«Ü¶}¤ß¡A¸ú¦b´Ö³Q¸Ì ¤]·|¯º¡A¨S·Q¨ì¾i®üÂA¤]¯àÁȤj¿ú |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/1 ¤U¤È 11:32:11²Ä 2041 ½g¦^À³
|
¥xÁÞ¤j ¥O¤H·q¨Øªº¬ã¨sºë¯« ½Ð¥t¥~¬Ý¼í¶®©« ¦³ÃöSTELLAR·s»Dµo¥¬ ÂX¤j»P¼í¶®¦X§@ §Ú¹w¦ô 822¦³®Ä Ãļt·Ç³Æ°Ó·~¤Æ¥Í²£ ¬O¶Ü |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/1 ¤U¤È 11:07:53²Ä 2040 ½g¦^À³
|
ª¾¤vª¾©¼ ¦Ê¾Ô¦Ê³Ó ¦A»{ÃÑù¤ó¶PÀù¥ ¨ÅÀùOBI822 ¸Ñª¼®É¬O»P ù¤óHerceptinªºÀø®Ä§@«ü¼Ð ¥H¤U¬OHerceptin»P¤Æ¾ÇÀøªk ¤£¦P²Õ¦XªºÀø®Ä (¸Ô²Ó½Ð¾\Ū36-39¶) «e±¤j³¡¥÷¦b»¡°Æ§@¥Î http://www.roche.com.tw/content/dam/corporate/RocheTW/download/Herceptin.pdf µo²{ Anthracycline + cyclophosphamide ªº Time to progression ¬O 5.7Ó¤ë ¦pªG§âAnthracycline ®³±¼ ·|¤£·| Time to progression ¤£¨ì5.7Ó¤ë ? ? ? ºî¦Xµ²ªG (¥H¤¤¦ì TTP(¤ë)¬°Æ[¹î) 1 Herceptin+©Ò¦³¤Æ¾ÇÀøªk(n=235) 7.2Ó¤ë 2 ©Ò¦³¤Æ¾ÇÀøªk(n=234) 4.5Ó¤ë Paclitaxel ªvÀø²Õ (¤Ó¥¬vµµ§ü¾J ) 3Herceptin+Paclitaxel (n=92) 6.7Ó¤ë 4Paclitaxel(n=96) 2.5Ó¤ë AC ªvÀø²Õ 5 Herceptin+AC(n=143) 7.6Ó¤ë 6 A C(n=138) 5.7Ó¤ë (¨Ï¥Î Anthracycline( doxorubicin ©Îepirubicin )+ cyclophosphamide¶i¦æ¤Æ¾ÇªvÀø http://www.tma.tw/ltk/100540703.pdf 17¶ ¦³ PFS DFS TTP ®t²§ |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/10/1 ¤U¤È 01:46:11²Ä 2039 ½g¦^À³
|
³g¤ß¬O¤H¤§±`±¡¡A¥ú§ë¸ê¥Í§ÞªÑ´N¦³¤H«sÂE¹M³¥ ¦ýY¥æµ¹§ë¸ê¤½¥q¡A©¹©¹·ÀI¦³¦h¤j´N¦³¦h¤j ¶R¥Í§ÞªÑ"À³¸Ó"ÁÙ¬On³]°±·l¡A·íªì±q455¨ì250¶^±o¥i¿×¤£»´ ¥u¤£¹L¥¼¸Ñª¼«e¡A¯uªº¤£ª¾¹D¦p¦ó³]°±·lÂI ¸Ñª¼¤é´Áº¥ªñ¡AÀ³¸Ó¤]¤£»Ýn¾á¤ß³oÓ°ÝÃD¤F¡A@¤ßµ¥µ²ªG«K¬O ¨º°¦¬Ý¤£¨ìªº¤â·|±a¨ìÀ³¸Ó·|¹w´Á¨ìªº»ù¦ì¡Aȱo´Á«Ý¡C ²{¦bÁ٪Ť⪺¤HÁÙ¬OnÂÔ·V¤@ÂI¡A¤p¤p¶R´N¦n¡A¤]¤£n¥þ©ã§â·ÀI±aµ¹¦Û¤v ¤]¯d¨ÇªÑ²¼µ¹¥~¸ê¨Ó¶R¡A§OÅý¥~¸ê¤£¶}¤ß ~~ «¢«¢ ¸ß»ù°éÁÊ°µ»ç §|±þ´²¤á 2015-09-29 10:47:11 ¸gÀÙ¤é³ø °OªÌ ³¯©É·O ¡u³oªF¦è´N¬O³g¡A§A³g¥Lªº§Q®§¡A¥L³g§Aªº¥»ª÷¡v¡A9¤ë19¤é¤U¤È¡A50·³ªº¶À¤t¡]¤Æ¦W¡^¦b¥x¥_¥«°êxªQ¤sÁ`Âå°|¹ï±ªº¥þ®a«K§Q°Ó©±±µ¨ü¥»³ø±Ä³X¡A½Í¤Î³o¥ó¥¿¦b¥xÆWªÀ·|¤Wºtªº§ë¸ê¤½¥q§|±þ´²¤á¨Æ¥ó¡A¦ôp¹O500¤H¨ü®`¡Aª÷ÃB¦Ü¤Ö¤T¡B¥|¤Q»õ¤¸¡C ±Ä³X¨º¤Ñ¡A«K§Q©±«e¥¿¦n¦³¤H¦b¯N¦×¡A¦ü¦b´£«eªï±µ¤¤¬î¸`¡C¶À¤t¬Ý¤F§Ô¤£¦í©IÆ~¡A¨º¨Ç¿fµÛ®a¤H¨p¤U§ë¸êªº±C±C¶ý¶ýÌ¡A¾¨¶q§â¨Æ±¡Åu¶}Á¿¡B¤£n´e¤ß¸Ì¡A¦]¬°¤w¦³¼Æ¦ì¦V¥Lªí¥Ü·Qn»´¥Í¡C ©E¦n³r¬Û³ø ¿Ë¤Í³Q³s²Ö ¦Ü©ó·íªì¡u©E¦n³r¬Û³ø¡v¡BÁܿˤͤ@°_§ë¸êªº¤H¡A¤]¤£n¦]¬°¤H»ÚÃö«Y¥þ·´¤F¡A´N·Q»¡n¥hÉ¿úÁÙ¤H®a¡C³g°ý¬O¤j®an¦@¦P¤À¾áªº³d¥ô¡A¤£n¤@¤H¿W¦ª¡C ¶À¤t¦]¬°³o¨Æ·l¥¢¤F3,800¸U¤¸¡A¨º¨Ç¹ê»Ú¨Ã¥¼¼·¤J¥L¤áÀYªº15¨ì20ÀɤW¥«ÂdªÑ²¼¡A¹³¬O¥ú¸t¡B«Â¼í¡B¥úÄ£¡B¤»¨¤¡B¯E¹©¡BF-±d¤Í¡BF-¤j¦a¡BF-¦Ê¹F¡B·~¦¨µ¥µ¥¡A³Ì«á¦¨¤F¥|Ó¦r¡G±ýúµL²\¡C 2013¦~4¤ë¡A¶À¤t¦b¿Ë¤Í¤¶²Ð¤U¡A¥[¤J¸U¨Æ¹F§ë¸ê¤½¥qªº¸ß»ù°éÁʦæ¦C¡C·~°Èû¸ò¥L»¡¡A¥xÆW¥ø·~¤W¥«Âdµo¦æ·sªÑ¡A³ßÅw¥Î¸ß»ù°éÁÊ¡A¦]¬°¤£¬O¥Î©âÅÒªº¡A½Ö¯à¶R¨ìªÑ²¼¡A¥Ñ©Ó¾Pªº¨é°Ó¨M©w¡C¸U¨Æ¹F¦³¨}¦nÃö«Y¡A¥i¦b¸ß°é¤¤³Ó¥X¡C ¾i®M±þ¤â¬q ¥Á²³Ãø©Û¬[ ¶À¤t©ó¬O®³¥X400¸U¤¸µ¹¸U¨Æ¹F¡A°Ñ»P«H÷~¬ì§Þªº¤WÂd¼Wµo·sªÑ»{ÁÊ¡A¸U¨Æ¹F´£¨Ñ¨âºØ§ë¸ê¼Ò¦¡¡A¨ä¤¤¤@ºØºÙ¬°«O¥»«O®§¡AÂ\º¡66Ó¥æ©ö¤é«á¡A¥i¦³10%³ø¹S¡F¥t¤@ºØºÙ¬°¤À¦¨¡A¥X°â«H÷~ªº¸ê¥»§Q±o¡A¶À¤t¥i¤À¨ì32%¡B¸U¨Æ¹F¤À¨ì68%¡C¶À¤tªì¸Õ¨¤â¡A¦U¦Û§ë¤F200¸U¤¸¡A®É¶¡¨ì¤F©Î½æ¥XªÑ²¼¤F¡A¸êª÷ªº½T³£¦³¶×¤J¶À¤tªº»È¦æ±b¤á¡C ¬°¤F³Ð³y½Æ§Q®ÄªG¡A¶À¤t§â§ë¸ê«H÷~ÁȨ쪺¿ú¡A³s¥»±a§Q¤Sºu¤J¤U¤@ÀÉ¡A2013¦~9¤ë¬O¤j¦¿¥ÍÂå¡A250¸U¤¸¡F¦P¦~12¤ë©³¬O½n³Ð³nÅé¡A500¸U¤¸¡A¨â¦~¦h¤U¨Ó¡A¦Xp§ë¤J¥»ª÷2,000¸U¤¸¡A¥[¤W±q¸U¨Æ¹FÁȨú¡B¦A§ë¤Jªº1,800¸U¤¸¡A¤@¦@3,800¸U¤¸¡C ¤µ¦~6¤ë18¤é¡A¸U¨Æ¹FµL¹wĵºM¾P¦b¸gÀÙ³¡°Ó·~¥qªºÀç·~µn°O¡A³s·~°Èû³£»¡¤£ª¾¥D¿Ñ¬O½Ö¡C ¶À¤t»¡¡A§ë¸ê¤½¥qªº¤âªk¥i¥H¾i®M±þ§Î®e¡A¥ý¬O¥Î¥»®§¦p´Á¼·¥Iªº¾i¡A¨ú«H©ó¤H¡F±µµÛÀWÁc±À¥X·sªÑ»{ÁÊ¡A®M¯Ñ¥Á²³¸êª÷¡B¶Vºu¶V¤j¡F³Ì«á¦A¥H¤H¥h¼ÓªÅ¡A±þ´²¤áÓ±¹¤â¤£¤Î¡C |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/9/30 ¤W¤È 11:15:42²Ä 2038 ½g¦^À³
|
¥xÁÞ¤j¡A±z»¡±o¯u¬O¤Ó´Î¤F ÁöµM«á¦³°l§L¡A¦ý¹jµÛ¥§Ã¹ªe¦³¥û²rªºÆs³½¡A¤@®É¥b¨è°l§L¨ì¤£¤F©¼©¤ µ¥¨ì°l§L¹L¤F©¼©¤¡A822¤w¸gª¦¨ì¦N§Q°¨¥¾Ã¹¤sµn³»·Ç³Æ¤U¤s¡A833¤]¤w¸g±µ´Î¦b¤s¸}¤Un±µµÛµn¤s nª`·NªÑ»ù¾ã²z¤§«á©¹©¹±µµÛ ¥Í§ÞÃþªÑµu¼È¥ð®§«á¡A25¤é¶R½L¤S«·s´é²{¡A¨ä¤¤¥Í§ÞªÑ¤ý¯E¹©¡]4174¡^¦¬½L382.5¤¸¡A§ó¬O³Ð¤U¤WÂd¥H¨Ó¦¬½L·s°ª¡A±a°ÊÂd¶R«ü¼Æ©¹¤W§ð°ª¡A§Y«K¥Í§ÞªÑ¤w¸g¤Ï¼u¤@Óªi¬q¡A¥Ø«eªk¤H¤´µM¬Ý¦h¡C Âd¶R«ü¼Æ25¤é½L¤¤¤@«×½¶Â¡A©Ò©¯¤¤³õ¹L«á¶R½L¤S¶i³õ©Ô©ï¡A¤¤³õÂd¶R«ü¼Æ¦¬116.76ÂI¤Wº¦1.14¢H¡C¨ä¤¤¡A¥Í§ÞÃþªÑ«ü¼Æ¦bÄ_ÄÖ¤½§iµÇŦ·sÃÄNephoxil¡]®³¦ÊÁC¡^¦p¹w´Á¨ú±o¼Ú·ù·sÃĤW¥«³\¥i¤§«á«°_º¦¶Õ¡AÃþªÑ«ü¼Æ¤Wº¦2.99¢H¡A¬O25¤éÂd¶R¥«³õº¦¶Õ³Ì±jªºÃþªÑ¡C ¤¸¤j§ëÅU¤ÀªR®v§õ¯\µ×ªí¥Ü¡A¤¸¤j¹ï©ó¥Í§ÞªÑªºªí²{¤´µM«ùÄò¬Ý¦h¡A¥Dnì¦]¬O¥Í§ÞªÑ¦b¹L¥h¤@¦~¤U¶^52¢H¡A§Y«Kªñ´Á¦³©Ò¤Ï¼u¡A¥Ø«e¤´µM³B©ó¬Û¹ï§C¾×¡A¥B¥Í§ÞªÑ¤§¤¤°£¤F°ò¨È¸Ñª¼µ²ªG¤£¦p¹w´Á¡A¨ä¥L¤½¥q¹³¬O´¼Àº¡]4162¡^¡B¯E¹©¡]4174¡^¡B¤¤¸Î¡]4147¡^¡BÄ_ÄÖ¡]1760¡^³£¨Ì·Ó¶i«×«ùÄò©¹«e¨«¡A³o¨Ç¦¨ÁZ¦³§U©ó¥Í§ÞªÑ²æÂ÷°ò¨È¸Ñª¼§QªÅªº³±Åµ¡C ¥xÆW¤u»È§ëÅU¸ê²`¸g²z¹ù©÷«G»¡¡A25¤é·sÃĪѤý¯E¹©°_º¦¡A±a°Ê¨ä¥L·sÃĪѤ¤¸Î¡B´¼Àº¦P¨B¤Wº¦¡A¨ä¤¤¯E¹©ªÑ»ù¦¬½L382.5¤¸¡A³Ð¤U±¾µP¥H¨Ó¦¬½L·s°ª¡A±N¬D¾Ô½L¤¤©Ò³Ðªº387¤¸°ªÂI¡C¥L»¡¡A¯E¹©3¤ë23¤é¤WÂd®ÉÃz¥X2.7¸U±iªº¤j¶q¡AÄw½X¤j¶q´«¤â¡A²{¦b»ù®æ¶V¹L·í®Éªº´«¤â°Ï¡A¥NªíÄw½X¤w¸g«·s¾ã²z§¹²¦¡Aµu½u¶R½L¥X³õ¡Aªø½u¶R½L¶i¾n¡A¹ïªÑ»ù¥¼¨Óªí²{¦³À°§U¡C(¤u°Ó®É³ø) |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/30 ¤W¤È 06:58:22²Ä 2037 ½g¦^À³
|
·q¨Ø¥xÁÞ¤jªº¬ã¨s¥\¤Ò §ó·q¨Ø±z¤£Âèp ¼Ö©ó¤À¨Éªººë¯« |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2015/9/30 ¤W¤È 12:38:47²Ä 2036 ½g¦^À³
|
¥xÁÞ¤j, «D±`·PÁ±z¶O¤ß¶O®É¦a¾ã²z¥X¸Ô²Óªº¸ê®Æ, ¨ü¯q¨}¦h! |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2015/9/29 ¤U¤È 11:42:57²Ä 2035 ½g¦^À³
|
¥xÁÞ¤j~~ ·PÁ±z¦p¦¹¸Ô²Óªº¸ê®Æ§e²{,Åý©Ò¦³¯E¤Í¦b«ù¦³¯E¹©ªº¸ô¤W¯à°÷§ó½ñ¹ê¡C ÁÂÁ±z |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/29 ¤U¤È 10:18:08²Ä 2034 ½g¦^À³
|
¦U¦ì¤j¤j 1Àù¯g¬ãµo¬O¤@Ó¥þ²yÄvª§ªººA¶Õ ,ÁA¸ÑÄvª§¹ï¤âªº¹ê¤O°ò¥»¤W¬O¥¿½Tªº¤è¦V ,Cliff¤j¦b¥t¤@ª©´£¨ìªº°l§L,Ó¤H»{¬°ªº½T»Ýn°lÂÜÃö¤ß,¤£¹L¤j®a¤]¤£»Ý¹L«×¾á¼~ ¦]¬°¹ï¤âÁÙ¦bpre-clinical Á{§É«eªº°Êª«¹êÅç ,n¶i¤JÁ{§É1 2 3 ´Á¨ì®³¨ìÃÄÃÒ¤Ö«h 10¦~©Î10¦~¥H¤W.¨ÅÀùOBI822¤w¶i¤J¸Ñª¼¼Æ¾Ú¤½§iªºË¼Æ¶¥¬q, ¥¢±Ñ¾÷²v´î§C«Ü¦h ¦¨¥\¾÷²v¼W¥[«Ü¤j 2 IgM ªºÀù²ÓM¬r±þ§@¥Î¡A²ºÙCDC ,IgG¬°¥Dªº¬r±þ§@¥ÎºÙ¬°ADCC ¤@¯ëÁÞ§Üì ¦]¬°§K¬Ìì©ÊImmunogenicity ®z¡A³y¦¨»¤µo«DT²ÓM¨Ì¿à«¬ªºIgM¦h¤@ÂI »¤µoT²ÓM¨Ì¿à«¬ªºIgG¤Ö¤@ÂI (¨Ã«D§¹¥þ¨S¦³) ±q¥x¥_°¨°ºÂå°|¤wµoªí§Z±_Àù¤G´ÁÁ{§É33¦ì¨ü¸ÕÁ{§ÉÆ[¬d¼Æ¾Ú 2014 11 GLOBO H-BASED IMMUNOTHERAPY IN TREATING OVARIAN CANCER ¦b°lÂܪº33¦ì¯f¤H¤¤¡A°lÂܤ¤¦ì¼Æ4Ó¤ë¡A¦b±µ¨ü¦Ü¤Ö¥|¾¯ªº±wªÌ¤¤¡A ¦³29¦ìÅ餺IgM ¿@«×¤W¤É88% ¦³14¦ìÅ餺IgG ¿@«×¤W¤É43%(¦³Æ[¹î¨ì43%»¤µoT²ÓM¨Ì¿à«¬ªºIgG) (¤£¬O§¹¥þ¨S¦³IgG) °£¤F¦³¤@¨Ç§C·Åªºµo¿N»P§½³¡ªº¥Ö½§¬õ¸~¤§¥~¡A¨S¦³«¤jªº°Æ§@¥Î¡C http://igcs.meetingexpert.net/igcs_300/poster_109574/program.aspx 3¨ÅÀùOBI822 ¦³¥[ low dose cyclophosphamide ¥H´£°ª§K¬Ì¤ÏÀ³ §ïµ½Âಾ©Ê¨ÅÀù¯f¤H Á{§Éµ²ªG,±q¤@´ÁÁ{§É¥O¤H¦L¶H²`¨èªºÀø®Ä¨ì¶i¤J2/3 ´ÁÁ{§É³o´X¦~¤¤¯E¹©ªº¬ãµo¤Hû»P ¦X§@Âå°|¬ãµo¤Hû¤]·|¤£Â_¶i¦æ¬ã¨s§ï¶i,´M§ä§ó¦nªº¸üÅé³J¥Õ»P¦õ¾¯,¦óªp¨ÅÀùOBI822 ³oÓÃĦ³Äè·À¨ÅÀù·F²Ó,¸Ñ°£ Global H Ceramide¹ïT²ÓMB²ÓMªº§K¬Ì§í¨î, §í¨îÀù²ÓM¦åºÞ¼W¥Í ³o¤T¤è±ªºªº¼ç¤O,¥t¥~¹ïGlobo H SSEA3 SSEA4¨ã±M¤@©Ê,¤£¶Ë®`¥¿±`²ÓM 4²Ä¤@¥Nªº¬Ì]GloboH KLH/QS21¡A²£¥ÍªºIgM ªº½T¤ñIgG¦h¡C¤µ¦~6¤ë3¤éªÑªF·| §E³Õ¤h´£¨ì T Cell¬O§K¬Ì¨t²Î³Ì¥Dnªº¬r±þ§@¥Î¡A¥i¬OB Cell¤]¬O¬Û·í«n¡A ¬Ì]¬I¥´¤§«á¤ÞµoªºB Cell·|ºCºCÂà´«¦¨T Cell¨Ó¬r±þÀù²ÓM¡A ¥Ø«eªì¨Bªº¼Æ¾Ú¤w¸gµo²{¨âªÌ¦³ÃöÁp¡C 5²Ä¤G¥Nªº¬Ì]Globo H-CRM197/QS21 ÁÞ¤À¤l·sÃÄOBI833 ¡AÀ³¸Ó¨S¦³IgG¸û¤Öªº°ÝÃD ²Ä¤G¥Nªº¬Ì]±N¨Ï¥Î¦b¹w¨¾»PªvÀø¤W ¦³§O©ó²Ä¤@¥Nªº¬Ì]¥u¨Ï¥Î¦bªvÀø¤W,¦]·|¶¡¹jªº¬I¥´,IgG¸û¤Öªº¼vÅT¤£¤j ²Ä¤G¥Nªº¬Ì]¨Ï¥Î¦b¹w¨¾¤W´N»Ýn¦³ªø´Á°O¾ÐIgG§ÜÅé(¹w¨¾©Ê¬Ì]±j½Õªø´Á°O¾ÐIgG§ÜÅé) 6¯E¹©¥¿¦bµû¦ô»P¤¤¬ã°|Ä~Äò¦X§@²Ä¤T¥N²£«~¡A²Ä¤T¥N¬Ì]¥¿¥Ñ¤¤¬ã°|¶}µo¤¤¡A ³oÓ²£«~¦b»s³y§ÜÅé¤Wªº¯à¤O§ó±j¡C¤¤¬ã°|¹Î¶¤§â³Ì·s¤@¥N²£«~ªº§Üì§ó´«¡A ·s¤@¥Nªº§ÜìÀÀ¦üÁÞ§Üì¦ý¤ñÁÞ§ÜìÁÙ±j¡A¥iÅý§ÜÅé¹ïÀù²ÓMªº§ðÀ»§ó±Ó·P¡C (¥Ø«eÁÙ¦bµ¥«Ý±ÂÅvñ¬ù¤½§i) 7 2014¦~ 4¤ë¥xÆW¯E¹©¥Í§Þ»P¤¤¬ã°|ñ¸pÁÞ¤À¤l¦X¦¨§Þ³N±MÄݱÂÅv,³oºØ»sÁÞ¤èªk ¬ð¯}¶q²£§Þ³N²~ÀV,¤j³W¼Ò»Ã¯ÀÁÞ¦X¦¨ªk 4Ó¦X¦¨¨BÆJÅý¶q²£Åܦ¨¥i¯à , ¦pªG¨S¦³³o¶µ§Þ³N¶i¦æÁÞ¤À¤l¦X¦¨¤£¬O±Á{«IÅv´N¬O¦X¦¨¦¨¥»¤Ó°ªµLªk¤j³W¼Ò¶q²£ 8¥xÆW¯E¹©¥Í§Þ¾Ö¦³¦h§â©|¤èÄ_¼C--- ±j¦Ó¦³¤OªºIP ,Pipeline ¦h¤¸, Global Series highly expressed on many tumors (up to 90%), ´£¨ÑÀù¯g¯f¤H»P®aÄݦnªº¥Í¬¡«~½è»P·ÓÅUªº¤è«K©Ê, º¡¨¬¥¼³Qº¡¨¬ªºÂåÀø»Ýn ¤¤ªø´Á¥Ø¼Ð¦¨¬°¥þ²yÀù¯g§K¬ÌÀøªkªº»â¾ÉªÌ 9 ¥¼¨Ó³W¹º¬ãµo+¥¿¥Ó½Ð¬ãµo¤¤+¤w¬ãµoªº¾AÀ³¯g¤w¹F13ºØÀù¯g a OBI822¤w¬ãµoÀù¯g:¨ÅÀù §Z±_Àù »P¯Ø¸¢Àù(¤w³W¹º¤¤) b OBI833¦V¬ü°ê¥Ó½Ð¥|ºØÀù¯g Âಾ©Ê( ªÍÀù ¤j¸zÀù GÀù ¨ÅÀù) ¬ü°ê¤w®ÖãÁ{§É ¥xÆW®ÖãªÍÀù»P¨ÅÀù (¦bµ¥¥x¤jÂIÀY) ¬ü°ê°µªº¾AÀ³¯g»P¥xÆW°µªº¾AÀ³¯gÀ³¸Ó¤£·|«Å| ¨ÅÀùOBI822¥ý¶}½æ¦A»¡ ,¥H«á¹J¨ì°l§L,¨ÅÀùOBI833³o§â©|¤èÄ_¼C´N·| ¶i¦æ¤G´ÁÁ{§É,Åý¯E¹©¨ÅÀùÃľ֦³³Ì°ªªºÄvª§¤O,¦óªp¨ÅÀùOBI822ÁÙ¥iµ¦²¤ ±Ä¨úÁp¦X¥ÎÃÄ c¥¼¨Ó¬ãµoªº·s¾AÀ³¯g(¨xÀù ¸£Àù ¤l®cÀVÀù ¤fµÄÀù µÇŦÀù ¹¹DÀù) ¥H¤W¸ê°T´£¨Ñ°Ñ¦Ò ¦p¦³¿ù»~½Ð§ó¥¿ |
|
|
·|û¡G¥¤ß¦Ó½×10139639 µoªí®É¶¡:2015/9/26 ¤U¤È 06:51:24²Ä 2033 ½g¦^À³
|
¬Q¤Ñ§Ú¹Ú¨ì´XӦѥ~±aµÛ382¤½§Jªº¶Àª÷¯ºCCªº¨Ó§Ú®a¡A¸ò§Ú»¡³o¨Ç¶Àª÷n¸ò§Ú´«822ÓÅÚ¤RÀY(Globo Head)¡A§Ú»¡³oÓÈ3¤½¤ç¶Àª÷¤£n´«¡A¦]¬°¤@Ó¥Õ¾v½G¤l»¡¹L¡A¥LÌ´N«Ü¥¢±æªºÂ÷¶}¡AµM«á§Ú´N¿ô¤F |
|
|
·|û¡G¥¤ß¦Ó½×10139639 µoªí®É¶¡:2015/9/26 ¤W¤È 08:23:35²Ä 2032 ½g¦^À³
|
¥¤ß¦Ó½×¡A²{¦b382©TµMÁÙ¤£¿ù¡A¥i§Ú400¥H¤W¶Rªº¤´¥¼¸Ñ®M¡A©Ò¥H¤£¥²¤Ó°ª¿³¡A¥xÆW¤H³£«Ü°·§Ñ¡AªL©^ªïÂA¨Å¦^¨ì¥«¥e²Ä¤G¡A¥Nªí³\¦h¥xÆW¤Hì½Ì¹©ªY ¯E¹©Y10¤ë±i¨ì455n½æ¶Ü¡H·|¤£·|¤S®M¤@¦¸ ¥u¯à»¡³o¦¸¯uªº¤£¦P¡A¦]¬°¸Ñª¼®É¾÷¤£·|ÄF¤H§a ·í¯E¹©1000¤¸¡A´CÅé·|³ø¾É¬°¦óÈ1000¤¸¡A3000¤¸¤]¬O¤@¼Ë¡A´N¹³¤j§Q¥ú¨ì3500«Ü¥¿±`¡AÀY¸ê¤H¤]·|²ßºD¤F¯E¹©3000¤¸¤@¼Ë¡AµM«á«Ü·F»¡¦Û¤v¬°¦ó300¡B400¤£¶R¡A¬Æ¦ÜÁٽ汼 ·íªì¥H¬°½æ¹ï¡AµL©`ªÑ»ù¨g¸¡A½æ±¼´NÃø°l¦^¡A©Î³\¥u¯à«á®¬¡A©¹¨Æ¥u¯à¦^¨ý¡A±æªÑ·t¦Û««²\¡I |
|
|
·|û¡G²´10000155 µoªí®É¶¡:2015/9/25 ¤U¤È 01:43:46²Ä 2031 ½g¦^À³
|
http://owenlin.pixnet.net/blog/post/45238064 ¨Ó·½¦b¤W¦Cªººô¶¤¤ ¨ä¤¤¤@¬qÀ³¸Ó¥i¸ÑÄÀ³Ìªñªº¥~¸ê§@ªk§a ¦Ü©ó¥~¸ê¬°¦óÁÙ¨S¶ix¥xÆW§ë¸ê¥Í§ÞªÑ?§Úı±o¬O¦]¬°±M·~¥~¸ê·|¶R¦bÃöÁäÂà§éÂI(inflection point)¡A¥H¬ü°ê¥«³õ¬°¨Ò¡AY¦³¤½¥q²£«~¶}µo¦¨¥\¡A©Î³\ªÑ»ù¤w¤jº¦¤T¦¨¦Ü¤C¦¨¡A¦ý¥~¸ê¦¹®É¤~·|¶i¨Ó¶R¡A¦]¬°«á±¥i¯àÁÙ·|¦Aº¦¤T¦Ü¥|¿¡A¥L̪º§ë¸êµ¦²¤¬Û·í·V«¡A¨S¥²n¥h·mµu½u¡C ÁÂ~~~ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/25 ¤U¤È 01:39:53²Ä 2030 ½g¦^À³
|
¥~¸ê»¡:³o¬O·m§T §â¿ú®³¨« ªÑ²¼¯d¤U |
|
|
·|û¡G¤p³¯10000133 µoªí®É¶¡:2015/9/25 ¤U¤È 01:32:48²Ä 2029 ½g¦^À³
|
·PÁÂ¥xÁÞ¤j¤j¤£§[¶Þ¤À¨É³o»òºëÅPªº¨£¸Ñ!! |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/9/25 ¤U¤È 01:19:20²Ä 2028 ½g¦^À³
|
¯uªº§ÖÀ~¦º¤F...³o¤£¬O·m§T¤°»ò¥s·m§T¡AÃø¹D¥H¬°¬O¦bªx¦à¶Ü?? èPO¤å¤~362,¤@¤U¤l¦£§¹©~µM¤w¸g380...¯uªº¹³¯E§J¤j»¡ªº¬~Äw½X¬~¥X¥hµM«á"³Q¥~¸ê·m§T" 380...¥i¯à¤]³Q¥~¸ê»{¬°¬O"®Ú³¡"©Ò¥H¥f°_¨Ó¶R¡A¦U®a¥~¸ê²`©È¨ì®ÉÔ¦¨¬°"·sªº¥xÆW¤§¥ú"¯Ê®uªÌ¶Ü? |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/9/25 ¤W¤È 10:22:27²Ä 2027 ½g¦^À³
|
¥xÁÞ¤j¡A ±z»¡ªº¯u¦n¡Aµ¹§A«ö¤@ÓÆg ¦pªG¯uªº®`©È¾á¤ßªº¸Ü´N»°ºò¥X²æ§K±o¨üÅå¡A¦³ÁÈ´N¶]¡A®¥³ß¤F ¬°¦ónÅó±ø±ø? ´X¶µ«ÂI 1.¬°¦ó¥Í§ÞªÑ¤j¶^¥u¦³¯E¹©¶^´T³Ì¤p¡A255/450=56%¶^44%, ¨ä¥L¥x·LÅé/´¼Àº/¦w¦¨ÃÄ/ÁÞÁp...þ¤ä³£¶W¹L50%,¬Æ¦Ü80% 2.þ¤ä¥~¸ê¦b¶R? ¦Ó¥B¶V¶R¶V²n¡A¶V¶R¶V¦h 3.þ¤ä¬O³Ì¦³¥i¯à¦¨¥\ªº«½S¯Å¤jÃÄ 4.þ¤ä¬O§Y±NÁ{§É¥½n¤½§G¸ÕÅçµ²ªG? 5.þ¤äÁ{§É¤@´Áµ²ªG¦n¨ìÅå¤H? ....©Ò¥H¯uªº¤£n¶Ì¶Ìªº¦Û§@Áo©úÁȵu½u¡A¥¼¨Ó·|ªá§ó¦h¿ú°l¦^... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/25 ¤W¤È 07:41:41²Ä 2026 ½g¦^À³
|
¦U¦ì¤j¤j 2015¦~9¤ë23¤éªk»¡·|²³øºõn,(µo²{¨C¶³£È±o¤@Ū¦AŪ¥H§Ö³t´x´¤¥xÆW¯E¹©ªº®Ö¤ßÄvª§¤O) ¥H¥xÆW³»¦y¥Íª«»sÃĤ½¥q¦Û³\´Á³\¦¨¬°¥þ²yÀù¯g§K¬ÌÀøªkªº»â¾ÉªÌ ¨ã°ê»Úµø³¥ªº»â¾É¤H ¸gÅçÂרKªº¬ãµo¹Î¶¤ ¸gÅçÂרKªº¸gÀç¹Î¶¤ ÁÞ¤À¤l¶}±Ò»sÃĪº·s®É¥N (¯f¤H²Õ´¤Á¤ù: SSEA-4 90% Globo H 60%-80% SSEA3 60%) ²{¦³¨ÅÀù¥Íª«¼Ð»xª«(Biomarkers)ªº¤À°t¤ñ¨Ò GloboSeries 60~80% ªñ¦~Âå¾Ç³Ì¤j¬ð¯}¡VÀù¯g§K¬ÌÀøªk aÀù¯gªvÀøªº²©R: §Q¥Î¤HÅé§K¬Ì¨t²Î¥h§ðÀ»Àù ³Ì¨Î§ÜÀù®ÄªG¡A¥i©µªøªvÀø®Ä¤O b¬ì¾Ç¬É¬°¤§¾_¾Ù :¬ì¾ÇÂø»x2013¦~«×³Ð·s¬ì§Þ ð¼ú¥Í§Þ¼ú¡X§ÜÀù§K¬ÌªvÀø c·~¬É°ª«×´Á«Ý:ªáºX»È¦æ¹w´ú±N¦¨¬°¥v¤W³ÌºZ¾PÃĪ«2023¦~³æ¦~¾P°âÃB±N¶W¹L¤Q¥ü¥x¹ô §K¬ÌÀøªk¬O¥¼¨ÓªºÀù¯gªvÀøªº¥D¬y US$ >350»õ by 2023 ¯E¹©²£«~½u¬ãµo¶i«× pipeline OBI-822/821 ²¤¶·s«¬§K¬Ì¸~½FÀøªk OBI-822/821 Á{§É¤@´Á¸ÕÅçµ²ªG(¥O¤H¦L¶H²`¨èªºÀø®Ä©M¦w¥þ©ÊÃÒ©ú) OBI-822¨ã³ÆBlockbuster ªº¼ç¤O OBI-822/821Àu¶Vªº³Ð·sÀøªk aº³ÐÃĪ« bÁ{§É¤@´Á¤ÏÀ³¨}¦n c ±M¤@©Ê¤£¶Ë¥¿±`²ÓM d¨}¦n¥Í¬¡«~½è ±M§Q»sÁÞ§Þ³N¬ð¯}¶q²£§Þ³N²~ÀV ¤j³W¼Ò»Ã¯ÀÁÞ¦X¦¨ªk 4Ó¦X¦¨¨BÆJÅý¶q²£Åܦ¨¥i¯à Summary: OBI-822 Innovative Immuno-Oncology Therapy Fulfills high unmet medical and market needs Global Series highly expressed on many tumors (up to 90%) Impressive Phase I Safety & Efficacy results demonstrated Better Quality of Life for Cancer patients & family Strong IP protection Carbohydrate synthesis technology:OPopSTM& Enzymatic Synthesis Enrollment completed for a multinational P2/3 MBC Study (topline est. 1H 2016) §Ö³t¦¨ªøªº§ÜÀùÃĪ«¾P°â¶q ³»¯Å«~µPÀù¯gÃĪ«2013¦~¾P°âª÷ÃB (2013 Roche ¥]¤U¥þ²yªvÀùÃĪ««e¤T¦W ¹F208»õ¬ü¤¸) »Ý¦³®Ä¤S¦w¥þªºªvÀùÃĪ« ¯E¹©¸gÀç¼Ò¦¡ a½T«OÀç¹B¸êª÷¥R¨¬µL¸· bµ¦²¤©Ê¶}µo¼ç¤O¶¯«p·s¥«³õ c´M¨Dµ¦²¤¦X§@¹Ù¦ñ dݨ֦¬ÁÊ ¯E¹©¤¤ªøµ{¥Ø¼Ð(by 2035)¥þ²yÀù¯gªvÀø»â¾ÉªÌ ¯E¹©Ä@´º ³Ð³y¥xÆW¥Í§Þ«~µP¡B¦¨¬°Àù¯gÀøªkªº¥þ²y»â¯èªÌ Ó¤Hµû»ù: ³o»ò¦³Ävª§¤Oªº¥Í§Þ¤½¥q¬°¦ó¤£ªø´Á«ù¦³? ¦³¤@¤Ñ·í¤@ªÑÃø¨Dªº¨Æ¥óµo¥Í®É §An¥Î¦h¤Ö¥N»ù¥h¶R¦^´¿¸g¾Ö¦³ªºªÑ¼Æ ? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/24 ¤U¤È 11:18:57²Ä 2025 ½g¦^À³
|
Faith¤j OBI822¤w¬ãµo¨ÅÀù §Z±_Àù »P¯Ø¸¢Àù(³W¹º¤¤) OBI833¦V¬ü°ê¥Ó½Ð¥|ºØÀù¯g Âಾ©Ê( ªÍÀù ¤j¸zÀù GÀù ¨ÅÀù) 4ºØ³£·|°µ ¬ü°ê°µªº»P¥xÆWÀ³¸Ó¤£·|«Å| ¥¼¨Óªº·s¾AÀ³¯g¬O«ü¥¼¨Ó·|³°Äò³W¹ºªº¬ãµoÀù¯g(¨xÀù ¸£Àù ¤l®cÀVÀù ¤fµÄÀù µÇŦÀù ¹¹DÀù) ¦Xp¤w¦³13ºØ ÁÙ¤£°÷¦h¶Ü? ¦æ¾P¦X§@±ÂÅv«á¥Ñ©ó¤jªº¥Í§Þ¤½¥q¸êª÷¶¯«p ,¦b¬ãµo¶O¥Î½Í§´«á¹w´Á·|¥[§Ö¸}¨BÂX¤j¾AÀ³¯gªº¬ãµo 3¤ëªk»¡¨S´£¨ì³o¦¸ªk»¡¦³´£¨ìn¯S§Oª`·N ²³ø²Ä11¶´£¨ì ¥Ø«e¥þ²y°ß¤@¶}µoGlobo SeriesÁÞ§ÜÅé¶i¤J¤¤±ß´Á¶¥¬qªº¥Í§Þ¤½¥q ²³ø²Ä23¶´£¨ì OBI-822¨ã³Æ Blockbuster ªº¼ç¤O(¦~¾P°â10»õ¬ü¤¸¥H¤W) ³z¹L 1³æÃĪvÀø Monotherapy 2Áp¦X¥ÎÃĪvÀøCombination Therapies A ¥Ø«e¨Ï¥Î¤¤ªºªvÀø Current Therapy: Hormone therapy, Chemotherapy, etc. B ·s¿³ªvÀøEmerging Therapy: Checkpoint inhibitors PD-1, CTLA-4, etc. 3 Maintenance Therapy 4 Theranostic Approach ¤j³¡¥÷¯E¤Í°í«H¤½¥qªºÄ@´º»P¯à¤O¸gÅç ,¨S¦³¤Hª¾¹D©ú¤Ñ·|µo¥Í¤°»ò«¤j§Q¦h,¥u¯àªø©ê¯E¹© ¦u®è«Ý¨ß,µLªk°ª¥X§C¶iÁÈ®t»ù,¦]¬°¨º¬O°ª¤â¤¤ªº°ª¤â,¥xÆWªÑ¥«¾ú¥v¸gÅç§i¶D§ÚÌ ¹ï¦³¼ç¤Oªº¦n¤½¥qªø½u§ë¸ê·|Áȳ̦h |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/9/24 ¤U¤È 02:57:46²Ä 2024 ½g¦^À³
|
¯E¹©ªk»¡·|²³øP29, RocheÀù¯g¤T¤jÃÄRituxan, Avastin, Herceptin 2013¦U75,67,66»õ¬ü¤¸¾P°âÃB¡A¦Xp¶W¹L200»õ¬ü¤¸ªº¦~À禬 Herceptin(¶PÀù¥)¥ý«e³\¦h¤j¤j¤w¦³¬ã¨s¡A¤£¦AÂØz ¦Ü©óRituxan, Avastin, ¥i¥H¬Ý¨ì¹êÅç²Õ¹ï·Ó²ÕM PFS®t²§¡A³sHerceptin¦b¤º¥i¥H»¡³o¨Ç³£¤£¬O¥P¤¦¡A¦ý¤w¸g¬O³yºÖ¤£¤Ö¤H¸s¥B½æ¨ìÃzªº³»¯ÅÀùÃÄ¡A³o¤]´N¬O§ÚÌ»{¬°¥un¹ï·Ó²Õ¦p¤½¥q»¡ªº¦b4~6¤ë¡A¦Ó822 M PFS¥un¤j©ó15,¬Û«H´N¦³·¥¤j¼ç¤O»P³o¤TÓÃĤñ«÷ ¥ý«e¦³¤j¤j»¡·|¤£·|ù¤ó·Qn¶R822, YÁ{§Éµ²ªG¤£¿ù¡A³o¬O«Ü¦³¥i¯à¡A¦]¬°Y¶PÀù¥+¶P¤Î§´+822,¹ïHer 2+±wªÌ§ó¦³§Q¡A¥t¥~«DHER2+±wªÌ¤]¾A¥Î¡A¤Ï¦Ón¬Ý¤½¥q·Q¤£·Q½æ¡An¤£n½æ? ¥úµ¦²¤Áp·ùª÷¹ï©ó¥u¦³17»õªÑ¥»ªº¯E¹©´N·|À~¦º¤H¡A¦pªG³¡¤À¦a°Ï(¬ü/¤j¤¤µØ°Ï)¥i¥H¶¶§Q¦Û¤v½æ¡A§ó¬OµLªk¦ôp¼ç¤O¡C³o¨â¤Ñ·í§@¬~½Lªº²f·Ò¡A250´N¨S¦b©È¤F¡A370´NÄò©ênÁקK³Q¬~±¼(¾á¤ß¶}½L¶}°ª¸É¤£¦^¨Ó) Rituxan(§Q§´©õ,²ö¶·½F):¬O¤@ºØ§K¬Ì§í¨î¥ÎÃÄ¡A¥DnÂǥѰ§CÅ餺ªºB²O¤Ú²y¼Æ¶q¥H¹F¨ìªvÀø«DÀN©_ª÷¤ó²O¤Ú½F©MÃþ··Ã©ÊÃö¸`ª¢ªº®ÄªG¡A¦ý±µ¨üªvÀøªº¯f±w¦P®É¤]·|¦]§K¬Ì¤O§C¤U¦Ó®e©ö¾D¨ü·P¬V¡C2006¦~12¤ë¡AFDA¤]´¿¬°¤F¤G¦W¦]±µ¨üRituxanªvÀø¾ÉP¿©±wPML¦ÓP¦ºªº¥þ¨©Ê¬õ´³©Ê¯T½H(Systemic Lupus Erythromatous, SLE)¯f±w¡Aµo§G¨Ï¥ÎRituxanªºÄµ§i°T®§¡C¥Ø«e¡A½Ã¥Í¸p»PFDA§¡¤´¥¼®ÖãRituxan¨Ï¥Î©óªvÀø¥þ¨©Ê¬õ´³©Ê¯T½H©Î¦hµo©Êµw¤Æ¯g(Multiple Sclerosis, MS)µ¥¦ÛÅé§K¬Ì¯e¯f(Autoimmune disease)ªº¥Î³~¡Chttp://www.hbmsp.sipa.gov.tw:9090/itri/tw/images/Risk6_1.htm ²ö¶·½F¬OB²ÓM«D¦óªNª÷¤ó²O¤Ú½FªºªvÀø¤W³Ì¨ã¬ð¯}©Êªºµo®i¡C¹ï©ó´_µo©Ê©Î¹ï¤Æ¾ÇÀøªk¦³§ÜÃĩʤ§§C´c©ÊªºB²ÓM«D¦óªNª÷¤ó²O¤Ú½F¡A³æ¿W¨Ï¥Î²ö¶·½F¥i¹F50%§¹¥þ½w¸Ñ²v(§¹¥þªv¡)¡A¦Ó87%ªº¯f±w¸~½F«h¦³©úÅ㪺ÁY¤p¡C§Y¨Ï¦A¦¸´_µo¡A¥H²ö¶·½F¦AªvÀøªº®ÄªG¤]¦³40%¡C ¬ü°ê¹«~ÃĪ«ºÞ²z§½¥ç®Öã²ö¶·½F¥i¥Î©óªvÀøÃþ·Àã©ÊÃö¸`ª¢¡Cì¦]¦b©óP¯f©ÊB²O¤Ú²ÓM°Ñ»PÃþ·Àã©ÊÃö¸`ª¢ªºP¯f¹Lµ{ªº«n©Ê¡A¦Ó²ö¶·½F¥i´î¤Ö³oÃþ²ÓMªº¼Æ¶q¡C https://zh.wikipedia.org/wiki/%E5%88%A9%E5%A6%A5%E6%98%94%E5%96%AE%E6%8A%97 RITUXAN + FC SIGNIFICANTLY IMPROVED PFS IN FIRST-LINE AND PREVIOUSLY TREATED CLL PFS RITUXAN IN COMBINATION WITH FC FOR PREVIOUSLY UNTREATED CLL : M PFS 39.8 VS 31.5 months RITUXAN IN COMBINATION WITH FC FOR PREVIOUSLY TREATED CLL : M PFS 26.7 VS 21.7 months http://www.rituxan.com/hem/hcp/cll Avastin(Àù«ä°±): 1. Avastin(bevacizumab)¬O¤@ºØ«²Õªº¤H¤Æ³æ®è§ÜÅé¡A¥i¿ï¾Ü©Ê¦aµ²¦X¦Ü¤HÃþ¦åºÞ¤º¥Ö¥Íªø¦]¤l(VEGF)¨Ã¤¤©M¨ä¥Íª«¬¡©Ê 2. Avastin·|§í¨îVEGF»P¦ì©ó¤º¥Ö²ÓMªí±¤Wªº¨üÅé Flt-1¤Î KDRµ²¦X¡A¤¤©M VEGF ªº¥Íª«¬¡©Ê¦Ó°§C¸~½Fªº¦åºÞ§Î¦¨¡AÂǦ¹§í¨î¸~½Fªº¥Íªø¡C 3. Bevacizumab (Avastin, Àù«ä°±)¬O¤@ºØanti-VEGFªº³æ®è§ÜÅé¡A§@¥Î¦bÀù¯g²ÓM¹Î¤¤ªº¦åºÞ¡AÅý¦åºÞµäÁY¡A¨Ï±oÀù²ÓM¦b±o¤£¨ì¾i¤Àªº±¡ªp¤U³vº¥¦º¤`¡C http://www2.cch.org.tw/lungcancer/avastin_2.htm Avastin M PFS: 10.2 VS 5.4 months http://www.avastin-hcp.com/indications/mrcc/efficacy-data#avoren_study_results Avastin M OS: 20.3 VS 15.6 months (First-line Study 2107) http://www.avastin-hcp.com/indications/mcrc/efficacy-data#1l_study_2107_results |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/23 ¤W¤È 10:27:38²Ä 2023 ½g¦^À³
|
¯}¤Ñ¯î¡I ½ÃºÖ³¡ÃĨƥqÂå°|µûŲ©eû·|¬Q22¤é³q¹L¡A ±ÄÁÊ°ê²£¥Í§Þ·sÃÄ ±N¦C¤JÂå¾Ç¤¤¤ßµûŲ«ü¼Ð |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/23 ¤W¤È 10:11:18²Ä 2022 ½g¦^À³
|
¯E§J¤j ¼í¶®¾Ö¦³Stellar biotechnologies inc ¤@®u¸³¨Æ ³oºØµ¦²¤¦X§@Áp·ùÅý¯E¹©»sÃÄì®Æ¨Ó·½¯à·½·½¤£µ´ °£¤Fì®Æ¨ÑÀ³¥~ ¦X²z±À´ú¦æ¾P¦X§@±ÂÅvÀ³¸Ó¦³¦b«ê½Í¤¤ (¤@¯ë¨Ó»¡¤@ÓÃĪ«¶i¤J¤T´ÁÁ{§É®É ÃĪ«»s³y»P¦æ¾P»Ý¶}©l«ê½Í) ¥u»Ý@¤ßµ¥«Ý©w®×¤½§i ¦p¦P¸Ñª¼¼Æ¾Ú¤½§i¤@¼Ë |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/23 ¤W¤È 07:30:23²Ä 2021 ½g¦^À³
|
¥xÁÞ¤j ·PÁ±z ½Ķ¤Ó±j¤F ¤ÀªR¦³²z STELLAR·~°È±N¤j¦¨ªø ¦ÛµM¬On¨ÑÀ³¥«³õ»Ý¨Dªü |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/22 ¤U¤È 11:51:38²Ä 2020 ½g¦^À³
|
³o®a¥Í²£KLHªºStellar¥Í§Þ¤½¥q ·Ç³ÆnÂX±i·~°È¡AÓ¤H±À´ú¥i¯à¦³ ¨âÓì¦] 1À³¥IÁ{§É¸ÕÅç»Ý¨D¡A¥i¬O¤ÀªR¥þ²y ¥HKLH¬°¸üÅé³J¥ÕªºÁ{§É¸ÕÅç¡A¤j¦h¦b ¤@¤G´ÁÁ{§É¡A¨ü¸Õ¤£»Ý«Ü¦h¤H¡A¦]¦¹Á{§É »Ý¨DµLªk³y¦¨¥¼¨Ó·~°È°ª¦¨ªøªº¨Æ¹ê 2¦³¨Ï¥ÎKLH¬°¸üÅé³J¥Õªº¤jÃÄn¤W¥«¡A ¦]¬°¬O¤jÃĨϥίf±w¦h¤~¥i¯à³y¦¨·~°È °ª¦¨ªø¡AÁo©ú¤S¦³¿W¥ß«ä¦Ò¯à¤Oªº¦U¦ì ¤j¤j²q¤@²q¬O¨º¤@Óì¦] |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/22 ¤U¤È 11:14:47²Ä 2019 ½g¦^À³
|
¨°¬P¤jªº OBI Pharma Observer ¤º®eÂ×´Iºë±m ªñ´Á¶K¤å ÁöµM¦Y¤£¨ì®üÂA ¦ý¥iªY½à¨ìKLH §§Æ[ªº¤À¤lµ²ºc ¨ÅÀùOBI822 ¬O¥þ²y¥HKLH¬°¸üÅé³J¥Õ¥H¨ÅÀù¬°¬ãµo¾AÀ³¯gªº°ß¤@ÃĪ« ¥þ²y¥HKLH¬°¸üÅé³J¥Õ¬ãµoªº¾AÀ³¯g»P¥Í§Þ¤½¥q (¤¤¤å½Ķª©) A ¤T´ÁÁ{§É phase3 ( ) ¬ãµo¤½¥q 1 Breast cancer ¨ÅÀù (OBI Pharma) 2 glioblastom ´c©Ê½¦½è½F (Celldex) B ¤G´ÁÁ{§É phase2 ( ) ¬ãµo¤½¥q 1 §J¶©¤ó¯g Crohn¡¦s disease¡A¬O¤@ºØª¢¯g©ÊG¸z¯f(NeoVac ) 2 lupus ¬õ´³©Ê¯T½H systemic lupus erythematosus (NeoVac ) 3 Alzheimer ªü¯÷®üÀq¯g (Affiris/GSK) 4 multiple myeloma¦hµo©Ê°©Åè½F (Abramson cancer center) 5 lymphoma ²O¤Ú½F (clinica navarro ) 6 melanoma ¶Â¦â¯À½F (Dermatologische Klinik) 7 Ovarian cancer §Z±_Àù (Loyola University Chicago)ªÛ¥[ôùģ©Ô¤j¾Ç 8 Sarcoma ¦×½F (MabVax ) 9 Ovarian cancer §Z±_Àù( MabVax/National Cancer Institute) 10 leukemia ¥Õ¦å¯f (National Cancer Institute) C ¤@´ÁÁ{§Éphase 1 ( ) ¬ãµo¤½¥q 1 Alzheimer ªü¯÷®üÀq¯g (Araclon/Grifols ) 2 Alzheimer ªü¯÷®üÀq¯g (AXON Neuroscience) 2 non-Hodgkin¡¦s lymphoma «D¦ó³Çª÷¤ó²O¤ÚÀù ( Bayer ) 3 Brain tumor ¸£Àù ( Rockefeller Cancer Institute ) 4 glioblastom ¸£³¡°ª«I¥Ç©Ê½¦½è½F (roswell park cancer institute) 5 Lung cancer ªÍÀù( MSKCC ) 6 neuroblastoma ¯«¸g¥À²ÓM½F (MSKCC) 7 Sarcoma neuroblast ¯«¸g¥À²ÓM½F ((National Cancer Institute) a ¦P¼Ë¥HKLH¬°¸üÅé³J¥Õ¬ãµoªº¾AÀ³¯g»Ý¦A²`¤JÁA¸Ñ¬O§_¦³¼Ð¹v©Ê (¦pOBI822ªºGlobo H SSEA3 SSEA4) b ¹ï¼Ð¹v¬O§_¦³±M¤@©Ê ¯à§_¦bcancer stem cell »Pcancer cell ¦³°ª«×ªí²{ c ¦õ¾¯¬O§_¬Û¦P d ¥Ø«e¬Ý°_¨Ó»POBI822 OBI833¥¼¨Ó¾AÀ³¦³Ävª§Ãö«Yªº¦³ ¤G´Áªº§Z±_Àù »P¤@´ÁªºªÍÀù ((À³°lÂܨäÀø®Ä) e ¥Ø«eOBI822 OBI833©|¥¼¬ãµo¸£Àù »P ¤@´Á»P¤T´Á¶i¦æ¤¤ªºªº¸£Àù¬ãµoÃĪ« ¥Ø«e©|µLÄvª§Ãö«Y (À³°lÂܨäÀø®Ä) f ¨ÅÀùOBI822 ¬O¥þ²y¥HKLH¬°¸üÅé³J¥Õ¥H¨ÅÀù¬°¬ãµo¾AÀ³¯gªº°ß¤@ÃĪ« ¥H¤W¹Á¸Õ½¦¨¤¤¤å ¦p¦³¿ù»~½Ð«ü¥¿ |
|
|
·|û¡G¹Ç§Ax±ø±ø10135894 µoªí®É¶¡:2015/9/22 ¤W¤È 11:41:40²Ä 2018 ½g¦^À³
|
µJÂIÃþªÑ¡GµLÄߧƩԿ¶¶æÁn¤Î¬ü¥Í§ÞªÑ¤j¶^¡A¥xÆW¥Í§ÞªÑÄò±j¡A½L¤¤¦hÀɤjº¦ °]°T·s»D 2015/09/22 11:05 ¦rÅé©ñ¤j ¤À¨É¦ÜFB ¤À¨É¦ÜTwitter ¡i°]°T§Ö³ø¡þ¦ó¬ü¦p³ø¾É¡j¬ü°ê¥Á¥DÄÒÁ`²Î´£¦W¼öªù¨¤³v¤H¿ï§Æ©Ô¿¶(Hillary Clinton)¶æÁnnµoªípµe¡A¥Ø¼Ðn²×¤îÃÄ»ù«¡©ï¡A¬ü°ê¥Í§ÞªÑ»DÁn¤j¶^¡A¬ü°êNASDAQ¥Í§ÞÃþ«ü¼Æ(NBI)§ó¤j¶^4.41%¡C¥xÆW¥Í§ÞªÑ¤£©È¡A±j¥Í(4747)¡B¦Ê²¤(4103)½L¤¤º¦°±¡AF*¤Ó´º(4157)¡BÁÞÁp(4168)¡B·ç°ò(4171)Äò±j¡C ¯Ã¬ù®É³ø¥»¶g¤@³ø¾ÉÃÄ°Ó¤º¹õ¡A´yz¤@®aÃÄ°ÓTuring Pharmaceuticals¦p¦ó±N¤w¸g¦³62¦~¾ú¥v¡B¨CÁû°â»ù13.5¬ü¤¸ªººÄ¯e¥ÎÃĹF©Ô¤ÇªL(Daraprim)«¡©ï¨ì¨CÁûn»ù750¬ü¤¸¡C¹ï¦¹¡A§Æ©Ô¿¶¦b±À¯Sµo¤å¶æÁnnµoªípµe¡A¥´À»¶Â¤ß·~ªÌ¡A¥Ø¼Ðn²×¤îÃÄ»ù«¡©ï¡C ¥xÆW¤u»È¸ê²`¸g²z¹ù©÷«Gªí¥Ü¡A¬ü°ê¬Fªv¤Hª«©ñ¸Ü¥´À»°ªÃÄ»ù®É¦³©Ò»D¡A¥h¦~ ¦N§Q¼wC«¬¨xª¢ªº¤fªAÃÄHarvoni¡A¤@ÁûÃÄn»ù1,125¬ü¤¸¡A¬Û·í©ó¬ù·s¥x¹ô3.4¸U¤¸¡A¤]´¿¤Þµo¥~¬É©áÀ»¡A¨Ã½ÄÀ»¬ü°ê¥Í§ÞªÑ¨«¶Õ¡C ¨Æ¹ê¤W¡A¥xÆW»P¬ü°ê¥Í§ÞªÑªº°ò¥»±¡B®ÉªÅÀô¹Ò¡B²£·~µ²ºc³£¤£¦P¡A¥ý«e¬ü°êNBI¤£Â_³Ð·s°ª¡A¥xÆW¥Í§ÞªÑ«h¸g¹L¤@¦~ªº©Ô¦^×¥¿¡A¥B·sÃĤ½¥q¦h¦bÁ{§É¶¥¬q¡AÁÙ¨S¸ó¤J¬ü°ê¥«³õ¾P°â¡C ¹ù©÷«G»{¬°¡A¬ü°ê¥Í§ÞªÑ©Ô¦^¹ï¥xÆW¥Í§ÞªÑ¼vÅT¦³¡A¤£¹L¡A±qOTC¥Í§Þ«ü¼Æ¨Ó¬Ý¡A8¤ë25¤é¬ù120ÂI¡A9¤ë21¤é¤w½Ä°ª¦Ü160ÂI¡Aµu½uº¦´T¶W¹L3¦¨¡A¨Ã±q¨ã·~ÁZ¡B°ò¥»±¤ä¼µªº¤@½uªÑ½ü°Ê¨ì¤G½uªÑ¡Aªñ´ÁY¶¶¶Õ¥ð®§¾ã²z¡A¤]¦ó¹Á¤£¬OÃa¨Æ¡C ¤µ¤é¥Í§ÞªÑ¦h§e²{º¦¦h¥ð®§¡A¯E¹©(4174)¡B¨¹¯S(4107)µ¥ºû«ù¥½L¡Aªñ¤é±j¶Õªº¨Õ¬ã¡B¼w^(4911)¡B«n¥ú(1752)¡B´¼Àº(4162)µ¥¤]©Ô¦^¾ã²z¡AF*¤Ó´º¡B±j¥Í¡B¦Ê²¤¡BÁÞÁp¡B·ç°ò«hºû«ù¤jº¦¡C |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2015/9/22 ¤W¤È 10:23:05²Ä 2017 ½g¦^À³
|
ÃÒ¥æ©Ò«¤j°T®§¤½§i (4174)¯E¹©-¤½§i¥»¤½¥q¨üÁÜ°Ñ¥[°ê®õÃÒ¨é(ªÑ)¤½¥q©ÒÁ|¿ì¤§¡y2015¦~©u«×½×¾Â¡z ²Å¦X±ø´Ú²Ä¥|±ø²ÄXX´Ú¡G12 ¨Æ¹êµo¥Í¤é¡G104/09/23 1.¥l¶}ªk¤H»¡©ú·|¤§¤é´Á¡G104/09/23 2.¥l¶}ªk¤H»¡©ú·|¤§®É¶¡¡G15 ®É 40 ¤À 3.¥l¶}ªk¤H»¡©ú·|¤§¦aÂI¡G¥x¥_¸U»¨°s©±(¥x¥_¥«¤¤¤s°Ï¼Ö¸s2¸ô199¸¹) 4.ªk¤H»¡©ú·|¾Ün°T®§¡G¥»¤½¥q¨üÁÜ°Ñ¥[°ê®õÃÒ¨é©ÒÁ|¿ì¤§¡y2015¦~©u«×½×¾Â¡z¡A±N©óªk¤H»¡©ú·|¤¤»¡©ú¥»¤½¥qÀç¹B·§ªp¤Î¥¼¨Ó®i±æ¡C 5.¨ä¥LÀ³±Ô©ú¨Æ¶µ¡GµL §¹¾ã°]°È·~°È¸ê°T½Ð¦Ü¤½¶}¸ê°TÆ[´ú¯¸¤§ªk¤H»¡©ú·|¤@Äýªí©Îªk»¡·| ¶µ¥Ø¤U¬d¾\¡C |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2015/9/21 ¤W¤È 11:59:35²Ä 2016 ½g¦^À³
|
¥ÃÂת÷±±(2890) ©u³ø¤Î¥b¦~³ø ¥ÃÂ׳Чë«ù¦³ª¬ªp 3/31 ¯E¹© 617±i ¤ñ²v0.36% 6/30 ¯E¹© 535±i ¤ñ²v0.31% 9/18(¤½§i) 386±i ¤ñ²v 0.23% |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2015/9/21 ¤W¤È 11:51:22²Ä 2015 ½g¦^À³
|
¹Ç¤j¡A¨â¥ó¨Æ±¡»¡©ú¬°¦ó¤£¬O¶°¤¤¦b¥ÃÂת÷ÃÒ¨é½æ¥X¡Aº¥ý¬Oªk¤H«ù¦³§ë¸ê¤½¥qªºªÑ²¼¡A¤@¤Ñ¤£¯à¶R½æ¶W¥X«ù¦³±i¼Æªº1/10¡A¥ÃÂ׳Чë¦b¤W¶g¤«ù¦³¯E¹©1214±i,¦]¦¹³æ®a¨é°Ó¤£±o½æ¶W¶W¹L124±i¡A¦]¦¹¥ÃÂ׳Ч륲¶·³z¹L¨ä¥L¨é°Ó½æ¥X¤~¦³¥i¯à½æ¨ì828±i¡C ¨ä¦¸¡A³q±`ªk¤H©Mªk¤H¤§¶¡³£¦³·~°È©¹¨Ó¦X§@Ãö«Y¡A¨Ò¦p§O®a¨é°Ó¨ÓÁʶR¥ÃÂת÷ªº°òª÷¡A°ò©ó¦^õXªº¤¬´fì«h¡A¦³¥i¯à¥ÃÂת÷ºX¤U¤½¥q·|Âà¥XªÑ²¼¨ì¨º®a¨é°Ó°µ·~ÁZ¡A¦]¦¹¥]¬A°ê¤º¨é°Ó¡A¥H¤Î¥~¸ê¨é°Ó³£¥i¯à¬O¥ÃÂ׳Чë¿ï¾Ü½æ¥Xªº¨é°Ó¡A´«¥y¸Ü»¡¡A¤]¦³¥i¯à¤W¶g¤½æ¶Wªº¥~¸ê¡A¨Ã«D¬O¯uªº¥~¸ê¡C |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/9/21 ¤W¤È 11:39:09²Ä 2014 ½g¦^À³
|
³o¥æ©ö¤é´Á§ÚÃhºÃ¬O¤½¥q¿é¤J¿ù»~, À³¸Ó¬O8/20-9/18,¤£¹L¤½¥q½æªº§¡»ù¬O¦b363, À³¸Ó¬O¶°¤¤¦b9/18½æ¥X¤£¤Ö¤~¹ï. |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/9/21 ¤W¤È 11:33:12²Ä 2013 ½g¦^À³
|
ÁÂÁ£~£~¤j¡Aì¨Ó¦p¦¹~~ |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2015/9/21 ¤W¤È 11:26:31²Ä 2012 ½g¦^À³
|
¥ÃÂת÷±±¥N¤l¤½¥q¥ÃÂ׳з~§ë¸êªÑ¥÷¦³¤½¥q¤½§i¥X°â¥xÆW¯E¹©¥Í§ÞªÑ¥÷¦³¤½¥qªÑ²¼ 1.ÃÒ¨é¦WºÙ: ¥xÆW¯E¹©¥Í§ÞªÑ¥÷¦³¤½¥q 2.¥æ©ö¤é´Á:103/9/20¡ã104/9/18 3.¥æ©ö¼Æ¶q¡B¨C³æ¦ì»ù®æ¤Î¥æ©öÁ`ª÷ÃB: ¥æ©ö¼Æ¶q¡G828¥aªÑ ¨C³æ¦ì»ù®æ¡G363.58¤¸ ¥æ©öÁ`ª÷ÃB¡G 3.01»õ¤¸ 4.³B¤À§Q¯q¡]©Î·l¥¢¡^¡]¨ú±o¦³»ùÃÒ¨éªÌ¤£¾A¥Î¡^: ³B¤À§Q¯q¬ù 2.85»õ¤¸ 5.»P¥æ©ö¼Ðªº¤½¥q¤§Ãö«Y:µL 6.¨´¥Ø«e¬°¤î¡A²Ö¿n«ù¦³¥»¥æ©öÃÒ¨é¡]§t¥»¦¸¥æ©ö¡^¤§¼Æ¶q¡Bª÷ÃB¡B«ùªÑ¤ñ¨Ò¤ÎÅv§Q¨ü±¡§Î¡]¦p½è©ã±¡§Î¡^: ¥ÃÂ׳Чë²Ö¿n«ù¦³¼Æ¶q¡G386¥aªÑ¡FÁ`ª÷ÃB¡G¬ù7.39¦Ê¸U¤¸¡F«ùªÑ¤ñ¨Ò¡G0.23%¡FÅv§Q¨ü¡GµL ¥ÃÂת÷ÃÒ¨é²Ö¿n«ù¦³¼Æ¶q¡G18¥aªÑ¡FÁ`ª÷ÃB¡G¬ù5.77¦Ê¸U¤¸¡F«ùªÑ¤ñ¨Ò¡G0.01%¡FÅv§Q¨ü¡GµL 7.¨´¥Ø«e¬°¤î¡A¨Ì¡u¤½¶}µo¦æ¤½¥q¨ú±o©Î³B¤À¸ê²£³B²z·Ç«h¡v²Ä¤T±ø©Ò¦C¤§¦³»ùÃÒ¨é§ë¸ê¡]§t¥»¦¸¥æ©ö¡^¥e¤½¥q³Ìªñ´Á°]°È³øªí¤¤Á`¸ê²£¤ÎÂkÄÝ©ó¥À¤½¥q·~¥D¤§Åv¯q¤§¤ñ¨Òº[³Ìªñ´Á°]°È³øªí¤¤Àç¹B¸êª÷¼ÆÃB: ¦ûÁ`¸ê²£¤ñ¨Ò¡G1.30 % ¦ûÂkÄÝ©ó¥À¤½¥q·~¥DÅv¯q¤§¤ñ¨Ò¡G 1.52 % ³Ìªñ´Á°]°È³øªí¤¤Àç¹B¸êª÷¼ÆÃB¡G ¤£¾A¥Î 8.¨ú±o©Î³B¤À¤§¨ãÅé¥Øªº:¹ê²{Àò§Q 9.¥»¦¸¥æ©öªí¥Ü²§Ä³¸³¨Æ¤§·N¨£:µL 10.¥»¦¸¥æ©ö¬°Ãö«Y¤H¥æ©ö:§_ 11.¸³¨Æ·|³q¹L¤é´Á:¤£¾A¥Î 12.ºÊ¹î¤H©Ó»{©Î¼fp©eû·|¦P·N¤é´Á:¤£¾A¥Î 13.¨ä¥L±Ô©ú¨Æ¶µ:µL ==================================================== 2.¥æ©ö¤é´Á:103/9/20¡ã104/9/18 |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/9/21 ¤W¤È 11:09:57²Ä 2011 ½g¦^À³
|
¦U¦ì¤j¤j¡A¦³¥ó¨Æ·Q½Ð±Ð¡A¦]¬°¤@ª½Ä±±o«Ü©_©Ç 9/18¥ÃÂת÷±±¥N¤l¤½¥q¥ÃÂ׳з~§ë¸êªÑ¥÷¦³¤½¥q¤½§i¥X°â¥xÆW¯E¹©¥Í§ÞªÑ¥÷¦³¤½¥qªÑ²¼ ¥æ©ö¼Æ¶q¡G828¥aªÑ ¨C³æ¦ì»ù®æ¡G363.58¤¸ ¥ÃÂת÷ÃÒ¨é·í¤Ñ¥u¦³127±i½æ³æ¡A¥[¤W¤¸´I433¡A¥É¤s133¡A¤é²±148,³Í°ò206...¤]¤~¦³828¥H¤W ¬O§_ªí¥Ü¥ÃÂ׳Чë¥Î«Ü¦h±b¸¹¦bª±¯E¹©? ÁÙ¬O»¡¥~¸ê½æ³æ¦³¥i¯à¬O¥ÃÂ׳Чë(°²¥~¸ê?) ½Ðª¾±¡ªº¤j¤j©ú¥Ü¤@¤U¡AÁÂÁ |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/9/21 ¤W¤È 10:27:11²Ä 2010 ½g¦^À³
|
¤µ¤Ñ¤j½L¤j¶^¡A¯E¹©¶}§C¨«°ª¡A¤p¤ß¤£n³Q¬~±¼ ±æ¦^¤£¦^¡A¤@¸ôªø¬õ¡A«áÄò¨«¶Õ¥i¯à·|«ÜÅå¤H¡A½æ±¼n¦b±µ¦^¨Ó®£©Èn¦hªá¤£¤Ö»È¨â¤F ¡i¤å¡þ®}¥É§g¡j ¤E¤ë¥|¤éÂd¶R¤¤¤ß×¥¿©ñ¼e«¤j°T®§µo¥¬³W½d¡A¨ä¤¤¹ï¬ãµo·sÃĪº¥Í§Þ¤½¥qµo¥¬«¤j°T®§¤º®e¥X²{§ó¤jªº¼u©Ê¡A¨ú¥Nì¥ý³Qµø¬°¡u°ò¨È±ø´Ú¡vªºÄY®æ³W½d¡A¥«³õ¤@P¸ÑŪ¡A¦¹Á|¥Nªí¬Fµ¦°µ¦h¥Í§ÞÃþªÑªº«eﯸ¡C°ò¨È±ø´ÚÃP¸j«á¡A¤WÂd¥Í§Þ«ü¼Æ¤@¸ô¥Ñ¤@¤T¡³¡D¤K¥|Ãk¤É¦Ü¤@¤¤T¡D¤¤»¢H¡Aµuµu¤KÓ¥æ©ö¤éº¦´T°ª¹F¤@¤C¡D¤T¤»¢H¡A¨Ã§Î¦¨¤ë¢Ù¢Ò§CÀÉ¥æ¤e¦V¤WªºÃø±o¦hÀY®ð¶Õ¡C ¦^ÅU¥Í§Þ«ü¼Æ¦Û¥h¦~¤C¤ë¦]¡u°ò¨È¨Æ¥ó¡v±q°ªÂIªº¤G¥|¤¡D¥|¥|ÂI¤U¶^¥H¨Ó¡A¥u¥X²{¹L¤@¦¸¦~©³µu¼Èªº§@±b¦æ±¡¤õªá¡F¤µ¦~ªì¡A¥«³õ±H¤©«p±æªº¯E¹©·sªÑ±¾µP¡A¤]¦]¬°¨ÅÀù·sÃÄOBI-822¤T´ÁÁ{§É¤£·|¦³´Á¤¤¤ÀªR³ø§i¡A¦b¨S¦³»e¤ë¦æ±¡ªºª^³ò¤U¡A¥Í§ÞªÑºt¥X¤F¤@³õ¦º®ð¨I¨Iªº§CÀɾ_Àú¦æ±¡¡CÀHµÛ¥«³õ®ø®§±²HÁ¡¡A¦A¥[¤W°ê»ÚªÑ¥«¨«¶^¡A¥Í§ÞªÑ¦b¨S¦³¶q¯àªº¤ä¼µ¤U¡A¥u¦³¤@¸ô±´©³¡C ¤T¦~¥bº²{¤ë¢Ù¢Ò¥æ¤e¦V¤W ¤£¹L¡A¤µ¦~¤U¥b¦~¥H¨Ó¡A¦b¤C¤ë©³ªº¥Í§Þ®iµ²§ô«á¡A¥xªÑÁö¤´¨ü°ê»ÚªÑ¥«ÅܰʼvÅT¡A¥Í§Þ²£·~«o¶}©l¥X²{¤£¤@¼Ëªº¨«¶Õ¡F¦Ó±q§Þ³N«ü¼Ð¨Ó¬Ý¡A°£¤F¤ë¢Ù¢Ò§CÀÉ¥æ¤e¦V¤W¥~¡A¤£¶È»â¥ý¢Ý¢â¢Ñ«ü¼Æ¤]»â¥ý¤j½L²v¥ý¥æ¤e¦V¤W¡A³o·N¨ýµÛ¥Í§ÞªÑ¤w¸g¸¨©³¡B¨Ã¥B¬O³Ì¦¤Ï¼uªº±Ú¸s¡C ¥«³õ¤]¦³¤@»¡¡A¥xÆW¬ì§Þ²£·~¨ü¨ì¬õ¦â¨ÑÀ³Ã쪺½ÄÀ»¡A¦A¥[¤WÄ«ªG·s²£«~ªº®Ä¯q¤@¥N¤£¦p¤@¥N¡A¦b¦b¥´À»¥xÆWªº¹q¤l²£·~¨ÑÀ³Ãì¡F¤ÏÆ[¥Í§ÞªÑ¡A¾¨ºÞ©|¥¼¥X²{²Ä¤@Áû¥xÆWªºì³Ð·sÃÄ¡A¦ý´N²£·~¨¤«×¦Ó¨¥¡A«o¬O³Ì¤£¨ü¸gÀÙ´º®ð¼vÅTªº±Ú¸s¡F¦AªÌ¡AªÑ»ù¤w¸g¶^²`¡B¬Fµ¦¨ã¥D¾É¤O¡A©ú¦~ªºÁ`²Î¿ïÁ|¦æ±¡¡A³Ì¨Îªº§@»ù¼Ðªº±Ú¸s´NÄݥͧ޲£·~¡C ¦Ó¥xÆWªºÂå§÷¡B»sÃIJ£·~¦b°ê»Ú¶¡¤w¨ãª¾¦W«×¡A¤×¨ä¤@¤T¦~©³¥[¤JPIC/S·|û°êªº°ê»Ú¤j¼tq³æªºÂà³æ®ÄÀ³¡A§ó¦b¤µ¦~¶}©l¨£¨ì¦¨®Ä¡A¥]¬A¤FªF¬v¡BÑÔ¼w¡B«n¥ú¡Fì®ÆÃĪº¦°´I¡B¥Í®õ¡B¥xÄ£µ¥¡A³£¦³±j«lªº¦¨ªø¤O¹D¡CÂå§÷Ãþ§ó¦b¨¹¯S¡BÁp¦X¤W¥b¦~Àò§Q³Ð¤U·s°ª¿EÀy¤U¡AªÑ»ù²v¥ý³Ð¤U¦^ÀÉ¥H¨Ó·s°ª»ù¡C ·sÃıڸs«h¨ü´f©ó¯E¹©¤T´ÁÁ{§É¸Ñª¼®É¶¡ÂI¤w½T©w¦b¤G¡³¤@¤»¦~¤T¤ë¥H«eµo¥¬¡AªÑ»ù¦Û§CÀɪº¤G¤¡³¤¸ötº¦¦Ü³Ì°ª¤T¤»¤G¤¸¡Aº¦´T°ª¹F¥|¥|¡D¤K¢H¡A³o¤j¤j¿EÀy¾ãÓ·sÃĬãµo¦¸²£·~ªº¤Ï¼u¦æ±¡¡A·í¤¤¤w¸g¦³Àò§Qªº±ÂÅv¼Ò¦¡«ü¼ÐªÑ´¼Àº¡A¤]±q§CÀɪº¤@¤G¤E¤¸¤Ï¼u¦Ü¤G¡³¥|¤¸¡A¥x·LÅé¤]«¦^¦Ê¤¸»ù¦ì¡C «ü¼ÐªÑ²v¥ýªíºA µM¦Ó¡A§Þ³N±¡BÄw½X±¡B°ò¥»±¦A¦n¡A³£¤£¤Î¬Fµ¦Ä@·N¥X¨ÓI®Ñ§ß´Ó¡A¤é«e¢Ð¢â¢Ñ¡]¥Í§Þ²£·~µ¦²¤¿Ôij©eû·|ij¢w³Qµø¬°¥Í§Þ¬Fµ¦«ü¼Ð¡^©ÒÁ|¿ìªº¦~«×¥Í§Þ½×¾Â¡A´N¦³©ú½Tªº¬Fµ¦µo®i¥Ø¼Ðµ¦²¤¡A¤¤¬ã°|°|ªø¯Î±Ò´f¤]©ú½T´£¥X¡A¥xÆWªº¥Íª«¸gÀÙ¤@¦~¤w¹F¤G¥ü¤¸²£È¡AY¥H¥Í§Þ²£·~ªº¦~½Æ¦X¦¨ªø²v¤¡D¤G¢Hpºâ¡A¨ì¤G¡³¤G¡³¦~¡A²£È±N·|¼W¦Ü¤T¥ü¤¸¡C¡]¥þ¤å¥¼§¹¡^ ¥þ¤å¸Ô±¡¤Î¹Ïªí½Ð¨£¡m¥ý±´§ë¸ê¶g¥Z¡n1848´Á¡A«K§Q°Ó©±¤Î¦U¤j®Ñ©±§¡¦³³c°â ©Î¤Whttp://weekly.invest.com.tw¦³§ó¦hºë±m·í´Á¤º¤åÂà¸ü ì¤åºô§}: ¥ý±´¡þ¥Í§Þµ´¦a¤j¤Ï§ð | ETtoday°]¸g·s»D | ETtoday ·s»D¶³ http://www.ettoday.net/news/20150919/566524.htm#ixzz3mKtUn9S2 |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/19 ¤U¤È 04:03:06²Ä 2009 ½g¦^À³
|
¼Ú¬üªÑ¥«18¤é¤j¶^¡A¥xªÑ¤U¶g±N¾_Àú¥[¼@¡AªF¬v¡]4105¡^µ¥12ÀÉ¡A¤ë½u»P©u½u¶Àª÷¥æ¤e¡A¤¤ªø½u¦hÀY¬[ºc±N«OÅ@µu½uªº¾_Àú¡C ±d©MÃÒ¨é¬ã¨s³¡¤ÀªR®v«À§g¹F»¡¡A³o12ÀÉÓªÑÃD§÷Â×´I¡C¨ä¤¤¡A¬ü°ê¬F©²¥»¶g»P¤Q®a¨®°Ó¹F¦¨¨óij¡A±N§â¦Û°Ê·Ù¨®¨t²Î¦C¬°¼Ð·Ç°t³Æ¡A¤]¥]§t¨¾¼²¹p¹F¡AF-IET¥h¦~¨ÖÁʪk°ê¤½¥qSoitec¡ASoitec¦b¨¾¼²¹p¹F´¹¤ù¥«³õ¥«¥e80¢H¡A¦³¾÷·|¨ü´f¡Aªñ´ÁF-IETªÑ»ùªí²{±j¶Õ¡A¥»¶g¤Wº¦15.62¢H¡C¦Ü©ó®¶Â`¡A²Ä¤T©u¥x¹ô¶SÈ¡A®¶Â`¦³¤j¶qªº¶×§I¦¬¯q¡A¦¹¥~¡A®¶Â`»P¤¸¤Ó¦X¸ê¤½¥q·Ç³Æ·m§ðAmazon¹q¤l®Ñ¡A²Ä¥|©u¹q¤l®Ñ¤j¶q¥X³f¡A®¶Â`·~ÁZ¦¨ªø¥i´Á¡C °w¹ï¶g¤º¦´T³Ì¤jªº¯E¹©¡A¥xÆW¤u»È§ëÅU¸ê²`¸g²z¹ù©÷«G»¡¡A¬F©²¦³·NÄ@Åý¥xÆW·sÃÄÁ{§É¼f¬dÅܱo§ó¦³®Ä²v¡A¬Û¸û©ó·sÃıN¦b¨ä¥L°ê®a¥Ó½ÐÃÄÃÒªº¤½¥q¡A·sÃĦ³¾÷·|¦b¥xÆW¥Ó½ÐÃÄÃÒªº¯E¹©³Ì¦³¾÷·|¨ü¯q¡CµØ«n§ëÅU¸³¨ÆªøÀx²»¥Í¤]»¡¡A¯E¹©·sÃĬO¥ÎÁÞªº§Þ³N¥¥x¡A¦pªG·sÃĦ¨¥\¨ú±oÃÄÃÒ¡A¥Nªí·sªº¥¥x¬O¥i¦æªº¡A¦³¾÷·|±q³oÓ¥¥xµo®i¨ä¥LÀ³¥Î¡A¶}µo¨ä¥L§ÜÀùÃĪ«¡C ¹ù©÷«G»¡¡A«n¥ú¤µ¦~À禬ÅãµÛ¸û¥h¦~¦¨ªø¡A°Ê¯à¥Dn¨Ó¦Û´À¤é¥»«È¤á¥N¤u»s³yDocetaxel¾Ç¦WÃÄ¡A«n¥ú¤é¥»¥«³õÀ禬¹L¥b°^Äm¨Ó¦Û¦¹¾Ç¦WÃÄ¡A¹wpDocetaxel·|«ùÄò§êºt¤µ¦~»P©ú¦~À禬ÅãµÛ¦¨ªøªºÃöÁä¦]¤l¡C¦b¥h¦~¤U¥b¦~¥H¨Ó¡A«n¥ú¦@¦³¤C¥ó¾Ç¦WÃÄ°w¾¯°e¤J¬ü°êFDA¡C(¤u°Ó®É³ø) |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/19 ¤U¤È 01:50:29²Ä 2008 ½g¦^À³
|
¤j¤á¤j ¤p§Ì¶É¦V»{¬°Äw½XºÉ¸¨¤j¤á¤â¤¤ ¨ä¥L·m³fªÌ ¦h¹L˳f |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/9/19 ¤U¤È 01:43:55²Ä 2007 ½g¦^À³
|
µu½u¤j¤á¨C¤Ñ¶R¤F½æ,½æ¤F¤S¶R. ¦ÛÀç°Ó,ªê§ÀÀ°.°ª¶¯ªº.³o¨Ç³£¬OÀA¤W²Kªáªº¬°¥D.¤j¾_Àú¶}©l§K¤£¤F¤F. |
|
|
·|û¡G·ºÞ10139074 µoªí®É¶¡:2015/9/19 ¤W¤È 10:24:33²Ä 2006 ½g¦^À³
|
¨S½T¹ê¼Æ¾Ú¥X¨Ó´N³Ûº¦¤Ñº¦¦aªº½Ð¦ÛÁ¾¡A¤§«e¤w«ù¦³ªº½Ð¦wÀR@¤ßµ¥«Ý¸Ñª¼¡A¤¤³~¥b¸ô¤W¨®ªÌ½ÐÂÔ·V§PÂ_ª`·N·ÀI¡AªÑ»ù¥¼¨Ó¦h¤Ö¨S¦³¤Hª¾¹D¡A¥u¦³§C¦¨¥»«ù¦³¤~¸g±o°_¤j·¤j®ö¡AÂԨѰѦҡC |
|
|
·|û¡G¥¤ß¦Ó½×10139639 µoªí®É¶¡:2015/9/19 ¤W¤È 09:48:12²Ä 2005 ½g¦^À³
|
¥¤ß¦Ó½×¡A¯E¹©³oºØº¦ªk¤w¸g¥¿¦¡¦V¥~«Å§i¦¨¬°¥xÆW²Ä¤@¥»¤g·sÃÄ¡A500¤¸¥H¤U³£¬O®Ú³¡°Ï ¦pªG¦~©³¨ì500¡A¤£¨ü»¤´b½æ¥Xªº¤HÀ³¸Ó·|«Ü¦h ½æ500¸ò½æ250¨ä¹ê®t§O¨S¦³«Ü¤j ¦]¬°½æ¤F¤£¬Ý¨S¨Æ¡A¬Ý¤F¤Sn«á®¬ ¦pªG©ú¦~1000¡A¦b³o¤§«e½æªºµù©wn«á®¬ §Ú´¿·Q¶R½æÁÈ®t»ù¡Aµ²ªG·l¥¢ºG« ¦]¬°¤j¶^°±·l¡A¤jº¦°±§Q µ²ªG³£¶R¿ù½æ¿ù¡A©Ò¥H¹³¬Y¤j³o¼Ë°µµu ¥i¥HÁȤ£¤Ö¡A¦ý¥i¯à«ÜÃøÁȦn´X¿ ¥~¸ê·|¶R¨ì500¡A1000§Ú¤£ª¾¹D¡A¦ý¥un¤@ª½¶R ªÑ»ù´N¤@¸ôº¦ «e´X¦~¥ÃÂת÷¦~¦~½æ¡A»ù¿ú¦h®t¡AÁöµM¦¨¥»20¡AÀH«K½æ ¦ýYÂ\¨ì²{¦b¡A¤@±i¤S¦hÁȦܤÖ10¸U¡A±i¼Æ¦h§ó¥iÆ[ ¿³Âd¥~¸ê¶R½æ¨ü¡A¤WÂd«á³Ìªñ¤j¶R´N¬On»¡·Ç³Æ¤jÁȤ@µ§¡A¥xÆW¤Hnı¿ô¡A¤£n¿ú¦bªÑ¥«Á`Åý¥~¸êÁȨ«¡A¦Û¤v¥xÆW¤HÁȤ£¬O«Ü¦n¶Ü |
|
|
·|û¡G¥¤ß¦Ó½×10139639 µoªí®É¶¡:2015/9/19 ¤W¤È 05:59:12²Ä 2004 ½g¦^À³
|
ª¾¹D½Ö¬Q¤Ñ¤j½æ¯E¹©¡A´N¬O¥ÃÂת÷ µL¥i«p«DѺª`Àò§Q¡A¶¥¬q¥ô°È»Ýn¡A³o½æÀ£®ø¤Æ±¼§ó¦n ¥Í§ÞªÑ²¼Ñºª`ª÷¿Ä·~Àò§Q¡C¥ÃÂת÷§ë¸êºë·Ç¡AºX¤U¤l¤½¥q¥ÃÂ׳Чë§ë¸ê¥Í§ÞªÑ·sªÑ¤ý¯E¹©¡AÀò§Q³B¤À«á¡A³B¤À§Q¯q¬ù2.85»õ¤¸¡AѺª`¬Û·í¦h¡C ¯E¹©¬°¤µ¦~¤WÂd¥Í§ÞªÑ¡AªÑ»ù¦Û¤µ¦~8¤ë©³¤@¸ôöt½Ä¡A±q250¤¸¤Wº¦¹F375¤¸¡AªÑ»ù¤Wº¦´T«×¶W¹L50%¡C ¥ÃÂת÷¬Q«Å¥¬¡A¤l¤½¥q¥ÃÂ׳Чë³B¤À828±i¯E¹©¥Í§Þ¡A¥H¨C³æ¦ì»ù®æ363.58¤¸½æ¥X¡A¥æ©öÁ`ª÷ÃB¬°3.01»õ¤¸¡A³B¤À§Q¯q¬ù2.85»õ¤¸¡C¥ÃÂ×ÃÒ¤´©|«ù¦³18±i¯E¹©ªÑ²¼¡C¥ÃÂת÷¬Qªí¥Ü¡A¤£²M·¡ºX¤U¤l¤½¥q¥ÃÂ׳Чë³B¤À±¡ªp¡C ¥xÆW¤u»È§ëÅU¤é«e¥X¨ã³ø§i¡A»{¬°¦b¤j½L¾_Àú¤§»Ú¡A¬F©²ºÝ¥X¬Fµ¦¥[«ù¥Í§ÞªÑ¡A¬ÛÃöÃþªÑªÑ»ù¦³±æ¦A§ð¤@ªi¡A³QÂI¦Wªº¯E¹© ¡BªF¬v¡B´¼Àº¡B«n¥ú¡B¤¤¸Îµ¥5ÀɥͧުѳsÄò¨â¤éªí²{±j¶Õ¡A¥Í§ÞÃþªÑ«ü¼Æ¤]³sÄò¨â¤é¦¬¬õ¡C ªk¤Hªí¥Ü¡A¯E¹©§Q¦h®ø®§±¦h¡AÀ³¤´¦³ªí²{¾÷·|¡A¥ÃÂ׳Ч릹¦¸³B¤À¡A¦ôpÀ³¸Ó»P¤µ¦~¤U¥b¦~ª÷¿Ä·~¨ü¨ì¤j½L¾_Àú¼vÅT¡A¾Ö¦³ÃÒ¨é¤l¤½¥qªºª÷±±Àò§Q¨ü¶Ë®`¡A¶}©l¥X²{½æ¥X¤â¤¤Àò§QªÑ²¼À±¸ÉÀò§Q³¡¤À·¼é¦³Ãö¡A¦ôp¥¼¨Ó±N·|¦³§ó¦hª÷±±ºX¤U¤l¤½¥q³v¨B¥X°â¤â¤¤Àò§QªÑ²¼¡C ¥ÃÂת÷¤µ¦~8¤ë³æ¤ë¦Ûµ²Àò§Q7.43»õ¤¸¡AÁöµM¥ÃÂ×»ÈÀò§Q¹F8.59»õ¤¸¡A¦ý¥ÃÂת÷ÃÒ¨é³æ¤ëÁ«·l1.03»õ¤¸©ì²Ö¾ãÅéª÷±±ªí²{¡C |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2015/9/18 ¤W¤È 11:17:12²Ä 2003 ½g¦^À³
|
«Ü¼F®` ³£¨ì2014/11-2015/2ªº360ªº¥¥x°Ï¤F ´Á«Ý¤@¤@§JªA ¥i¥Hªº |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/18 ¤W¤È 11:01:47²Ä 2002 ½g¦^À³
|
±ø±ø¤j ¯E¹©ªñ´Áªí²{¦p§A©Ò¨¥ ¯u¬O¬Ý¶Ì¤F ªÑ¥«¦p¦P¾Ôª§¤@¼ËÅܤƦhºÝ ¥H¤U¶È¨Ñ°Ñ¦Ò ¤Å«H¥H¬°¯u 378°ª¦a ¼Ä¤è¤Ù§L«Ü¦h ¦ý¾Ô²¤¾Ô³N¤í¨Î, §Y±N³Q¦h°êÁpx¤§¥ý»º³¡¶¤§ð¤U(¥ýÁn¹Ü¤H) 404°ª¦a ¼Ä¤è¤Ù§L¤£¦h ¦h°êÁpx,§L¦h±N¼s ,¥i»´©ö¦û»â 455°ª¦a §L®a¥²ª§¤§¦a, ¼Ä¤è¤Ù§L¤]¤£¦h ,¦h°êÁpx¥¿¸É¨¬ªZ¾¹§L¤O , ¹BÄw±cØò, ¿Ñ©w¦Ó«á°Ê, ¤@Á|®³¤U¨î°ªÂI |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/9/16 ¤U¤È 03:26:22²Ä 2001 ½g¦^À³
|
¯u¬O¬Ý¶Ì¤F 8/25=250, ¦b¹M¦a«sÀz¡A¦³ªÑ¬Ò´dªº¦P®É¨Ó¨ì¤Fªñ´Á³Ì§CÂI¡AµL½×¤é/¶g/¤ë/©uK½u¥þ³¡¦º¤`¥æ¤e¥B¦V¤U 16Ó¥æ©ö¤é«á9/19=358, ¤Wº¦(358-250)/250=43.2%¡A¨Ó±o¤S«æ¥B²r ¦¶Rªº¤H¯ºCC¡A¦½æªº¤H«á®¬¦º¡A¨S¶Rªº¤H¬Ý¶Ì²´¡A¨S½æªº¤H¨S·Pı(µ¥¸Ñª¼) ¤µ¤Ñ¦w¦¨ÃÄ/¥x·LÅé..µ¥¦hÀɺ¦°±¡A©TµM¬O¶^²`¤Ï¼u©Î¬O¦b¯E¹©«áªº"¤ñ»ù®ÄÀ³"¨ÏµM Anyway,½Ö¤~¬O¯u¦³®Æ¤j®a¤ß¸Ì¦³¼Æ¡AÁöµM·íªì°h¼é¦b»rªaªº¤Hº¦¼é®É¤]¬Ý¤£¨ì ¦ý¬O¥«³õ¨º°¦¬Ý¤£¨£ªº¤â¡A·|§â¯E¹©±À¦Vì¸Ó¦³ªº°ª«× 2014¦~1¤ë©Ò»¡2013¦~200, 2014¦~400....½T¹ê¬O¨ì¤F¡A¤£¹L©ºªA452°ª¦a«á¤S³Q§ð³´1¦~¤F ·íªì»¡2015¦~800..¥u³Ñ¤U3Ó¥b¤ë¬Ý¨Ó¾÷·|©Î³\¤£¬O«Ü¤j¡A¦ý¬Û«H©ú¦~3¤ë¸Ñª¼«áªº1Ó¤ë 2016/4...©Î³\800´N««¤â¥i±o¡A«e´£ÁÙ¬O"«H¤£«H¥Ñ§A" ¿³ÂdÂà¤WÂd¨º¤Ñªº27,000±i¤j¶q¡A¦¬¦b³Ì§C355,¤µ¤Ñ¦¬½L358¬O¯}¤F ¦ý¯à§_»´©ö§ð¤W378·í¤Ñ³Ì°ª»ù¡An¬Ý¼í¦Ñ¤j/¥~¸êµ¥ªk¤H¬O§_«ùÄò¤O®¼¨ì©³ ¤H¦]¹Ú·Q¦Ó°¶¤j¡A822·sÃÄ¥i³yºÖ¯f¤H¤]³yºÖ¥xÆW¥Í§Þ²£·~/¤½¥qû¤u/©Ò¦³ªÑªF...«ø¥Ø¥H«Ý «e´£ÁÙ¬O"«H¤£«H¥Ñ§A"¥B»Ý"ª`·N§ë¸ê¦³·ÀI" |
|
|
·|û¡G99910140657 µoªí®É¶¡:2015/9/15 ¤W¤È 09:29:03²Ä 2000 ½g¦^À³
|
¥xÁÞ¤j¤j «e½ú¡K·P¿E±z¡I ±zªº¶K¤å«ü¾É»P¤è¦VÁ`Åý¤H¦³·Pªº¨£¨ì¡y¦³¥ú¡z¡A¡y¦³«G¡z¡K¦P®É¤ß¤¤±o¨ì¨ü·ÓÅU¡A«Ü·Å·xªº·P¨ü¡C¯uÁÂÁ±z¦³±ÐµLÃþ¡A¤£§[¦Û¤v¦pª÷¦ü¥ÉÄ_¶Qªº®É¶¡¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/15 ¤W¤È 09:13:07²Ä 1999 ½g¦^À³
|
¾ú¦~FDA ®ÖãÀù¯gÃĪ« FDA Approved Drugs for Oncology 1996--2000 ¥§¡¨C¦~®Öã 11.4 Áû 1996 --19 1997 --12 1998 --14 1999 --8 2000 --4 2001-2005¥§¡¨C¦~®Öã 6.2 Áû 2001 --7 2002-- 8 2003 --8 2004 --6 2005 --2 2006--2010 ¥§¡¨C¦~®Öã 6.2 Áû 2006 --4 2007 --6 2008 --5 2009 --9 2010 --7 2011--2015 ¥§¡¨C¦~®Öã12.6 Áû 2011 --12 2012 --19 2013 --12 2014 --10 2015 --¹w¦ô10 ( ¦Ü9 ¤ë 15¤é7Áû ) ±qFDA®ÖãÀù¯gÃĪ«¤ÀªR²Îp 2011¦~¶}©l¨C¦~®Öã³£¤j©ó10ÁûÃÄ ¨ä¤¤¥H1996 2012¦~®Öã19ÁûÀù¯gÃĪ«³Ì¦h 2015¦~¦Ü9¤ë15¤é¤î¤w¦³7ÁûÀù¯gÃĪ«³QFDA®Öã ¥[¤W´¼Àº±ÂÅv¥X¥h¨ºÁû¯ØŦÀù ªºÃijq¹L¾÷²v«Ü°ª ±À´ú2015¦~¦³¾÷·|¹F¨ì10Áû ±q1996¦~¶}©l¤¦~¥§¡¼Æ¤ÀªR 1996--2000 ¤Î 2011-- 2015§e²{Âù®p²{¶H ÀH³oÀù¯g§K¬ÌÀøªkªº¿³°_ 2016¦Ü2020 ¨C¦~®ÖãÁû¼ÆÀ³¥i¹F¨ì©Î¶W¶V2011¦Ü2015¦~¥§¡¼Æ https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/15 ¤W¤È 12:25:27²Ä 1998 ½g¦^À³
|
±i¸³¤w¶}¥Ü¤j®a¶R¤F¯E¹©nÂê¦b«OÀI½c ¦nªÑ°µ¤Óµu·|¯d¤U¿ò¾Ñ¡A¥H«e½æ±¼¥H¬° ¬O°ª»ù¡A²{¦b§óµL§C»ù¥i¦^¸É¡A¬ü´º¤w¤£¦b Åý¦n¬K³u¥^¥^Á`¬O¥O¤H±{±¤ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/14 ¤U¤È 10:38:51²Ä 1997 ½g¦^À³
|
§ó¥¿ ¹ê¤O¬£ªººq¤â¦¿¿·°Û²Ä¤@¥y´N¯à¥O¤H«Ü¦³·P ´Á¬ß¹ê¤O¬£ªºÁÞ¤À¤l·sÃIJĤ@ÁûÃĨÅÀùOBI822 ¤]¤@¼Ë¦b²Ä¤@©uµe¤U§¹¬ü¥O¤H«Ü¦³·Pªº¦s¬¡¦±½u |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/14 ¤U¤È 10:01:25²Ä 1996 ½g¦^À³
|
¯E¹©±N®i¯ÍÂù¦Ð ¿¬µ¾¤Ñ»Ú¡@ ¦u®è«Ý¨ß ªø´Á«ù¦³ ¥H§K¬î¥h¥V¨Ó¬ü´º¤£¦A ¦n¬K³u¥^¥^ ¹ê¤O¬£ªºÁÞ¤À¤l·sÃÄ ²Ä¤@ÁûÃÄ ¹³¹ê¤O¬£ªººq¤â¦¿´f¤@¼Ë °Û²Ä¤@¥y´N¯à«Ü¦³·P ¬îÂÍ §@µü§@¦±¡G§õ¤l«í ¦X°Û ¦¿´f ¶O¥É²M https://www.youtube.com/watch?v=i83yQ64HA0w Å¥§Ú§â¬K¤ô¥s´H¡@¬Ý§Ú§âºñ¸¶Ê¶À ½Ö¹D¬î¤U¤@¤ß·T¡@·ÏªiªL³¥·N«Õ«Õ ªá¸¨¬õ¡@ªá¸¨¬õ¡@¬õ¤F·¬¡@¬õ¤F·¬ ®i¯Í¥ôµ¾Âù¦Ð¿P¡@§Ú³oÁ¡¦ç¹L±o´Ý¥V Á`Âk¬O¬î¤Ñ¡@Á`Âk¬O¬î¤Ñ ¬K¨«¤F¡@®L¤]¥h¡@¬î·N¿@ ¬î¥h¥V¨Ó¬ü´º¤£¦A ²ö±Ð¦n¬K³u¥^¥^¡@²ö±Ð¦n¬K³u¥^¥^ |
|
|
·|û¡G99910140657 µoªí®É¶¡:2015/9/14 ¤U¤È 12:22:45²Ä 1995 ½g¦^À³
|
¯uªº¡K¡I¯uªº¡I¤@¤Á¬O¯uªº¡I¡m¯E¤Í·|¡n¡K¹ê¬O¡i¥xÆWµÐÂĸs^·|¡j¡I |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2015/9/14 ¤W¤È 10:26:15²Ä 1994 ½g¦^À³
|
§Ú¤÷¿Ë¤§«e¬OB«¬¨xª¢±aì, «á¨Ó73·³¥ª¥kµo²{¤F¬ù¨â¤½¤Àªº¸~½F.¦b¥x¥_ºaÁ`¶}¤M¤Á°£,²{¦b¤w¸g§Ön90·³¤F. |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2015/9/14 ¤W¤È 10:16:50²Ä 1993 ½g¦^À³
|
Russell ¤j ¨x¯f¨¾ªv¤¤¤ß¥x¤j±Ð±Â³\ª÷¤t¡A´¿Á|¤@Ó¨Ò¤l¡A ¥L«ÌªF¦³¤@¦ì¿Ë±¡Aµo²{®É2¤½¤À¡A ¥L«Øij¨º¦ì¿Ë±»°§Ö¶}¤M¡A ¥i±¤¨º¦ì¿Ë±¬Û«H¤¤Âå±Æ¬rªvÀø¡A 2¡A3¦~«á¸~½Fªø¤j¶W¹L10¤½¤À¥H¤W¡A¶i¤J¥½´Á¡A ½Ð¸ê¸ß¦U¤jÂå°|±M·~Âå®v¡A±µ¨ü¥¿³WªvÀø |
|
|
·|û¡G´µ¯S10135783 µoªí®É¶¡:2015/9/14 ¤W¤È 07:10:12²Ä 1992 ½g¦^À³
|
¥ª°¼¨x¸~½F¤Á°£,¥Ø«e¬O«D±`²³æªº¤â³N ¤¤³¡«Ü¦h¤@¯ë¥~¬ìÂå®v³£¥i¥H³B²z Âå®v·|µû¦ô³Ñ¿ò¨xŦ¥\¯à°÷¤£°÷,¤~¯à¶}¤M ¶}¤M¤~¬O®Úªvªº¤èªk ¦pªG¨xŦ¥\¯à¤£¦n,¥i¦Ò¼{¼öÀW¿N¨`(RFA) |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/14 ¤W¤È 01:10:41²Ä 1991 ½g¦^À³
|
¤j®a¬°Russell ¤jªº¥À¿Ë¬èºÖ ¯¬¦o¦¤é±d´_ ¥xÆW¦b¨x¸~½FªvÀø©~¥@¬É»â¥ý ¤£n¤Ó¾á¤ß ¦p¬O¦´Á¥ý¦b¥x¤¤ºaÁ` ©Î¤¤°ê »P¥DªvÂå®v°Q½×«á¶Eªv (¨x³¡¥÷¤Á°£·|¦Aªø·s¨xŦ ) °ª¶¯ªø©°¨xÀù¹Î¶¤¡Gº³ÐÁp¦Xªù¶E¡A¤K¬ìÂå¥Í¤@°_¬Ý¯f¤H «Øij§ä³¯»F¶©Âå®v (À³¤w°h¥ð ¦³±Ð¾É¤@§å«Ü±jªº¨x²¾´Ó»P¨xÀùªvÀø¹Î¶¤ ¥H¨xŦ²¾´ÓªvÀø¨xÀù¡A°ª¶¯ªø©°¨ì2013¦~Á`¦@§¹¦¨407¨Ò¡A¨ä¤¤¬¡Åé¨xŦ²¾´Ó385¨Ò¡A ¥H¬¡Åé¨xŦ²¾´ÓªvÀø¨xÀù¡A¤¦~¦s¬¡²v90% ¬O°ê»Ú¤W³Ì¦nªº¦¨ÁZ¡C http://m.commonhealth.com.tw/article/article.action?nid=63151 https://www.cgmh.org.tw/2012/cgmh/news/news_02_dtl.asp?id_seq=131009001 |
|
|
·|û¡GRussell10140734 µoªí®É¶¡:2015/9/14 ¤W¤È 12:03:33²Ä 1990 ½g¦^À³
|
¦í¥x¤¤¡AÁÂÁ |
|
|
·|û¡GRussell10140734 µoªí®É¶¡:2015/9/13 ¤U¤È 11:53:43²Ä 1989 ½g¦^À³
|
®a¥À¥ªÃä¨xŦ´c©Ê¸~½F¬ù3.3¤½¤À¡A¦]¥k¨x¦¤w¦]µ²¥Û¤Á°£¡Aª¾¦WÂå¥Íªí¥Ün¦Ü¤Ö¤Á°£5¤½¤À ª©¤W¦U¦ì¤j¤j¦h¬°Âå¾Ç±M®a¡A¥i§_«Ø¨¥ ¤â³N¤Á°£ªº¸Ü¨xŦ¶È¦s¤£¦h¡A¥i¦æ¶Ü? ÁÙ¬O¤¤Âå¥i§_§í¨î¸~½FÂX¤j ¤^¨Dª©¤W¤j¤j«Ø¨¥¡A©Î±ÀÂˤ¤Âå¨}Âå |
|
|
·|û¡GRussell10140734 µoªí®É¶¡:2015/9/13 ¤U¤È 11:47:17²Ä 1988 ½g¦^À³
|
®a¥À¥ªÃä¨xŦ´c©Ê¸~½F¬ù3.3¤½¤À¡A¦]¥k¨xµ²¥Û¤w¤Á°£¡AÅv«Âª¾¦WÂå¥Íªí¥Ün¦Ü¤Ö¤Á°£5¤½¤À ª©¤W¦U¦ì¤j¤j¦h¬°Âå¾Ç±M®a¡A¥i§_«Ø¨¥ ¤â³N¤Á°£¦n¡AÁÙ¬O¤¤Âå½Õ²z§í¨î¦n ¤^¨Dª©¤W¦U¦ì¤j¤j±q±M·~¨¤«×µ¹¤©«Ø¨¥ |
|
|
·|û¡G99910140657 µoªí®É¶¡:2015/9/13 ¤U¤È 10:20:39²Ä 1987 ½g¦^À³
|
¥xÁÞ¤j«e½ú ÁÂÁ±z©ú½Tªº«ü¾É¡I±z¯uªº¦n¯«³á¡I¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/13 ¤U¤È 09:57:23²Ä 1986 ½g¦^À³
|
±Û«a¤j 1»{¦P§AªºÆ[ÂI: ¤j®a»ô¤ß°J¤ß¦V¯E¹©¬èë¡A¬ß¦¹Áû·sÃÄ¡A¥¿¦¡´¦òUÁÞ¤À¤l·sÃıϥ@·s¬ö¤¸ 2Ó¤H°í«H §ë¸ê¦nªº¥Í§Þ¤½¥q, Åý¸Ó¤½¥q¯à¬ãµo¥X±Ï¤HªºÃĪ«¤]¤@ºØµ½Á| 3µo®i¥Íª«¸gÀÙ¤w¬O°ê®a¬J©w¬Fµ¦,¸òÀH¬F©²¸}¨B¨«´N¹ï¤F(µo®i¥Íª«¸gÀÙ¬O¬FÄÒ¶¡³Ì¤jªº¦@ÃÑ) ¥Íª«¸gÀÙ½d³ò«Ü¤j n¿ï¬ãµoÃĪ«ªº¥Í§Þ¤½¥q ¬ãµoÃĪ«ªº¥Í§Þ¤½¥q«Ü¦h,n¿ï¬ãµoÀù¯g(©Î·R´þ¯f)ªº¤½¥q (Àù¯g¤H¤f¥¼¨Ó·|¤£Â_¼W¥[) ¿ï¬ãµoÀù¯gªº¤½¥qn¿ï¬ãµo·s¤@¥NÀù¯g§K¬ÌÀøªkªº¤½¥q ·s¤@¥NÀù¯g§K¬ÌÀøªkn¿ï¥D°Ê§K¬ÌÀøªkªº¤½¥q ·s¤@¥NÀù¯g¥D°Ê§K¬ÌÀøªkn¿ï¬ãµoÁÞ¤À¤l·sÃĪº¤½¥q ·s¤@¥NÀù¯g¥D°Ê§K¬ÌÀøªk¬ãµoÁÞ¤À¤l·sÃÄn¿ï¤w¶i¤J¤T´ÁÁ{§É §Y±N¶i¤Junblind ªº¤½¥q |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2015/9/13 ¤U¤È 07:19:05²Ä 1985 ½g¦^À³
|
¥xÁÞ¤j¡I¦¼µ¥¤ß¦sµ½©À¡A¥¿±¯à¶q¦@®¶¦Pµ¥ÀW²vªº¯E¤Í¡A©µ¦ùÂX®i´¶¤Î¥þ²y²³¥Í¡A¤×¨äW©ó¨ÅÀù¥|´Áªº¯f±w(¤Ñ¤U¶ý¶ýÌ)¡AÄ@¦³©¯»P±z»ô¤ß°J¤ß¦V¯E¹©¬èë¡A¬ß¦¹Áû·sÃÄ¡A¥¿¦¡´¦òUÁÞ¤À¤l·sÃıϥ@·s¬ö¤¸¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/13 ¤U¤È 06:27:29²Ä 1984 ½g¦^À³
|
¥t¥~¦p±aª¨ª¨ ¶ý¶ý ªü¤½ ªü¶ý °µÀù¯g¿z¿ï ¤ÎÅý¤j¥x¥_¦a°Ï»P®Ö¤T¦¤é°£§Ð,»·Â÷®Ö¨a«Â¯Ù ¦p¼w°ê¤@¼Ë¥þ¤Oµo®iºñ¦â¯à·½,µo®i¤j¥x¥_¥« ¹q°Ê¤½¨®»P¾÷¨®(¤½¨®¤£n¦b¨Ï¥Î·|¦Ã¬VÀô¹Òªº®ãªo) ¤]¬O«Ü¦nªºµ½Á| |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/13 ¤U¤È 06:04:15²Ä 1983 ½g¦^À³
|
¤µ¤Ñ¥¿¦¡¶i¤J¥ò¬î¡A¬î¤Ñ¦±ßµy¦³ ²D·N¡A¦bµ¥«Ý¼Æ¾Ú¤½§i®É¨è¡AÀ³¤ß¦s µ½©À¡A¦æµ½¿n¼w¡A¸gÀÙ±¡ªp¤£¬O«Ü¦n ªº¯E¤Í¤]¥i¦æµ½¡A¦æµ½¤£¤@©wnµo«Ü ¦h¿ú¡A¥i°w¹ï¹¦w¡AªÅ¦Ã ¹D¸ô¦w¥þµ¥ ·|¼vÅT°·±d»P¥Í©R¦w¥þªºÄ³ÃD¦V·í¦a¥ß©e¡A ¿¤¥«¬F©²´£¥X«Ø¨¥¡A¶V¦h¥Á·N¤ÏÀ³¡A¥ß©e½Ñ¤½ »P¿¤¥«¬F©²«K¤£´±¹HI¥Á·N |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/13 ¤U¤È 05:10:24²Ä 1982 ½g¦^À³
|
999¤j A 8¤ë©³ªº¤½§i Ó¤H¬ã§P¶}©l¸Ñª¼ ²Îp¼Æ¾Ú ²×¤îÁ{§ÉÆ[¹î·|¸¨¤J¥ò¬î topline ·|¦b²Ä¤@©u«e¤½§i B ¦pªG¤£¦Ò¼{¥«³õ»P¾Ç³N¦¨´N¼ú¡A¥H2016¦~²Ä¤@©u¸Ñª¼¾÷²v¾÷·|¸û¤j (2016 ²Ä¤@©u¸`¶}©l¸Ñª¼ ²Îp¼Æ¾Ú ²×¤îÁ{§ÉÆ[¹î)topline ·|¦b¤W¥b¤½§i C ´CÅé³ø¾Én·Ç³Æ°Ñ»P°ê»Ú¬ÛÃöÀù¯g«n·|ij»P´Á¥Zµoªí¦pªGÄݹê topline ·|¦b¤T¤ë«e¤½§i D ¬Û«H±M®a·|ij»P¬ü°êÅU°Ý¹ïUnblind ªº¨M©w (±M®a´N¬O¤ñ§ÚÌÁÙ¦æ ÁÙ±M·~ §ó¯à´x´¤³Ì¨Î®É¶¡ÂIÅýPFS¦b³Ì«GÄRªº®É¶¡«GÄR ) OBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016 E ¦]¬°Á{§É¸ÕÅç¬O¤@Ó¤£Â_Åܰʪº¹Lµ{ , Åý¤@¤Á¦^Âk¦ÛµM ¥Ê¼ô¸¦¸¨ let it be |
|
|
·|û¡G99910140657 µoªí®É¶¡:2015/9/13 ¤U¤È 02:51:09²Ä 1981 ½g¦^À³
|
¥xÁÞ¤j«e½ú ±z¦n¡I«·s¾ã²z«ôŪ±zªº¶K¤å«ü¾É¡I ¦b2015/06/20±z¶K¤å¹w´ú¤¤¦³¬q¬ã§P«ü¾É¤å (OBI822¡Ð¡Ð¡Ð¤£¦Ò¼{ºÉ¦¤W¥«·m§ð¥«³õ»PÀ禬©Î¯Î°|ªø¿Õ¨©º¸¾Ç³N¦¨´N¼ú¡A¥H2016¦~²Ä¤@©u¸Ñª¼¾÷²v¾÷·|¸û¤j¡A¬ã§P¦b³½»Pºµ´x¤£¥iݱoªº±¡ªp¤U¬°¤F¡y«GÄRªºPFS¡A¯E¹©±N´L«±M®aÅU°Ý¸s·N¨£¡K¡K¡K¡K¡K)¡I¡I ²{¯E¹©ªº¤½§i¦p±z¬ã§Pªº¬O©ó2016/03¥H«e¤½§i¸Ñª¼²Îp¼Æ¾Ú¡I ½Ð±Ð±z¨Ì³o®É¶¡¡A³o·N«ä¬O«ü¯E¹©¬O¿ï¾Ü¤F¾Ö¦³¡i«GÄRªºPFS¡jªº®É¶¡¤~¤½§i²Îp¸Ñª¼¼Æ¾Ú¡H¡H¡H¤p§Ì¥i¥H¥Î¦p¦¹Æ[©À¸àÄÀ¶Ü¡H ¥xÁÞ¤j«e½ú³Ò¾r±z¤£§[«ü¾É¡IÁÂÁ±z¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/13 ¤W¤È 06:38:59²Ä 1980 ½g¦^À³
|
Ä«ªG·s»D ¥Í§ÞªÑªñ´Á¤Wºt¤j´_¬¡¡A¤£¶È8¤ëÀ禬¬¡Â۶øõ¡A±a°Ê©±ÀY¥«³õ°f¶Õ½Ä°ª¡A¥B¤£¤ÖӪѧl¤Þ§ë«H»P¥~¸êªk¤H«ùÄò¥[½X¡C ªk¤H»{¬°¡A¨ü´fªÑ»ù§CÀÉ¡B¿Ä¸ê´îªÎ¡B¬Fµ¦ÃP¸j¡B¸êª÷Âà¦V»PÁ`²Î¤j¿ïÃD§÷µ¥5¤j§Q¦h¡A쥻´N¬Oªø¦hªº¥Í§ÞªÑ¡A¥i±æ¦A¦¸©Ô¥X¤@ªi¦æ±¡¡A¥u¬O§ë¸ê¤HÀ³¸Ó¥Hªø½u§ë¸ê¬Ý«Ý¡A¦Ó«Dµu½u¶i¥X¾Þ§@¡C ¥HÁ`²Î¤j¿ï¦Ó¨¥¡A¸UÄ_§ëÅU°õ¦æªø¤ýºa¦°«ü¥X¡A¥Ø«eű³Ì¤jªº¥Á¶iÄÒ¥D®u½²^¤å¡A»P¥ø·~¬ÉÃöÁp«×³Ì°ªªº´N¬O¥Í§Þ·~¡A¦]¦¹¥Í§ÞªÑ¦b°ò¥»±»P¸êª÷±¤§¥~¡AÁÙ¦³¤j¿ïªº·Q¹³ÃD§÷¡C ¥x·s§ëÅU¬ã¨s³¡¸g²z½²¶h½å¤]«ü¥X¡A½²^¤å¤£¶È´¿¥ô¤¤¸Î·sÃÄ¡]4147¡^«e¨¦t©÷¥Í§Þªº¸³¨Æªø¡A¦o©ó¦æ¬F°|°Æ°|ªø¥ô¤º¡A¦b³W¹º°êµo°òª÷ªº§ë¸ê¤è¦V®É¡A¤]¬O²Ä¤@Ó´£¥Xn§ë¸ê¥Í§Þ·~ªº©xû¡A¡u¦pªG½²^¤å·í¿ï¡A¥Í§ÞªÑ·|º¦Â½¡v¡C ½²¶h½åªí¥Ü¡A¥Í§ÞªÑ¤¤ªº·sÃĪѡA¤µ¦~§Ön¶}ªáµ²ªG¡A¯S§O¬O±M§ðÀù¯gÃĪº¯E¹©¡A»P¥D§ð·R´þ¯fÃĪ«ªº¤¤¸Î¡C¥H¤¤¸Î¬°¨Ò¡A¹wp11¤ë©³±q¿³ÂdÂà¤WÂd¡C §ó«nªº¬O¡A¤¤¸Î¤w§¹¦¨2´ÁÁ{§É¹êÅ窺·R´þ¯f·sÃÄTMB-355¡A¹w´Á9~10¤ë±N°µ§¹3´Á¹êÅç¡A¥B¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^¯S§Oµ¹¤©§Ö³t¼f¬d¡A·N¨ýY3´Á¹êÅç¼Æ¾Ú¨S°ÝÃD¡A¦~©³«e¥i¯àÀòµoÃÄÃÒ¡A©ú¦~»{¦CÃe¤j±ÂÅv»P¤À¼íª÷ÃB±N«ü¤é¥i«Ý¡C ¥L¤ÀªR¡A¥Ø«e¥þ²y¦³500¸U·R´þ¯f±w¡A¨ä¤¤¬ü°ê¬°¼Æ¤£¤Ö¡A¥Ø«e¤S¯Ê¥F¦³®Äªº·R´þ¯fÃĪ«¡A¦]¦¹«ÈÆ[¨Ó¬Ý¡A¥un¤¤¸ÎTMB-355ªº3´Á¼Æ¾Ú¨S°ÝÃD¡A³oºØ·sÃÄ©ú¦~°_±N¦¨¬°¬ü°êªvÀø·R´þ¯fªº¥DnÃĪ«¡A·N¨ý¤¤¸Î»PI«á¤jªÑªF¡B¦æ¬F°|°êµo°òª÷³£±N¬O¤jĹ®a¡C ¦AªÌ¡A®Ú¾Ú¬ü°ê¥Í§Þ·~©¹¨Ò¡A¦b¤W¥b¦~´£¥Xªº¦U¶µÁʨ֮שΧë¸ê®×¡A³q±`·|¦b¦~©³«e©çªO¡A¦]¦¹¨C¦~²Ä4©uªº¥Í§Þ·~Áʨ֮׬۹ﰾ¦h¡A±N¦³§UÀç³y¥xÆW¥Í§ÞªÑªº¥«³õ®ðª^¡C ½²¶h½å«Øij¡A§ë¸ê¤H²{¦b¿ï¾Ü¥Í§ÞªÑ¡A¯S§O¬O·sÃĪѡAnÂê©w¦³°ê»Ú¦X§@¹ï¶H¡B´`¬ü°êªk³W°µÁ{§É¹êÅç¡A©Î¬O¶}µo¤¤ªº·sÃĨü¨ì°ê»ÚÃļtª`·NªºÓªÑ¡C¡]¼B·Ø«Û¡þ¥x¥_³ø¾É¡^ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ ¤j®a»{¬°©O? |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2015/9/12 ¤W¤È 07:35:25²Ä 1979 ½g¦^À³
|
ÁÂÁ¦ѥv¤jÄÀºÃ¡AÁöµM©|¤£¯àÃÒ©ú¹êÅç²ÕPFS¦³¦hÀu²§¡A¦ý§ó°í©T¤ä¼µ¹ï·Ó²ÕPFS¬ù6Ӥ몺¨Æ¹ê¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/11 ¤U¤È 11:45:35²Ä 1978 ½g¦^À³
|
·PÁ¦ѥv¤j¤À¨É¡AºëÅP¤ÀªR¤@»yÂI¯}¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/9/11 ¤U¤È 10:08:27²Ä 1977 ½g¦^À³
|
¸`¿ý¦Û¥ý±´¶g¥Z µ¥¤@Áû·sÃĪïÀY»°¤W °£¤F¨ã³Æ°ò¥»Àò§Qªº±Ú¸s¥~¡A¥Í§Þ·sÃĬO§ë¸ê¤H¤S·R¤S©Èªº¦¸²£·~¡A±q¬ü°ê¨º´µ¹F§J¥Í§Þ«ü¼Æ(¢Ü¢Ð¢×)ÀW³Ð·s°ªªº¤º²[¤¤¥i¥H¬Ý¥X¡A¥Ø«eÁ`¥«È«e¨â¤j¤À§O¬O¦N§Q¼w(GILD)»P¦w¶i(AMGN)¤À®x§Ü§¡A¦N§Q¼w¦]¬°Ä~·R´þ¯fÃĪ«TruvadaÀò¢Ô¢Ò¢Ï³q¹L¨ã¦³¹w¨¾®ÄªG«á¡Aºò±µµÛ¤S³q¹L¨ä¢Ñ«¬¨xª¢ªº¤fªAÃÄHarvoni¡Aµuµu¨â¦~ªÑ»ù¦Û¥|¤»¡D¤C¬ü¤¸¤jº¦¦Ü³Ì°ªªº¤@¤G¤T¡D¤T¤C¬ü¤¸¡Aº¦´T°ª¹F¤@¡D¤»¥|¿¡A¥Ø«eÁ`¥«È¤@¥|¤E¤C¡D¤K»õ¬ü¤¸¡C¦w¶i«h¬O¥ý«á¨âÁû¦¨¥\°Ó·~¤Æªº¥Íª«§Þ³N·sÃÄEPO¤ÎG-CSF¡A±N¤½¥q±a¶i¥þ·s»â°ì¡A¨Ã³z¹L¨ÖÁʧ§¤j¹ê¤O¡A¥Ø«eÁ`¥«È¤@¤@¤@¥|¡D¤K»õ¬ü¤¸¡C ¥xÆWÁöµMÁÙ¨S¦³¤@Áû¯u¥¿¦Û¥D¬ãµo¦¨¥\ªº·sÃÄ¡A¤£¹L¡A³oÓ¯à¶q¤w¸g¦b¯E¹©¡]4174¡^¨¤W¬Ý¨£¥ú©M¼ö¡A©ú¦~¤T¤ë¨ÅÀù·sÃÄOBI-822¤T´ÁÁ{§É¼Æ¾Ú¸Ñª¼¡A±N¦¨¬°¥xÆW·sÃĨ«¦Vªº«n¤À¤ôÀ¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/11 ¤U¤È 07:27:48²Ä 1976 ½g¦^À³
|
ÁÂÁ¦ѥv¥S±zªº»¡©ú ¨ü±Ð¤F ·sÃĬã¨s ¯uªº¤Ó¶ø¯µ¤F ¤§«e¦U¦ì¤j¤jªº¥ß½× ¦p¤µ¤@ª½¥i¥H°í©w¬Ý«Ý ¯u¬O¤£¿ù |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2015/9/11 ¤U¤È 07:02:09²Ä 1975 ½g¦^À³
|
HI ¯E§J¥S ªk°ê560¬O¥b¦~«eªº¬G¨Æ¡A·½ÀY¨Ó¦Û¸s¯qªº³ø§i¡A¥²´I½Ñ¦ì¤j½å¤w¸g°Q½×¹L §Ú©úª¾16.3Ӥ몺¼Æ¦r«Ü©_©Ç¡A«o¤SµLªk±j¤O¤Ï»é¡A¦]¦¹³o¥b¦~¨Ó¯Õ¯Õ©óÃh >>¦pªG822¹ï·Ó²ÕPFS¦³Ó¸U¤@öt¨ì16.3Ó¤ë¡A¤j®aªº§V¤O°Z¤£ªF¬y¤ô¡H §Ú¼g³o¬q¤å¦rªº¥Øªº¥u¬O·Q¤Æ¸Ñ¤ß¤¤ªº¤@µ·µ·¤£¦w §Ú¤µ¤Ñ¤]»P¸Ó¬ã¨sûÁpµ¸¹L ¥L»¡¥u¬On±j½Õ¤£¥i©¿µø¶Pº¸»XÃĪ«¹ïPFSªº°^Äm¡A·íµM¤£¥i¥H±N16.3Ӥ몽±µ®M¥Î¦b¹ï·Ó²Õ ¬JµM¹ï·Ó²ÕPFS¤£¤Ó¥i¯à²§±`öt°ª «h¥²´I½Ñ¤j½å¥H¹ï·Ó²Õ6Ӥ묰°²³]°ò¦ªº±À½×¤´µM«ÜéT ¦Ü©ó"¶i¤@¨B±À½×822¹êÅç²ÕPFS·|§ó¤["´N¤£¬O§Ú¯à±À½×ªº |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/11 ¤U¤È 01:54:06²Ä 1974 ½g¦^À³
|
½Ð±Ð¦Ñ¥v¤j Y±zªº±À½×¥¿½T ¬O§_¥i¥H¶i¤@¨B±À½×»¡ 822¹êÅç²ÕPFS·|§ó¤[? |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2015/9/11 ¤W¤È 11:10:39²Ä 1973 ½g¦^À³
|
§Ú·QÁÙ¬OÀ³¸Ó»P¤j®a¤À¨É¡ã¡ã ¡u®Ú¾Ú¤@¥÷ªk°êªº¬ã¨s¦@¤ÀªR¤F560Ó¯f¤H¡AY¯f¤H¦b±µ¨ü§¹²Ä¤@½uªº¤ÆÀø«áÄ~Äòºû«ù¶Pº¸»XÀøªk¡APFS¥i¥Ñ7.77Ӥ멵ªø¨ì16.3Ó¤ë¡v¡A²³¦ì¦³¬Æ¦h°Q½×¡A¦ý§Ú¤@ª½¯Õ¯Õ©óÃh¡Aª½¨ì¬Q¤Ñ¡A§Ú¬Ý¨ì¸Ó³ø§i¤@¥y¸Ü¡A§Ú¶}Ãh¯º¤F¡Aì¨Ó°ÝÃD³o»ò¦n¸Ñ¨M¡C¨º¥y¸Ü¬O¡G Statistical analysis The duration of PFS is defined as the time from the beginning of first line chemotherapy treatment to the date of progressive disease or death. ¡@¡@ ¡@¡@ªk°ê³ø§iªºPFSpºâ¤è¦¡¬O±q¶}©l±µ¨ü¤ÆÀø°_ºâ¡Aµ²§ô¤ÆÀø«á±µµÛ¨Ï¥Î¶Pº¸»XÃĪ«¡Aª½¨ì¥X²{´c¤Æ©Î¦º¤`¡C822ªºPFS¬O±qÀH¾÷¤À²Õ¶}©l¨ì´c¤Æ©Î¦º¤`¡A¤]´N¬O»¡¡A822ªºPFS¨S¦³§â¤ÆÀø´Ápºâ¦b¤º¡C¨ÅÀù³Ì±`¨£ªº¤ÆÀø¬O¤p¬õ²ù©Îµµ§ü¾J¡A3~4¶gªvÀø¤@¦¸¡A¼Ð·ÇÀøµ{»ÝªvÀø4~6¦¸¡A¤ÆÀøªºPFS´N°^Äm¤F4~4.5Ó¤ë¡F¤]´N¬O»¡¸Ó³ø§i»¡ªº16.3Ó¤ë¡A¥²¶·¦©°£4~4.5Ó¤ë¡A³Ñ¤Uªº¤~¬O¶Pº¸»X°^ÄmªºPFS¡A¤j¬ù¥u³Ñ12Ó¤ë¡C¦¹¥~¡A822Á{§É«e¥²¶·°±¤î¤ÆÀø4~6¶g¡A¨Ìªk°ê³ø§iªºpºâ¤èªk¡APFSÁÙ¶·¦©°£1~1.5Ó¤ë¡A¬O¬G¶Pº¸»X°^ÄmªºPFS³Ì¦h¥u¦³10.5~11Ó¤ë¡C¦ý§ÚÌ¥²¶·¦Ò¼{¨ì¡A¥|´Á¨ÅÀù°±¥Î¤ÆÀø4~6¶g«á¤~¨Ï¥Î¶Pº¸»XÃĪ«¡A¥¼¥²À£±o¦í¸~½F´c¤Æ¡A±qAmyªº§ÜÀù¹Lµ{¥i¥Hª¾¹D¡A¶Pº¸»XªºÃĮįà§_¹F10.5~11Ó¤ë¡H§Ú¤£¤Ó¬Û«H ¡@¡@¦¹¥~¡A822¥u¦³°©ÀYÂಾªÌ¤£¦¬Subjects with metastasis limited to the bone only are excluded¡A¥ç§Y·Q¥[¤J822¡u´X¥G¡vn¦³¨â³B»·ºÝÂಾ¡A°£¤F°©ÀYÂಾ¡AÁÙn¥X²{¨ä¥LŦ¾¹Âಾ¡C®Ú¾Ú´_¨Å¯ÇLetrozole¦h¹F453¤HªºÁ{§É¼Æ¾Ú¡A±ß´Á§½³¡´_µoPFS¬O 12.1Ó¤ë¡]±ß´Á«ü²Ä¤T´Á¡^¡A°©ÂಾPFS°¬°9.5¡AŦ¾¹Âಾ°¬°8.3¡A¨xŦÂಾ¶È³Ñ3.8Ó¤ë¡C®õ²ö¦èªâTamoxifen¦h¹F454¤HªºÁ{§É¼Æ¾Ú¡A¤]§e²{Ãþ¦ü±¡ªp¡A§Y±ß´Á§½³¡´_µoPFS6.4Ó¤ë³Ì¨Î¡A°©ÂಾPFS°¬°6.2¡AŦ¾¹Âಾ°¬°4.6¡A¨xŦÂಾ¶È¦³3Ó¤ë³Ì®t¡C822Á{§É¯f¤H´X¥G³£¬O¨â³B»·ºÝÂಾªº¥|´Á¯f±w¡A¦Ó¥BÂಾ¨ìŦ¾¹¡Aªk°ê560¤H¤¤³æ¤@Âಾ¦û56%¡C¨âªÌ¯f±w±ø¥ó¤j¤£¬Û¦P¡Aªk°êªº¼Æ¾ÚY©ñ¦b822¤W¡A¤@©w·|¦A¤UסC§Ú»{¬°822¹ï·Ó²Õ¦³ºû«ù¶Pº¸»XªvÀøªÌ¡APFS·|±q10.5~11Ó¤ë¦A©¹¤U°¨ì8Ӥ륪¥k ¡@¡@¥i¬O¹ï·Ó²Õ¤¤¨Ã«D©Ò¦³¤H³£·|±µ¨ü¶Pº¸»XªvÀø¡A¥H±`ºA¤À§G¨Ó¬Ý¡AHer2+¥H¤Î¤T³±©Ê¨ÅÀù¬ù¦û40~50%¡A³o¨Ç¤H¹ï¶Pº¸»XÃĪ«¬O¨S¦³¤ÏÀ³ªº¡A¦o̱µ¨ü¤ÆÀøªºPFS«ÜÃø¶W¹L6Ó¤ë¡C¤]´N¬O»¡¦o̯ǤJ822¹ï·Ó²ÕÁ{§É«á¡A¦]¬°¨S¦³¥´¨ì822ÃĪ«¡A³q±`3Ӥ륪¥k´N·|´c¤Æ¡]½Ð°Ñ¦ÒAmyªº§ÜÀù¹Lµ{¡^¡C40~50%ªº¤H3Ó¤ë·|´c¤Æ¡A50~60%¦³¶Pº¸»XÃĪ«¤ä«ùªºPFS¤j·§8Ó¤ë¡Aºî¦¹µû¦ô822¹ï·Ó²ÕPFSÀ³¸Ó¤£¨ì6Ó¤ë¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/11 ¤W¤È 10:46:49²Ä 1972 ½g¦^À³
|
°ê®a¥Í§ÞÂåÀø²£·~µ¦¶i·|ªø³¯ºû¬L«ü¥X¡A¤¤¬ã°|¡B°ê½Ã°| ¦bÁÞ¤À¤l¡B°ò¦]ÂàĶµ¥¤À¤lÃĪ«¦X¦¨»â°ì²Ö¿nªº°ò¦¡A¥i±æ »â¥ý¥þ²y¶}µo¥XªvÀø¦hºØÀù¯gªºÁÞÃþ§ÜÅé¬Ì]ÃĪ«¤Î§ÜÅéÃĪ«¡C http://www.ibmi.org.tw/client/ActivityDetail.php?REFDOCID=0nslpqpt7tzla3er |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2015/9/10 ¤U¤È 10:21:19²Ä 1971 ½g¦^À³
|
·Q½Ð±ÐªO¤Wªº¥ý¶i.¦b¤U¹ï¥Í§Þ¤ÓÁ}²`ªº²z½×¨Ã¤£¬O«ÜÀ´.³Ìªñ¦³¨ì¤@ÓªB¤Íªº¿Ë±¬O¦b°µ¬ÛÃöªº¬ã¨s(¦³¨ÇªF¦è¤£¤Ó¤è«K»¡ªº¤Ó©ú¥Õ). ·Q½Ð°Ý¤@¤U±N¨Ó822©Î¬O833±N¨Ó¦b°Ó«~¶q²£¤W¦³ÃöÅܲ§©Êªº°ÝÃD.½Ð°Ý¦³¤HÀ´³o¤è±ªº°ÝÃD¶Ü?Åܲ§©Ê¦pªG¤Ó¤j,¬O§_¥Nªí¶q²£¤WÁÙ»Ýn¦AÀu¤Æ¤~¥i¥H³q¹LFDAªº¬dÅçµ¥µ¥ªº. |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/9/10 ¤U¤È 02:15:51²Ä 1970 ½g¦^À³
|
«¢«¢«¢.... ·Q¤£¨ìµS¦p±ó¤§±Íᢪº¥Í§ÞÃþªÑ¤µ¤Ñ²±ªpªÅ«e¡A¤@¦~¥H¨Ó³\©Ò¥¼¨£¤F °ò¥»±»P»ùȤ@ª½³£¦b¨ºùØ¡A¬Ý»ù®æªºÅÜ°Ê°µµu½u¯uªºÁȤ£¤F¤j¿ú ÀHµÛ822©ú¦~Q1¸Ñª¼®É¶¡ªº±µªñ¡A¥~¸êªk¤H·|§ó¥[¿n·¥ªº¥h§G§½«Ø¥ß«ùªÑ³¡¦ì ·Ó³oºØÁͶլݨӡA¸Ñª¼«e¬D¾Ô¾ú¥v°ªÂIÀ³¸Ó¤]¬O¾÷²v·¥°ª ²¦³º³oºØ«½S¯Åªº¤jÃĬOÅý¥xÆW¥Í§Þ²£·~²£È¬ð¯}¥ü¤¸ªºÃöÁä«´¾÷ ¹ï·Ó¹q¤l²£·~ªº«áÄ~µL¤O¡A¥ÍÂåÃþªÑ¤w¸g¿i®±ÀNÀN·Ç³Æ¤@®i¨¤â «Ü¦³¥i¯à¦¨¬°¦~¾P°â10»õ¬ü¤¸¥H¤Wªº¤jÃÄ¡AªÑ»ù¤~10¬ü¤¸¡A¥~¸ê»Pªk¤H¯à¤£¤ß°Ê¤~©Ç Åý§ÚÌÄ~Äò¬Ý¤U¥h~~ ·PÁ¯ΰ|ªø/¤¨¦Ñ/±i¸³ÅK¤T¨¤§Y±N³y´N¥t¤@Ó¥xÆW©_ÂÝ~~ |
|
|
·|û¡G99910140657 µoªí®É¶¡:2015/9/10 ¤W¤È 11:37:13²Ä 1969 ½g¦^À³
|
¡i¥¼¨Óªº¸ô¤W¡A°O±o¦³¦ì¯E¤Í´¿¸g¤À¨É¹Lªº¡j¡K¡K¡K ¦ó¤î¦p¦¹¡K¡K¡H §Ú·Q§Ú³o¤@¥Í¦Ü¦Ñ¤H·ö§b¡A³£·|¥Ã»·»Ê°OCliff¤j¡A¥xÁÞ¤j¡A¦Ñ¥v¤j¡A¤p©_¤j¡A²q·Q¤j¡A«¼C¤j¡K¡K½Ñ¦h«e½ú¤j¡K¡Kªº·½d¡A ¨ä¹ê§ÚÓ¤Hì¹ï¥xÆW«Ü¦h¨Æ»P¥¼¨Ó«Ü·tµM¡K¡K¤×¨ä¬Fªv³y¦¨ªº½Ñ¦h´c±þ²£·~ªº¡yµL¯à¤S¦U¦Û¬°¬F¡A¦Û¥H¬°¬Oªº¬Fµ¦¤§¤h¡z¡K¡K¡I ¦ý¯u¥Ø¸@¨ì¡A¯E¤Í·|¤¤¤£¤U¢°¢¯¼Æ¦ì«e½úªº·½d»P¹ï±ß½ú¤£§[¦Û¤v¦pª÷¦p¥Éªº®É¶¡´`´`µ½»¤ªº«ü¾É¯E¤Í¡A¦³±ÐµLÃþªº«ü¾É±ß½ú¡K¡K¡I¤~¯u¥¿¨£¨ì¥xÆW¤§¥ú¡C Ó¤H¦]±o¹J²`¦³·PIJ¡A¦pªG¥xÆW·|¦³¥¼¨Ó»P«e³~¡A´N¬O¦]¬°¦³±z̳o¸s¦³¯à¡A¦³¼w¡A¦³ºÖªºªøªÌ¦b¤ä¼µµÛ¡A½Ñ¦ì«e½ú·PÁ±zÌ¡A¤]´À§Ú¥®¨à̦b¦¸·PÁ±zÌ¡I ¡i¯¬ºÖ±z̥û·ºÖ³øº¡º¡¡j¡I¤p§Ì¸Û¼°·q¤W¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/9/10 ¤W¤È 10:02:58²Ä 1968 ½g¦^À³
|
ÁÂÁÂCliff¤j.¦Ñ¥v¤j.¥xÁÞ¤j ¬Ý¨Ó¨ä¥LÃĪ«ªº°Æ§@¥ÎÁÙÆZ¦hªº 822¥ú¦b°Æ§@¥Î¤W´NÅý¯f¤HµÎªA¦h¤F Cliff¤j~ÁÂÁ±z´£¨Ñªº¸ê®Æ,ÁÙ¯u¬Ý±o·wÀYÂà¦Vªº,«¢«¢«¢ ¯E¤ÍÌ ¥¼¨Óªº¸ô¤W,°O±o¦³¦ì¯E¤Í´¿¸g¤À¨É¹Lªº ½_ÁJ¶V¹¡º¡ÀY¶V§C °í«ù¬Û«H¥[ªo |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/10 ¤W¤È 09:54:11²Ä 1967 ½g¦^À³
|
¤µ¤Ñ«n¸ê°T ·j´M BTC ³¬¹õ ¥Í§Þ§Q¦h¤j©ñ°e BTC ¥Í§Þ²£·~µ¦²¤¿Ôij©eû·|ij |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2015/9/10 ¤W¤È 08:53:37²Ä 1966 ½g¦^À³
|
¦U¦ì¤j¤j ¥i§_½Ð±ÐOncoMed»P¯E¹©822¨ºÓ¸û¦³Ävª§¤O? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/10 ¤W¤È 12:20:23²Ä 1965 ½g¦^À³
|
¦Ñ¥v¤j¼F®`¡A¤@¥Ú¤¤ªº¡C ³o®aOncoMed¤ñ¯E¹©±ß¨â¦~¦¨¥ß¡A¨´¤µ¦³6¶µÃĪ«¶i¤JÁ{§É¡F¥t¥~6¶µÃĪ«¦bÁ{§É«e¬ã¨s¡C³£¬O°w¹ïÀù·F²ÓMªº·s¿o§Üì§@¬ãµo¡G Key¡udevelopmental¡vpathways strongly implicated in cancer¡G ¡VNotch ¡VWnt ¡VRSPO-LGR ¡VHippo °£¤F²Ä¤@¶µ¥~¡A¨ä¥Lªº¡AÓ¤H³£¬O²Ä¤@¦¸¨£¨ì¡C ¦p¦Ñ¥v¤j©Ò¨¥¡A¥Ø«e³Ì§Öªº¶i«×¬ODemcizumab¡A¥´ºâ¥Î©óªvÀø«D¤p²ÓMªÍÀù»P¯ØŦÀù¡]Phase II¡^¡B§Z±_Àù¡]Phase Ib/II¡^¡C¦bPhase Ia¤¤¦³5%´¿¥X²{Grade III¥H¤Wªº°Æ§@¥Î¡C¨ä¤¤36%¬O¦åÀ£¤É°ª¡A7%·|³Ý¡A7%¥X²{¥i°f©Êªº¤ß°IºÜ¡C³Ì«á¨º¤@¶µ³Ì³Â·Ð¡A»P°ª¾¯¶q¦³Ãö¡A³£¦b¥ÎÃÄ«á100¤Ñ«á¥X²{¡]107-112¤Ñ¤§¶¡¡^¡A¤@¥¹°±ÃÄ¥i¥H³vº¥±Ï¦^¨Ó¡C¤½¥q«ØijnÅçBNP¡]B-type Natriuretic Peptide¡^§@¬°¥Üĵ¶µ¥Ø¡A¤@¥¹¤É°ªn§Öµ¹¸ÑÃÄ¡C Phase Ib for NSCLC¡G PD¡G13% CR¡G3% PR¡G48% SD¡G38% Response rate¡G50%¡]3%+48%=51%¡A»¡¬O50%¡HÀ³¸Ó¬O¥|±Ë¤¤JªºÃö«Y¡^ Clinical benefit rate¡G88%¡]3%+48%+38%=89%¡A¹D²z¦P¤W¡^ PFS¡G5.3-5.8 months¡]¦³¥|ºØ¾¯¶q¡^ OS¡G8 months ¨ä¥Lªº³¡¤À¦³¿³½ì¥i¥H¬Ý³oÓ²nª©¡]2015/04/29Á|¿ì¤½¥q¬ãµo¤éµoªíªºÂ²³ø¡^¡A»¡¬O²n«o¤]¬v¬vÅxÅx146±iSlide¡A¨S¬Ý¨ìÀY·wºâ§A±j¡C ¡uhttp://posters.omed.s3.amazonaws.com/rdday-presentation-42915.pdf ¡v |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/9 ¤U¤È 11:01:14²Ä 1964 ½g¦^À³
|
³o¥«¤@Ó¦´Á¦X§@¶}µoÃĪ«ªº¦X¬ù ¦@È33»õ¬üª÷ À³¬O¦b preclinical ¦Ü phase1 ¶¥¬qñ¬ùªº OncoMed Pipeline - OncoMed Pharmaceuticals http://www.oncomed.com/Pipeline.html |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/9 ¤U¤È 10:49:05²Ä 1963 ½g¦^À³
|
¦Ñ¥v¥S §A¤Ó¯«¤F ¯uªº¬O33»õ¬ü¤¸, ±M¤@©Ê¤£¬O«Ü¦n´N¦³³oºØ¦æ±¡,»¡©ú§ÜÀù¯g·F²ÓMªºÃĪ«ªº¤í¯Ê Celgene ¹ï¬ãµo§ÜÀù¯g·F²ÓMªºÃĪ«¤£±¤«ª÷±ÂÅvªí¬O§ÜÀù¯g·F²ÓMªº«n©Ê ©Ò¿×¾à¸é¥ý¾à¤ý ±Ù¯ó¤£°£®Ú¬K·§j¤S¥Í Licenser OncoMed Licensee Celgene Products Six anticancer stem cell drugs Biodollars (upfront; milestones) $3.3 billion ($177 million; $3.15 billion) |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2015/9/9 ¤U¤È 05:03:05²Ä 1962 ½g¦^À³
|
¥xÁÞ¥S §Ú²qÀ³¸Ó¬OOncomed³o®a¤½¥q °w¹ïÀù·F²ÓM¬ãµo³æ§ÜÃĪ« ¹vÂI¬Æ¦h¡A©Ò¥H¶}µoªº³æ§ÜÃĪ«¤]¦h ³t«×³Ì§Öªº¬ODemcizumab¶i¤J¤G´Á 2013¦~12¤ë»PCelgeneñ¤U¦X§@¶}µo ñ¬ùª÷1.7725»õ¬üª÷ ¥[¤W¤»Ó¦X§@¶}µoÃĪ«ªº¦X¬ù¦@È33»õ¬üª÷ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/9 ¤U¤È 12:34:02²Ä 1961 ½g¦^À³
|
¥xÁÞ¤j ·PÁ±zªºªÖ©w ¤p§Ì´NÄ~Äò¦bÄw½X°Q½×©«¤¤¼W¥[§Þ³N¤ÀªRªº¸gÅç¤À¨É ¨Ñ¤j®a°Ñ¦Ò ¦ý¬O¦Ñ¸Ü¤@¥y: §ë¸ê¦³·ÀI ¶R½æ½Ð¤p¤ß |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/9 ¤U¤È 12:14:23²Ä 1960 ½g¦^À³
|
¯E§J¤j ÁÂÁ§A´£¨Ñªº§Þ³N¤ÀªR «Øij ¯E¹©ªºÄw½X°lÂÜ©« §ó¦W¬° ¯E¹©ªºÄw½X»P§Þ³N¤ÀªR°lÂÜ©« §ó¯à¹üÅã§Aªº±Mªø §Þ³N¤ÀªRªº®ÑÄy«Ü¦h «Ü¦h¯E¤Í¤]¥i¤À¨É¤@¤U ¬ã¨s°ò¥»±¥~°t¦XÄw½X»P§Þ³N¤ÀªR·|§ó¶g©µ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/9 ¤W¤È 11:39:51²Ä 1959 ½g¦^À³
|
¥xÁÞ¤j ¤WÂd¥ÍÂå«ü¼Æ ¥»¤ëK½uKD½T¹ê¶Àª÷¥æ¤e K 21.83> D 20.54 ¶q¤]·|¥X¨Ó ¦ý¬OMACD§CÀɤϼu¤¤ ¥»©PK½uKD¶Àª÷¥æ¤e¶}¤f«ùÄòÂX¤j K 34.02> D 26.32 ¯E¹©¤ëK½uKD§Y±N§Î¦¨¶Àª÷¥æ¤e ¶}¤fÁY¤p¤¤ ¹wp¥»¤ë«Ê³¬¶}¤f ¤U¤ë¶Àª÷¥æ¤e ©PK½uKD ¤w¸g¶Àª÷¥æ¤e ¶}¤f«ùÄòÂX¤j¤¤ K 56.78> D 40.72 ¥»©PK½u³s2¬õ MACD½T©w¤Ï¼u ¦^¨ì300¥H¤W À³¸Ó¥i¥H¬O½T©wªø´Á©³³¡ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/9 ¤W¤È 10:44:12²Ä 1958 ½g¦^À³
|
1 ±M¤@©Ê(specificity)¥Íª«¤uµ{¤¤¦³¥H¤U´XºØ§t¸q¡G http://cht.a-hospital.com/w/%E4%B8%93%E4%B8%80%E6%80%A7 2 ¥t¥~¦bÀËÅç ¶EÂ_(Diagnosis) ¤]·|¬Ý¨ìSpecificity Sensitivity (±Ó·P«×)¡G¬°¦³¯fªÌ¶EÂ_µ²ªG¬°¶§©Êªº¤ñ²v ·í°ªÆF±Ó¶EÂ_¸ÕÅ窺µ²ªG¬°³±©Ê¡A¦¹¬°¥¼¿©±w¦¹¯e¯f¬Û·í¥i¾aªº«ü¼Ð Specificity (¯S²§«×)¡G¬°¨S¯fªÌ¶EÂ_µ²ªG¬°³±©Êªº¤ñ²v ¦b±M¤@©Ê°ªªº¶EÂ_¸ÕÅç¡Aµ²ªG¶§©Ê§Yªí¦³¯f¡A¦]¬°¨u¨£°°¶§©Ê °²¶§©Ê¡G¬O«ü°·±dªº¤H¶EÂ_¸ÕÅçµ²ªG¬°¤£¥¿±`¡A¦p¦PµL¶dªº¤H °²³±©Ê¡G¬O«ü¦³¯fªº¤H¶EÂ_¸ÕÅçµ²ªG¬°¥¿±`¡A¦p¦P®ø»»ªk¥~ªº¤ï®{ http://www.mmh.org.tw/taitam/medical_edu/www/?contentID=644 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/9 ¤W¤È 09:41:52²Ä 1957 ½g¦^À³
|
¦V«e¦æ¤j «Ü¦h¤Hµ¥Ônµo°Ý ¤@®É¤]§Ñ±¼À³¸ÓÄ~Äò°l°Ý , ¤£¹Lµ¹ªºµª®×¤w¨¬°÷¤F ¦]¬°¥Ø«e¬ãµoªºÀù¯gÃįప±M¤@©Ê ¹v¦VÀù·F²ÓMÀ³ÄÝÁÞ¤À¤l·sÃĤF,¥¼¨Ó©Î³\·|¦³¨ä¥LÃĪ«¤]¯à °ª±M¤@©Ê¹v¦VÀù·F²ÓM ¦ýn«Ü¤[«Ü¤[¥H«áªº¨Æ¤F ÃĪ«¬ãµo ¥»½è¤W´N¬O¤@³õÄvÁÉ (¿ïÃD ¤H¤~ ´¼¤~ ¿ú°]) ÁÂÁ¤p©_¤j ¦Ñ¥v¤j ¤Î¦U¦ì¤j¤jªñ´Áªº¸ê°T¤À¨É ¯E§J¤j ¨C¤Ñ³£n¬Ý§Aªº¸`¥Ø ÁÂÁ OTC¥Í§Þ«ü¼Æ¦n¹³ ¤ëKD §CÀɶÀª÷¥æ¤e ¬O§_¥¿½T? |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2015/9/9 ¤W¤È 08:51:34²Ä 1956 ½g¦^À³
|
¥xÁÞ¤j:©êºp§Ñ¤FºÙ©I |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2015/9/9 ¤W¤È 08:40:47²Ä 1955 ½g¦^À³
|
³o¬O105¤p®É«eªº°Ý¹F¡A³o¦ì°ê»Úª¾¦Wªº¬ì¾Ç®a ªº¦^µª¥O§Ú³¶ÅD¡A¦]¬°³oÃö«Y¨ì¨ÅÀù·sÃÄOBI822 ¥¼¨ÓªºÄvª§ªÌ °ÝÃD:¥Ø«e¥@¬É¨ä¥L¥Í§Þ¤½¥q¦b¬ãµoªºÀù¯g ÃĦ³¦p¦PÁÞ¤À¤l·sÃĤ@¼Ë¥i¹v¦VÀù·F²ÓM? ¦^µª:¦³ÃĪ«¦b¬ãµo¤¤¡A¥i°w¹ï·F²ÓM¡A ¦ý±M¤@©Ê¤£¨Î ¥i§_¤À¨É¨Ó·½³B? ¦ý±M¤@©Ê¤£¨Î? ¥t±oª¾¤½¥qºA«×¬O«D±`«O¦u,¦ý¬O¹ï822¬O¼ÖÆ[ªº,¹ï©ó¼Æ¦r¬O¦h¤Ö¤£³zÅS |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/9 ¤W¤È 07:00:35²Ä 1954 ½g¦^À³
|
±i©À·O¡G¥Í§Þ·~¦³¸³¨Æªø¤F 2015-09-09 03:15:29 ¸gÀÙ¤é³ø °OªÌ¶À¤å©_¡þ¥x¥_³ø¾É ¥Í§Þ¾ã¦X¨|¦¨¤¤¤ß¡]Si2C¡^²×©ón¡u°_¦º¦^¥Í¡v¡A¯E¹©¸³¨Æªøº[¦æ¬F°|¥Í§Þ²£·~µ¦²¤¿Ôij©eû±i©À·O¬Q¡]8¡^¤éªí¥Ü¡A¤¤¬ã°|°|ªø¯Î±Ò´f±µ¤USi2CÁ`¥l¶°¤H¤§«á¡A¥xÆW¥Í§Þ²£·~´N¦³¡u¸³¨Æªø¡v¤F¡C Si2C¬O2008¦~¦æ¬F°|BTC·|ijªº¨Mij¡A¥Ñ¤w¬Gº®uÅU°ÝĬÃh¤¯´£¥X¡A·~¬É«ü¥X¡ABTC¥l¶}¦h¦~¡A¦n¤£®e©ö§âSi2C¼½ºØ§¹¦¨¡A¦pªG¤~¥¿nµoªÞ´N¬\µä¡A¯u¬OªP¶O¤@µfºë¯«¡C¯Î±Ò´fµªÀ³«¾ãSi2C¤§«á¡A¤@¤Á±N§ïÆ[¡C BTC©eû·¨¨|¥Áªí¥Ü¡A¥xÆW¥Í§Þ¤@ª½¯Ê¤@Ó²£·~ªº°õ¦æªø¡]CEO¡^¡A°µ¾î¦V¡BÁa¦Vªº¾ã¦X¡A¯Î±Ò´f¬O³Ì¾A·íªº¤H¿ï¡C ±i©À·O¸É¥R¡ASi2C¥l¶°¤H¥Dn¬O©wµ¦²¤¡Bµ¹¤è¦V¡A¤£¶È¥i¥H°µ¨ìCEOªº¥\¯à¡A®Ú¥»´N¬O¡u¸³¨Æªø¡v¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/9 ¤W¤È 12:42:22²Ä 1953 ½g¦^À³
|
³o¬O105¤p®É«eªº°Ý¹F¡A³o¦ì°ê»Úª¾¦Wªº¬ì¾Ç®a ªº¦^µª¥O§Ú³¶ÅD¡A¦]¬°³oÃö«Y¨ì¨ÅÀù·sÃÄOBI822 ¥¼¨ÓªºÄvª§ªÌ °ÝÃD:¥Ø«e¥@¬É¨ä¥L¥Í§Þ¤½¥q¦b¬ãµoªºÀù¯g ÃĦ³¦p¦PÁÞ¤À¤l·sÃĤ@¼Ë¥i¹v¦VÀù·F²ÓM? ¦^µª:¦³ÃĪ«¦b¬ãµo¤¤¡A¥i°w¹ï·F²ÓM¡A ¦ý±M¤@©Ê¤£¨Î |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/9/7 ¤U¤È 01:30:07²Ä 1952 ½g¦^À³
|
°Ñ¥[¨â¤Ñªº"2015¥Í§Þ°·±d°ª®p½×¾Â"¡AÅ¥¤F³\¦h»P·|±M®aºëÅPºt»¡ Á`µ²³o¨Ç¤º®e¡A§ë¸ê¥Í§ÞÃþªÑ³Ì¤jªº§Q¦h¬O: 1.¬Fµ¦°µ¦h: ¨Ò¦p¬°¦ónÁ|¿ì³oÓ·|ij?¥Ø¦aÅý§ó¦h¥Á²³²M·¡¤F¸Ñ(¥¿½T»{ª¾)§ë¸ê¥Í§ÞªÑ ¦A«h°ò¨È±ø´ÚªºÃP¸j¡AÅý·sÃĤ½¥q¯à°÷"¾A·íªº"µo§G¬ãµo¦¨®Ä 2.¶^±o°÷²`¡G §ë¸êÁקK°l°ª±þ§C¡A§ë¸ê¥Í§ÞªÑ³Ì¤j§Q¦h´N¬O¶^±o¤w¸g°÷²`¡A¤UÀɧCÂI¦³ 3.®¶¾Ä«½S¯Å·s»Dn°Ý¥@¡G ¤¤¸Î±N¨ú±oFDAÃÄÃÒ¡A´¼Àº10¤ëFDA±N¤½¥¬¯ØŦÀùÃÄÃÒ³q¹L»P§_,¯E¹©©ú¦~Q1±N¤½¥¬Á{§Éµ²ªG ³\¦h±M®a³£¦³´£¨ì¥B¬Ý¦n¯E¹©ªº¥¼¨Ó ** ¥~¸ê¤w¸g³°Äò¤£¬ù¦Ó¦Pªº¥[½X¯E¹©¡A¬Ý¨Ó¥¼¨Ó¨«¶Õºë±m¥i´Á¡A©IÀ³±i¸³»¡ªº"¦nÀ¸¦b«áÀY" ** ¥xÆW¦³³\¦h¥Í§ÞªÑªÑ»ù¤w¸g³Q"ÄY«§C¦ô"¡A±N¨ÓÀ³¸Ó³£·|¦³¤£¿ùªºªí²{ |
|
|
·|û¡G99910140657 µoªí®É¶¡:2015/9/7 ¤U¤È 12:09:37²Ä 1951 ½g¦^À³
|
¤p©_¤j«e½ú ÁÂÁ±zªº«ü¾É¡Aªñ¤é¸g½Ñ¦h¦ì«e½ú¦h¤èÄ_¶Qªº´£¿ô»P·RÅ@¡A¦p¦¹§Ú»ÝnÆ[¹î°lÂܪº½ü¹ø¶V¨Ó¶V²M´·¤F¡I¸Û¤ßÁÂÁ¦U¦ì«e½ú¤j¤j¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/9/7 ¤W¤È 10:50:51²Ä 1950 ½g¦^À³
|
¥v¥S¡A³øºp ¤p§Ì¦b¡uµoªí®É¶¡:2015/9/4 ¤U¤È 07:12:36¡v¶K¤å®É¨S¦³¥J²Ó®Õ¥¿ ¦³¤@¥y¸Ü¿ù±oÂ÷ÃÐ ²Ä¤T¬q ¡y1.Globo³±©Ê»P®z¶§©Ê¦û20%¡A·|¦³¤j¬ù233*0.2=46¤H«Ü¦´NPD¡A³o46¤H¥]§t¤F2014¦~¦¬61¤H¤¤ªº¡u61*0.2=12¤H¡v¡A¦]¦¹±z¤Wzªº12¤HÀ³¸Ó¬O©ñ¦bÃöÁäAªº«e³]¸ê®Æ¤¤100¤H¤¤ªº12¤H¡A³o12¤H¤£©y®³¨Ó±ÀºâÃöÁäAªº¥X²{¤ë¥÷¡C¡z Globo³±©Ê»P®z¶§©Ê¦û20%¡A¤£ºÞ¬O¥þ³¡¦¬®×®É¬qªº233*0.2=46¤H¡A©ÎªÌ¬O±ß¦¬®×®É¬qªº¡u61*0.2=12¤H¡v¡A³£¬O¤wPD¡APD´N¸Ó¦C¤J137¤HªºPD¤§¤¤¡A¤£¬O©ñ¦bÃöÁäAªº«e³]¸ê®Æ¤¤100¤H¤¤¡C ¬Ý§¹±z¡uµoªí®É¶¡:2015/9/5 ¤U¤È 03:07:52¡v¡A¤p§Ì²M·¡±zªº·N«ä¤F Y822¬O¡u¦³®Äªº¤H·|«Ü¦³®Ä¡A¨S¦³«Ü¦³®Äªº´N¥i¯à¬O´¶³qÀø®Ä¡v¡A§âÆ[¹î®É¶¡©Ôªø¡AÅý³o¨Ç±ß¦¬®×¥B«Ü¦³®Äªº±wªÌ¦³¨¬°÷ªº®É¶¡Åã¥Ü¥X¥L̪º¯u¹êÀø®Ä¡A½T¹ê¦bM PFS¤W·|¦A¦h±o¨ì¤@ÂI¦n³B¡C53¦ìªø§Àn«ç»ò¤À°tPD©Î¥¼PD¤~¤ñ¸û±µªñ¨Æ¹ê¡A¦b¥u¦³187©M229¨âӼƦrªº±¡ªp¤U¡A¤]µLªk¦A¶i¤@¨B±À´ú¤F¡A´Nµ¥¶}ª¼®É´¦¶}Á¼©³§a¡C ¥v¥S¡A¤v±ý¥ß¦Ó¥ß¤H¡A¤v±ý¹F¦Ó¹F¤H¡A¤p§Ì¤ß¤¤µÛ¹ê¨ØªA¡I |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/9/7 ¤W¤È 09:32:16²Ä 1949 ½g¦^À³
|
999¤j¡A ¦A¦h¬Ý1~3Ӥ몺¼Æ¾ÚÅܤơA ¦ý©³¬O°Ñ»P°ê»Ú¬ÛÃöÀù¯g«n·|ij»P´Á¥Zµoªíªº³Ì«á´Á¤£¯à¿ù¹L ¨S¦³¥¿±¤]¨S¦³t± ±M®a·|ij«áÃĮĤw¤jP©³©w ¤@¤Á²Å¦X¹w´Á |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/7 ¤W¤È 08:57:39²Ä 1948 ½g¦^À³
|
ªñ´Á¥Í§Þ°·±d°ª®p½×¾Â «n°T®§ °Ñ¦Ò´N¦n °O±o¹LÂo¸ê°T ·j´M: 1 ÂåÀø²£·~ ¬OºØ¾ð¦Ó«DºØ¯ó 2 ¥þ²y¼öªù²£·~ ¥Í§Þ5¦~«á¥´±Ñ¸ê³q°T 3 ¤j³°²MÜ¥O ¥x¼t§Q¦h 4 °ò¨È±ø´Ú ¢²¤è¦VÃP¸j 5 ¯Î±Ò´fÁÞ¤À¤l¬ã¨s¬ð¯} §ÜÀù§Q¾¹ 6 ³Ð§Q¡I ¥Íª«¸gÀٮɥN¨ÓÁ{ 7 ·s¿³§K¬ÌÀøªk ªvÀù«¤j¬ð¯} |
|
|
·|û¡G99910140657 µoªí®É¶¡:2015/9/5 ¤U¤È 11:02:47²Ä 1947 ½g¦^À³
|
½Ñ¦ì«e½ú¤j¤j ·PÁ¦A·PÁ¡K´Ü¨Ø¦A´Ü¨Ø¡I ¤p§Ì²`«H½Ñ¦ì¬Ò¬O¦³¯à¦³ºÖ¤H¡A¦ý«o¦³µL¤W¤§¼w¤£§[¥H¦Û¤vÄ_¶Qªº®É¶¡«ü¾É±ß½ú¡A ¤µ¤é«ôŪ½Ñ¦ì«ü¾É¤§¤º®e¡A¦b²`«ä¤¤²ß¤§¡A¤ß¤¤»®µM©ú¥Õ¯E¹©¥Í§Þ¾Ö¦³¦p¦¹¦hªº(¦³¯à) (¦³¼w)¤§¤h»{¦P¨Ã¤©¥Hªø§ë¡A¥²µM¤]n¦³©ÒºÖ®ð¤~·|¾Ö¦³¡C ¤@¤Áªº¦³¯à¦³¼w¦³ºÖ¤§¤h¦@»E¤@¤ß¤@©À¡I ºÖ³ø°Ú¡I¤Ñ·N°Ú¡I¦A¦¸·PÁ½Ѧì«e½ú¤j¤jªº«ü¾É¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/5 ¤U¤È 10:45:41²Ä 1946 ½g¦^À³
|
6 ¹ï¨ÅÀù·sÃÄOBI822ªº±À´ú¥H ²{¶HÆ[¹îªº¾ã¦X¯à¤O³Ì¬°«n 7 ¸Ñª¼¤é´Á¯E¹©´x´¤¤F¦Û¥D©Ê¡A ¤µ¤Ñªº¬ÛÃö´CÅé³ø¾É¡A¨ä¹ê¤£n ¤Ó°õµÛ©ó¦ó¤ë¦ó¤é¡A§Ú¬ã§P²Ä¤@©u ¸Ñª¼¡AÅý¯E¹©¦³¤F¼e¼sªº®ÉªÅ¨Ó§e²{ ÁÞ¤À¤l·sÃĪº·ªö 8 ¸Ñª¼«en¦A«×´£¿ô·ÀIºÞ²z¡A¤£½×822 ¦³¦h¦n¡AÄY±±§ë¤J¸êª÷¤ñ²v¬O«Ü«nªº ³o¤]¾A¥Î¥ô¦ó§ë¸ê¼Ðªº |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/5 ¤U¤È 10:21:36²Ä 1945 ½g¦^À³
|
1 ±i¸³¥|¤~»¡¬Ý¦ü«Ø¨¥¡A¹ê¬°¦Û§ÚªÖ©w¡A ¤£½×¿ïÃD¡A¸êª÷¡A¤H¤~¡A´¼°]¯E¹©¨ÅÀù ·sÃÄOBI822¤]»á²Å¦X³o¥|¤j±¬Û 2°Ñ¥[°ê»Ú·|ij»Pµoªí´Á¥Z¡A¨S¦³ ¤T¨â¤T«ç¯à¤W±ç¤s 3««ª½¾ã¦X¤¤³Ì»Ýn¨ÖÁʦ³«~µPªº ¦æ¾P¤½¥q¥H§Q¥¼¨Ó822 833 888 ÁÞ´¹¤ù¤§¦æ¾P¡A822¨S¦³¤Q¨¬«O´¤ ªá¿ú¨ÖÁÊ¡AÅý¨º¨Ç¾P°â¤Hû»â¿ú µLÃÄ¥i½æ¡A¥i¥H¶Ü? 4 ¨ÖÁʪºÁnµ¤wµo¥X¡A¨ÅÀù·sÃÄ822 ¨S¦³¥¢±ÑªºÅv§Q 5 ¿ïªÑ¬O¤@ÓÅÞ¿è±À²zªº¹Lµ{ |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2015/9/5 ¤U¤È 08:48:58²Ä 1944 ½g¦^À³
|
Cliff¥S ......³o¤@¤j¬qÀ³¸Ó¬O°OªÌ¦Û¤v¥h°Ý¨Óªº¡A±i¸³¤U¥x«á¡A¤£¤@·|¨à´NÂ÷¶}¤F¡A©Ò¦³¤H³£¦bì®y¦ìÄòÅ¥¤U¤@Ó¥DÃD¡A³õ¤ºµL¤H¥h°ô¥L¡A²¦³º³o¬O¦w±Æ²³¦h±M®aªº¤@¨t¦CºtÁ¿¡A¤£¬O¦b¶}ªÑªF·|¡A¥L¨ì³õ¥~«áµo¥Íªº¨Æ´N¤£²M·¡¤F¡C §Ú¦]¬°n¦^¤½¥q³B²z¨Æ±¡¡AÅ¥§¹±i¸³ºtÁ¿´NÂ÷¶}¤F¡A¸g¹L¶Q»««Ç¬Ý¨£¨â¦ì°OªÌ¤@¨k¤@¤k¥¿¦b³X°Ý±i¸³¡AÀ³¸Ó¬O³o®ÉÔµo¥Íªº |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/5 ¤U¤È 05:29:26²Ä 1943 ½g¦^À³
|
999¤j¡G ¬Q¤Ñ¥uµ¹±i¸³25¤ÀÄÁ¡A¯àÁ¿¨Ç¬Æ»ò¤º®e©O¡H°ò¥»¤W¬O¥O¤H¥¢±æªº¡C ²Ä¤@¡B®É¶¡«Üµu¡AnÁ¿¡u¥xÆW¥Í§Þ·sÃIJ£·~ªº¾÷·|»P¬D¾Ô¡v³o»ò¤jªºÃD¥Ø¡A¦Ó¥B¬O°w¹ï¤jÀô¹Òªº¤½¼h±½×z¡A¨S¦³´£¨ì822ªº¨p¨Æ¡C¶}©ñ¤Q¤ÀÄÁªºQ&A®É¡A¥x¤U¤]ª¾½ì¦a¨S¤H°Ý°_³o¤è±ªº°ÝÃD¡C ²Ä¤G¡B±i¸³³sSlide³£¨S·Ç³Æ¡A²³¤H²´¸C¸C¦a¬ÝµÛ¨q¦b¤TÓ§ë¼v¹õ¤Wªº¦P¤@±iÁy¡AÅ¥¥L¤@±i¼LÁ¿20¦h¤ÀÄÁ¡C ´CÅé³ø¾Éªº¤º®e¦pªG¤£·Ç½T¡A¤£ª¾¦³¦ó¦s¦b»ùÈ¡C¤@³õµuµuªººtÁ¿¤U¨Ó¥i¬Ý¥Xþ®a´CÅé°OªÌ¤ñ¸û¥Î¥\¡A°]°T§Ö³øªº¦ó¬ü¦pªº³ø¾É¤ñ¸û¶Kªñ¨Æ¹ê¡]http://www.investor.com.tw/gxonlineNews/NewsContent.asp?articleNo=14201509040080 ¡^¡F®É³ø³¢ÂE¼zªº³ø¾É¤¤²Ä¤T¶µ¬O¡u´¼¡v°]¤~¹ï¡C¦Ü©ó±`±`¥X¿ùªº¸gX¤é³øªº¶ÀXX¡A©x«ô¡u¸gX¤é³ø²£·~¤¤¤ßºî¦X²£·~²Õ¥l¶°¤H¡v¡A°w¹ï¦¹¦¸½×¾Â°µ°Q½×¡A¥i°Ñ¬Ý¼vµ¡G¡uhttps://video.udn.com/news/366288 ¡v¡C ²q·Q¤j´£¨Ñªº¿½¿Pµ¾³ø¾Éªº·s»D¡A¤×¨ä¬O³Ì«á¨º¤@¬q¡G¡u¤é«e¯E¹©¤]¤½§i¡A¨ÅÀù·sÃÄOBI-822ªº¸Ñª¼®É¾÷±N¸¨¦b©ú¦~3¤ë©³«e¡A¥L¸ÑÄÀ¡A¸Ó®É¶¡ÂI¬O¥H·Ç³Æ°Ñ»P°ê»Ú¬ÛÃöÀù¯g«n·|ij»P´Á¥Zµoªíªº³Ì«á´Á¦^±À¡A¥H¥Ø«e±M®a·N¨£¨Ó»¡¡AÀH®É³£¥i°±¤î¼Æ¾Úªº»`¶°¡A¶i¦æ¸Ñª¼¡A¦ý½T©w®É¾÷ÁÙn¦h¤è°Ó°Q«á½T»{¡C¡v³o¤@¤j¬qÀ³¸Ó¬O°OªÌ¦Û¤v¥h°Ý¨Óªº¡A±i¸³¤U¥x«á¡A¤£¤@·|¨à´NÂ÷¶}¤F¡A©Ò¦³¤H³£¦bì®y¦ìÄòÅ¥¤U¤@Ó¥DÃD¡A³õ¤ºµL¤H¥h°ô¥L¡A²¦³º³o¬O¦w±Æ²³¦h±M®aªº¤@¨t¦CºtÁ¿¡A¤£¬O¦b¶}ªÑªF·|¡A¥L¨ì³õ¥~«áµo¥Íªº¨Æ´N¤£²M·¡¤F¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/9/5 ¤U¤È 03:19:10²Ä 1942 ½g¦^À³
|
ÁÂÁ¤p©_¤j¡B¦Ñ¥v¤jªººëÅP»¡©ú¡AÆg ¦Ü©ó°ò¨È±ø´ÚªºÁ`Á`·ªi¡A¤£¸TÅý¤H³Ú¯º¬Ò«D ¥Ã»·ºC¤F¤@¨B¡A´N·í¦¨µo®i¥Í§ÞÂI£¸±ø¥²¸gªº¸ô§a ¸gW¤jªº»¡©ú«á ¤p§Ì¤Ï¦Ó¤£§Æ±æ¤½¥q¤½¥¬¤°»ò¼Æ¾Ú¤F ¯E¤Í¤ß¤¤À³¸Ó³£¦³Ó©³ ¤½¥¬¤Ï¦Ó®e©ö³Q¾Þ§Ë¡A¹L«×¸ÑŪµL½×¬O¥¿t±³£¤£¦n ´NÅý§Ú¥HÌÀR¤ßµ¥«Ý§a |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2015/9/5 ¤U¤È 03:07:52²Ä 1941 ½g¦^À³
|
ÁÂÁ¤p©_¥S¶O¤ß§ä¥X§Ú«ä¸ôÂÕ»~¤§³B¡A¨Ì§Ú×¥¿«á±Àºâ¡A§Ú½T¹ê¤£¸Ó©wÁã¦b5/25¡A §Ú¥²¶·©¹«e¤UÁã¦b3¤ë©³¡A«·s±ÀºâªºPFS»P±zªº½d³ò®t¤£¦h¡A³o´N¤£²Ó¸[¤F¡CÃö©ó ªø§ÀPD¡A§Ú³]·Qªº¤H¼Æ¤ñ¸û§C¡A¥Dn¦Ò¼{¨ì¥D°Ê§K¬ÌÀøªkªºÃĪ«¯S©Ê¡A¤W¶g¹ù³Õ¤h ´£¨ì¡G¡u¥Ñ©ó¥Ø«e¸ÕÅ礤¥¼´_µoªº¯f¤H¡A´_µo²v§C¡A¦Ó¥ý«e·|´_µoªº¯f¤H¤]³£¤jP ´_µo¤F¡A¬G²{¦b¨C¤ë´_µo¤H¼Æ·¥§C¡C¡v¥t¥~±i¸g²zµe¤F¨â±iK-M¹Ï³¯zImmonotherapy »PTargeted Therapyªº®t²§¡A·N«ä¤]¬O»¡§K¬ÌÀøªk·|¦³«Ü¦hªø§À³]¸ê®Æ¡A©Ò¥H §Ú¦Û¤v²q·Q822ªºÃĮĬO¡u¦³®Äªº¤H·|«Ü¦³®Ä¡v¡A¤£¤Ó®e©ö´_µo¡Aªø§ÀPD·|«Ü¤Ö¡C ¦]¦¹§Ú¤~·Q¹³¡A±µªñM PFSªº«e³]¯f¤H¡A¦h¸g¹L3~5Ӥ몺Æ[¹î¡A°ò©ó¡u¦³®Äªº ¤H·|«Ü¦³®Ä¡v¡A©Ò¥H¡u¦b¤µ¦~5/25¶}ª¼®É·|³Q°O¿ý¬°³]13+¡B14+¡B15+¡B16+¡B 16.9+¡A¥Ñ©ó822¸Ñª¼ªº¸ê®ÆºI¤î¤é¥i¯à¦b10¤ë©³¡A³o¨Ç13+¡B14+¡B15+¡B16+¡B 16.9+«e³]ªº¤H·|©¹«á²¾¨ìªø§À³]Åܦ¨18+¡B19+¡B20+¡B21+¡B21.9+¡v¡A¤£¤Ó ®e©öPD¡C¦p¦¹¤@¨Ó¡A«e³]¤H¼ÆÅܤ֡AK-M¦±½u¤U°±×²vÅܽw¡APFS¦]¦Ó²¤·L©µªø¡C ³o³¡¤À¯ÂÄÝÁr´ú¡A¶·«Ý¸Ñª¼«á¤~¯à±oª¾¡C§Ú¥Dn¥Øªº¬O§Æ±æ§ä¨ì§ó²³æªº¸ÑÄÀ¤è ªk¡A¦nÅý§Ú©P¾Dªº¿ËªB¦n¤Í¹ï822Àø®Ä¦³ÓÃСA²{¦b¬Ý¨Ó¡A§Ú×¥¿«áªº±Àºâ¤è¦¡§K ¤£¤Fn¡u¬Û¥Í¬Û·À¡v¡A§Ú¶OºÉ®B¦Þ®£©ÈÁÙ¬O·|Åý¿ËªB¦n¤Í³´¤J¤Q¨½Ãú¡A«¢«¢¡CÁÂÁ¤p©_¥S¶O¤ß¡I ªü®¶¥S¡A§Ú¬Q¤Ñ¬Ý¨ì¤p¤Ñ¨Ï±a¨Óªº²Ä¤GÓ¦n¹Ú¡I¥¼¨Ó±ÂÅv¦X§@¸ô¤W¡A§Æ±æ¤p¤Ñ¨Ï¤]¯à±`¥X²{ |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/9/5 ¤W¤È 08:12:41²Ä 1940 ½g¦^À³
|
Âd¶R©ñ¼e°ò¨È±ø´ÚºÞ¨î ¤¤®É¹q¤l³ø§@ªÌ»a¥°·O¢¬¥x¥_³ø¾É | ¤¤®É¹q¤l³ø ¡V 2015¦~9¤ë5¤é ¤W¤È5:50 . . ¤¤°ê®É³ø¡i»a¥°·O¢¬¥x¥_³ø¾É¡j Âd¶R¤¤¤ß¬Q¤é«Å¥¬¾A«×©ñ¼e¡A¦]°ò¨È±ø´Ú¦Ó¥Íªº¡u¤W¡]¿³¡^Âd¤½¥q«¤j°T®§µo¥¬À³ª`·N¨Æ¶µ°Ñ¦Ò°Ýµª¶°¡v¬ÛÃöºÞ¨î¡FÂd¶R¤¤¤ßªí¥Ü¡A¥¼¨Ó¤W¡]¿³¡^Âd¤½¥q±q¨Æ¬ãµo¶¥¬q¤¤¡Aµo¥Í«¤j¸É¥ó©Î¨ä¥L¨¬¥H¼vÅT¬ãµo«nµ{§Ç±¡¨Æ¡A¥B¦³©ú½T«ÈÆ[ÃҾڮɡA¥i¥H¤½¶}¬ÛÃö°T®§¡C °ò¨È¥h¦~¦]¤½§i·sÃÄ¥¼³q¹LÁ{§É¹êÅç¡AªÑ»ùÀH¤§¥´¤J¶^°±¡AW§]19®Ú¶^°±ªO¡AÅýÂd¶R¤¤¤ß¯S¦a§ä¨Ó¥Í§Þ²£·~±M®a¶}·|¡AÀÀ¤`¦Ï¸É¨c¡A«á¨ÓÁö¦]°w¹ï©Ê¤Ó±j§@½}¡A¦ý¤´¦³q¥X¡u¤W¡]¿³¡^Âd¤½¥q«¤j°T®§µo¥¬À³ª`·N¨Æ¶µ°Ñ¦Ò°Ýµª¶°¡v¡C °Ýµª¶°¤¤¡A©ú½T³W©w·sÃĬãµo¶i¤J·sÃĽլd¥Ó½Ðµ¥5Ó¶¥¬q¡A¥u¦³¦b¬ãµo¦¨ªG³q¹L©Î¤£³q¹LÃÒ©ú®É¡A¤~¥i¥Hµo¥¬«°T¡A¤Þµo¤£¤Ö·~ªÌ¤Ï¼u¡A»{¬°¨î¤Ó¦h¡A²¿ÃªÃø¦æ¡C Âd¶R¤¤¤ßªí¥Ü¡A°Ýµª¶°¤W¸ô¤wªñ¤@¦~¡A¦Ò¶q¦U²£·~°·¥þµo®i¡A¨ÃÝÅU¸ê¥»¥«³õ¸ê°T´¦ÅSì«h¡A¬G¶i¦æ×¥¿¡A¥¼¨Ó¤W¡]¿³¡^Âd¤½¥q±q¨Æ¬ãµo¶¥¬q¤¤¡Aµo¥Í«¤j¸É¥ó©Î¨ä¥L¨¬¥H¼vÅT¬ãµo«nµ{§Ç±¡¨Æ¡A¦³©ú½T«ÈÆ[ÃҾڮɡA±o¤½¶}¬ÛÃö°T®§¡C ¤£¹L¡AÂd¶R¤¤¤ß±j½Õ¡A¤W¡]¿³¡^Âd¤½¥qµo¥¬«¤j°T®§¤´À³¥»½Ñ¨Æ¹ê¡A¨ÃÁקK¦³¸ØÄ£©Ê©ÎÃþ¦ü¼s§i«Å¶Çªº¤å¦r¡A»~¾É§ë¸ê¤H¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/9/4 ¤U¤È 07:12:36²Ä 1939 ½g¦^À³
|
¥v¥S¡A ±zªº±Àºâ¤èªk»á¨ã³Ð·s©Ê¡A¥t¤H¦Õ¥Ø¤@·s¡A¦ý¤ÏÂЫä¦Ò«á¡A¤p§Ìı±o©|¦³ºÃÂI¡A¥H¤U´XÂI»P±z¤Á½R°Q½×¡C ´M§ä¨å«¬ªºÃöÁäA¬O¦bþÓ¤ë¥÷¥X²{ªº°²³]°ò¦¡G°²³]¦³¤@ӫܼF®`ªº±M®a¡A¦bÆ[¹î¨ì¬YӼƶqªºPD¥X²{¤§«á¡A¥ß¨èºë·Çªº§PÂ_ÃöÁäA¥¿¥©¥X²{¤F¡A¦¹®É¥´¶}¬Ý233¦ì¹êÅç²ÕªºPFS§Ç¦C¡A±N1¡A1.5¡A2+¡B¡B¡B13¡A15+¡A18+¡A20¡A23+¡A24+ªº§Ç¦Cµe¦bK-M¨ç¼Æ¤W¡A¹Ï«¬¶V¹L0.5¤ô¥½u¤§«áÁÙ¦³¤@¨Çªø§ÀªºPD»P¥¼PD¡A¦¹®É»P0.5¤ô¥½u¬Û¥æªº´N¬OÃöÁäAªºPFS¡C¤ñÃöÁäAµuªºPFS¡A³]ªº¦³100¦ì¡APDªº¦³79¦ì¡AÃöÁäA¬O²Ä80¦ìPDªº¼Æ¾Ú¡A¥t¥~¤j©óÃöÁäAªºªø§ÀPFS¦@¦³53¦ì¡Aµ}¸¨ªºµe¦b¹Ï«¬¤W(¤H¼Æ¬Û¸û180¤Ö«Ü¦h)¡A³o53¦ì¦³ªº¤wPD¡A¦³ªº¦ìPD¡AÁÙ¦³¤@¨Ç¶i¤J24+ªº¤ÑªáªO¡C 100¦ìÃöÁäAªº«e³]¼Æ¾Ú¡A¥]¬A¹êÅç²Õ¤¤³~Â÷¶}¥H¤Î¤ñÃöÁäAªºPFS®É¶¡µuªº±ß¦¬®×¥B¥¼PD±wªÌ¡F79¦ìÃöÁäA¤§«eªºPD¼Æ¾Ú¡A¥]¬AGlobo³±©Ê»P®z¶§©Ê±wªÌ¥H¤ÎÀø®Ä¤ñÃöÁäA¨Ó±o®tªº±wªÌ¡AÁp¦PÃöÁäA¦@80¦ì¡A³o100Ó³]»P80¦ìPD¨M©w¤FÃöÁäAªº¥X²{¡A¦ý¦]¬°ÁÙ¦³¤@¨Ç¤j©óÃöÁäAªºªø§ÀPD·|³QÆ[¹î¨ì¡A©Ò¥H¹ê»Ú¤W³o¦ì±M®a¦b§PÂ_¤W·|µ¥¹êÅç²ÕªºPD¹L¤F80¤§«á¦A¶W¹L¤j¬ù20´X¦ìªºªø§ÀPD¡A¤~·|¥h°µÃöÁäA¤w¥X²{ªº§PÂ_¡C ¡÷¹êÅç²Õ¤j¬ù100¦ì¥XÀYªºPD¥X²{¡A´N¬OÃöÁäA¥X²{¡A¨ä¤¤¶W¹L80¦ìªºPD´N¬Oªø§ÀªºPD¡C ¨Ì±zªº°²³]¡G ¡y¦^±À§ä¨å«¬ªºÃöÁäA¬O¦bþÓ¤ë¥÷¡AÁÙ®t180-137=43¡C2014¦~¹êÅç²Õ¤j·§¦¬61¤H¡A§Ú°²³]Globo³±©Ê»P®z¶§©Ê¦û20%¡]¯Î°|ªø»¡¤£¥Î¿z¯f¤H¡A¦]¬°8¦¨¹À¡I¹ù³Õ¤h»{¬°¨S§@¥Î¤ñ¨Ò¬O25~30%¡^¡A61*0.2=12¡C¤§«e°²³]¹êÅç²Õ¦³13¤H°h¥X¡A«ö¤ñ¨Òpºâ2014¦~¦¬®×61¤H¤¤¡AÀ³¸Ó¦³3¤H°h¥X¡A43+12+3=58¡C137¤H¤¤À³¸Ó¦³´X¦ì¦´Á¦¬®×ªºªø§ÀPD¡A¦¹¼Æ¦r«ÜÃø¹w¦ô¡A«O¦uªº¤H¦ô¤Ö¤@¨Ç¡A¼ÖÆ[ªº¤H¦ô¦h¤@¨Ç¡A¥Ñ©óPFSÆ[¹î´Á¦³24Ó¤ë¤W¡A§Ú¥H«O¦uì«h»P¤è«Kì«h¦ô3¤Hªø§ÀPD¡K¡z 1. Globo³±©Ê»P®z¶§©Ê¦û20%¡A·|¦³¤j¬ù233*0.2=46¤H«Ü¦´NPD¡A³o46¤H¥]§t¤F2014¦~¦¬61¤H¤¤ªº¡u61*0.2=12¤H¡v¡A¦]¦¹±z¤Wzªº12¤HÀ³¸Ó¬O©ñ¦bÃöÁäAªº«e³]¸ê®Æ¤¤100¤H¤¤ªº12¤H¡A³o12¤H¤£©y®³¨Ó±ÀºâÃöÁäAªº¥X²{¤ë¥÷¡C 2. ¤§«e°²³]¹êÅç²Õ¦³13¤H°h¥X¡A³o13¤H³£À³¸ÓÄÝ©óÃöÁäAªº«e³]¸ê®Æ¤¤100¤Hªº¤@³¡¥÷¡A¡u«ö¤ñ¨Òpºâ2014¦~¦¬®×61¤H¤¤¡AÀ³¸Ó¦³3¤H°h¥X¡v¤]¤£©y®³¨Ó±ÀºâÃöÁäAªº¥X²{¤ë¥÷¡C 3. ªø§ÀPD+ªø§À¥¼PD¦@¬O53¤H¡A±z¡u¥H«O¦uì«h»P¤è«Kì«h¦ô3¤Hªø§ÀPD¡v¡A³o¼Ë¤l¦ôpªº¸Ü¡Aªø§À¥¼PD=53-3=50¤H¡A³o¼Ëªº¦ôp·N«ä´N¬O¡A¦pªGPFS¯à°÷¶W¹LM PFS(´N¬O¤ñÃöÁäAÀø®Ä¦n)ªº±wªÌ¡A·í¶}ª¼®É¤j³¡¤À50/53=94%³£¤£¤Ó·|´c¤Æ¡A¦AÆ[¬d´XÓ¤ë«Ü¦³¥i¯à´N¶i¤J24+ªº¤ÑªáªO¡A¤p§Ìı±oªø§ÀPD=3¤H¤ñ¨Ò¤Ó§C¤F¡C ¤p§Ìªº·Qªk¡G ¨Ì±zªº°²³]¡A©wÁã¦b5¤ë©³¹êÅç²Õ¦³137¤HPD(LR)¡A³o137¤H¤¤¦³¨Ç¤ñ¨ÒÄÝ©óCR®É§ï§P¦¨³]¡A¥²¶·©ñ¨ìÃöÁäAªº«e³]¸ê®Æ¤¤ªº100¤H¡A»Ý±q137¤H¤¤¦©°£¡F¥t¥~ÁÙ¦³ªø§ÀªºPD¦ôÓ20¤H¦n¤F(53ªø§À¤¤¦ô20¤HPD¡A33¤H¥¼PD)¡A¤]»Ýn±q137¤H¤¤¦©°£¡C¤§«á§Ų́ӬÝÃöÁäA¥X²{ªº¤ë¥÷À³¸Ó¤ñ5¤ë¦©Î±ß¡A¦pªGn«e²¾©Î«á²¾ªº¸Ün²¾´XÓ¤ë¥÷¡C 1. 2015/5®É¡A°²³]CR=LR¡A¦]¦¹³o®Én¦ôÃöÁäA¤§«eªºPD¤H¼Æ=137-20-0=117¡A¦©°£20¦ìªø§ÀªºPD¡A¦A¦©°£¥²¶·©ñ¨ìÃöÁäAªº«e³]¸ê®Æªº0¦ì¡A¦@¦³CRªºPD=117¤H¡A¦ýÃöÁäA¬O80¤HPD´N¥X²{¡A¦b2015/5¦h¤F117-80=37¤HPD¡An±À¨ì¯u¥¿ªº80¤HPD¥X²{ªº¤ë¥÷¡A©Ò¥H¥²¶·±q2015/5©¹«e±À37¤H(¤j¬ù¨C¤ë6¤H)¡A±À¨ì2014/11¤ë©³¥h¤F¡C 2. 2015/5®É¡A°²³]CR=0.9*LR¡A¦]¦¹³o®Én¦ôÃöÁäA¤§«eªºPD¤H¼Æ=137-20-(137*0.1)=103¡A13.7=14¤H¥²¶·©ñ¨ìÃöÁäAªº«e³]¸ê®Æ¡A¤]¦©°£20¦ìªø§ÀªºPD¡A¦@¦³CRªºPD=103¤H¡AÁÙ¬O¶W¹L80¤H¡AÃöÁäAªº¤ë¥÷¥²¶·©¹«e±À¡A±À103-80=23¤H¡A¤j¬ù±À¨ì2015/1¤ë©³¡C 3. 2015/5®É¡A°²³]CR=0.8*LR¡A¦]¦¹³o®Én¦ôÃöÁäA¤§«eªºPD¤H¼Æ=137-20-(137*0.2)=89¡A(13.7*0.2)=28¤H¥²¶·©ñ¨ìÃöÁäAªº«e³]¸ê®Æ¡A¤]¦©°£20¦ìªø§ÀªºPD¡A¦@¦³CRªºPD=89¤H¡AÁÙ¬O¶W¹L80¤H¡AÃöÁäAªº¤ë¥÷¥²¶·©¹«e±À¡A±À89-80=9¤H¡A¤j¬ù±À¨ì2015/4¤ë¤¤¡C ¥H¤W¬O¤p§Ì¥Î±zªº°²³]©Ò°µªºÃöÁäA¥X²{ªº¥i¯à¤ë¥÷¡A¤£¦Pªº°²³]³£¥i¥H¦A°µ½Õ¾ã¡C ¥t¥~¡A¡y2014¦~12¤ë¬O¨å«¬ÃöÁäAªº¥X²{¤ë¥÷¡APFS¬O17Ó¤ë¡A¥Nªí2014¦~1~4¤ë¦³Àø®Äªº¯f±w¡A¦b¤µ¦~5/25¶}ª¼®É·|³Q°O¿ý¬°³]13+¡B14+¡B15+¡B16+¡B16.9+¡C¥Ñ©ó822¸Ñª¼ªº¸ê®ÆºI¤î¤é¥i¯à¦b10¤ë©³¡A³o¨Ç13+¡B14+¡B15+¡B16+¡B16.9+«e³]ªº¤H·|©¹«á²¾¨ìªø§À³]Åܦ¨18+¡B19+¡B20+¡B21+¡B21.9+¡A·íµM¡A¥i¯à¦³´X¦ìÅܦ¨ªø§ÀPD¡A¦ý³o¤£·|¼vÅTPFS¡C¤]´N¬O»¡¡A¦hÆ[¹î5Ó¤ë·|Åý¤j¬ù30¦ì«e³]ªº²¾¨ìªø§À³]¡A«h¨å«¬ÃöÁäAªº¥X²{¤ë¥÷¥i¥H¦A©¹«e²¾3Ó¤ë¡z °ò¥»¤W·íÃöÁäA¤w¸g¥X²{¤F¤§«á¡A¦A¦hÆ[¹î´XÓ¤ë¤]¤£¤Ó·|¼W¥[·|´î¤ÖM PFS¡A¦]¬°¦A¦hÆ[¹î´XÓ¤ë¥u¬OÅý±ß¦¬®×ªº¤HªºÀø®Ä¤]Åã¥Ü¥X¨Ó¡A¦pªG³o¨Ç2014¦~±ß¦¬®×ªº61¤H¤p¼Ë¥»ªºÀø®Ä»P2013/12¤§«e¦¬®×ªº¸û¦h¼Ë¥»ªº±wªÌªºÀø®Ä®t¤£¦h¡A«h³o61¤H¡AÀ³¸Ó»¡61*0.8=48¤HªºPFS¸g¹L¨¬°÷ªº®É¶¡ªºÆ[¹î¤§«á¡A³o48¤HªºÓ§OPFS·|§Î¦¨¥k°¾¤À¥¬¦bÃöÁäAªºPFS«e«á¡C ¤]´N¬O¡u¦b¤µ¦~5/25¶}ª¼®É·|³Q°O¿ý¬°³]13+¡B14 |
|
|
·|û¡G99910140657 µoªí®É¶¡:2015/9/4 ¤U¤È 06:52:43²Ä 1938 ½g¦^À³
|
¤p©_¤j¤j ·q½Ð«ü¾É¡KÁÂÁ±z¡I ¢°¡n¡G¨Ì±z©Ò¶Kªº¤å¡A±i¸³¨Æªø©Ò¨¥ªº·N«ä¬O³ÌºC¢²¤ë¤½§i¼Æ¾Ú¦ý¤]¦³¥i¯à´£¦¡K¡H¡H¡H ¢±¡n¡G³o¦pªG´£¦¬O¥¿±ÁÙ¬O¦³¾÷·|¬Ot±¡I¡H Cliff¤j¤j¡F¡F¥xÁÞ¤j¤j¬O§_¥i¥H³Ò·ÐǦì«e½ú©Î¨ä¥L«e½ú¤j¤j°w¹ï±i¸³¨Æªø¤µ¤é¤½¶}¹ï¯E¹©ªº½×z¡A´£¥X¨£¸Ñ¡K¡K¡H¬O¥¿¦VÁÙ¬Ot¦V¡K¡K¡H Àµ°U¤]ÁÂÁ¤j®aªº«ü¾É¡K¡I¡H ¹Ç§AÅó±ø±ø¤j¤j«e½ú ½Ð±Ð±z¡A±z¤µ¤é²{³õ¦³Å¥¨ì¥i¥H¡§®¶¾Ä¡¨ªº®ø®§¶Ü¡H¨Ì±zªº¨£¸Ñ¤µ¤é±i¸³©Ò¨¥ªº¤º®e¬O§_¦³¦ó¨ä¥L§t·N¡K¡K¡H¥i§_³Â·Ð±z¡A´£¥X±zªº¨£¸Ñ«ü¾É¤p§Ì¡K¡H |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/9/4 ¤U¤È 01:06:18²Ä 1937 ½g¦^À³
|
²q·Q¤j¡A ¡y¸Ó®É¶¡ÂI¬O¥H·Ç³Æ°Ñ»P°ê»Ú¬ÛÃöÀù¯g«n·|ij»P´Á¥Zµoªíªº³Ì«á´Á¦^±À¡A¥H¥Ø«e±M®a·N¨£¨Ó»¡¡AÀH®É³£¥i°±¤î¼Æ¾Úªº»`¶°¡A¶i¦æ¸Ñª¼¡A¦ý½T©w®É¾÷ÁÙn¦h¤è°Ó°Q«á½T»{¡z ¡yÀH®É³£¥i°±¤î¼Æ¾Úªº»`¶°¡A¶i¦æ¸Ñª¼¡z 2015/8¬Ý¨ìªº3Ó¤ë«eªºCR¼Æ¦r¡A¦A±À´ú3Ó¤ë«á2015/8¤ëLR·|ÂàÅܦ¨ªºCR¼Æ¦r¤w¦¨¼ô¡H ¡y¦ý½T©w®É¾÷ÁÙn¦h¤è°Ó°Q«á½T»{¡z ³Ì²×¸ê®Æ¦¬¶°¤éÁÙ¨S½T©w¡H ¡y·Ç³Æ°Ñ»P°ê»Ú¬ÛÃöÀù¯g«n·|ij»P´Á¥Zµoªíªº³Ì«á´Á¦^±À¡z ³Ì²×¸ê®Æ¦¬¶°¤é+¸Ñª¼«e¸m§@·~ªº¤u§@¤Ñ¼Æ¡÷¶}ª¼¤é´Án¨Ó±o¤Î²q»PASCO¦~·|¡H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2015/9/4 ¤U¤È 12:39:04²Ä 1936 ½g¦^À³
|
Âà¶K MoneyDJ·s»D 2015-09-04 12:06:38 °OªÌ ¿½¿Pµ¾ ³ø¾É http://www.moneydj.com/KMDJ/News/NewsViewer.aspx?a=ae6d8e33-562f-4656-b32a-cb40ce9c50d5 ¯E¹©±i©À·O¡G½Ä¦Ê»õ¬ü¤¸¥«È¡AÆ~¬F©²±ÀTop Down¾ã¦X ¯E¹©¥Í§Þ(4174)¸³¨Æªø±i©À·O(ªþ¹Ï¸ê®Æ·Ó¤ù)¤µ¤é«¥Ó¡A°ê¤º¥Í§Þ·~n¶ix°ê»Ú¡AÁ`¥«È¶·¹F¦Ê»õ¬ü¤¸¡An¹F¦¹¥Ø¼Ð¡A»Ýn¬F©²Top Down(±q¤W¦Ó¤U)ªº¾ã¦X¡C¦Ó¹ï¯E¹©¦Ó¨¥¡A²{¶¥¬q¤ñ¸û«nªº¬O¦b¼Ú¬üµ¥¥D¬y¥«³õªº««ª½¾ã¦X¡Aµo´§¤@¥[¤@¤j©ó¤Gªº®Ä¯q¡C ±i©À·Oªñ¤é°Ñ»P½Ñ¦h¥Í§Þ½×¾Â³õ¦X¡A³£¤½¶}ªí¹F§Æ±æ°ê¤º²£·~¯à¡u¤Æ¾ð¬°ªL¡v¡A³Ð³y±o¥H¶ix°ê»Ú¥«³õ³W¼ÒªººXÄ¥¥Í§Þ¤½¥q¡A¨ä¤¤Á`¥«È¶·¹F¦Ê»õ¬ü¤¸¤ô·Ç¡C¦Ó¦]¥Ø«e°ê¤ºÓ§O¤½¥q¨ã¦¹¼Ð·Ç¬Æ»·¡A¥L¤]¼Æ«×¹ï¬F©²´£¥X«Ø¨¥¡A§Æ±æ±q¬Fµ¦¹ªÀy¥Xµo¡A±À°Ê±q¤W¦Ó¤Uªº¾ã¦X¡C ±i©À·Oªí¥Ü¡A¥xÆW¥Í§Þ¤½¥q¾a¦Û¤vªº¤O¶q¡AÃø¥H¾ã¦X¥X¦Ê»õ¬ü¤¸¥«Èªº¤½¥q¡A»Ýn¬F©²±q¤W¦Ó¤Uªº¾ã¦Xµ¦²¤¨ó§U¡C¦Ó¥H°ê»Ú¸gÅç¨Ó¬Ý¡A¬ü°ê¬O¬Û¹ï¦¨¼ôªº¥«³õ¡A¦ý¤ñ¸û¤jªº°ÝÃD¬O¦nªº¥Í§Þ¤½¥q³£³Q¸ó°ê¥ø·~¶R¨«¡A¦X¨Ö«á¤ÏË¥¢¥h¤F®Ä²v¡AˬO¼Ú¬w°Ï¦³¨Ç¤pªº°ê®a¦p¥H¦â¦C¡A¦b¹ªÀy¹Ò¤º¥Í§Þ²£·~¾ã¦X¤W¡A¸gÅçȱo¥xÆW¾Ç²ß¡C ¥L»¡¡A¥xÆW¥ø·~Ãø¥H¾ã¦X¡A¤@¤è±°£¥xÆW¥ø·~¥D³£·Q·í¦ÑÁ󪺤å¤Æ¥~¡A¬F©²¬Fµ¦¤]¤£¹ªÀy¾ã¨Ö¡A¦pªGn¥H¬Fµ¦¤O¶q¾ã¦X¥XºXÄ¥«¬¥Í§Þ¤½¥q¡A»Ý«ä¯Á¬Fµ¦ªº»¤¦]¡A¬Æ¦Ü¬O¨ã±j¨î©Êªº¥D¾É¡C ±i©À·O¤]±j½Õ¡A©Ò¿×ªº¾ã¦X¥i¤À¬°««ª½»P¥¦æ¨âºØ¡A«eªÌ¬O±q¬ãµo¦Ü¥Í²£¡B¾P°âªº¾ã¦X¡A«áªÌ«h¬O²£«~Pipelineªº©Ý®i¡C¦Ó¹ï¯E¹©¦Ó¨¥¡A²{¶¥¬q««ª½¾ã¦X¸û¬°«n¡A¯S§O¬O¦b¼Ú¬ü¥D¬y¥«³õªº©µ¦ù¡A¦pÂǨÖÁʨú±o¦³«~µP¡B¦³«~½èªº¾P°â¹Î¶¤¡A¹ï¦P¤¯¤]¬O¤@ºØ¾Ç²ßªº¾÷·|¡Aµo´§¤@¥[¤@¤j©ó¤Gªº®Ä¯q¡C¤£¹L¡A¥L¤]±j½Õ¡A²{¶¥¬q°ê¤º¡B¥~ªº¾÷·|³£¦bµû¦ô¡C ¤é«e¯E¹©¤]¤½§i¡A¨ÅÀù·sÃÄOBI-822ªº¸Ñª¼®É¾÷±N¸¨¦b©ú¦~3¤ë©³«e¡A¥L¸ÑÄÀ¡A¸Ó®É¶¡ÂI¬O¥H·Ç³Æ°Ñ»P°ê»Ú¬ÛÃöÀù¯g«n·|ij»P´Á¥Zµoªíªº³Ì«á´Á¦^±À¡A¥H¥Ø«e±M®a·N¨£¨Ó»¡¡AÀH®É³£¥i°±¤î¼Æ¾Úªº»`¶°¡A¶i¦æ¸Ñª¼¡A¦ý½T©w®É¾÷ÁÙn¦h¤è°Ó°Q«á½T»{¡C |
|
|
·|û¡G¶Wô10139528 µoªí®É¶¡:2015/9/4 ¤U¤È 12:03:41²Ä 1935 ½g¦^À³
|
¯E¹©±i©À·O¡G¥xÆW¥Í§Þ·~³W¼Ò¤p¡A¾ã¨Ö¦³§Q°ê»ÚÄvª§ ®É³ø°OªÌ³¢ÂE¼z¥x¥_³ø¾É¡j¤¤¬ã°|¤Î¥Íµ¦·|µ¥¦@¦P¥D¿ìªº2015¦~¥Í§Þ°·±d°ª®p½×¾Â¤µ¤éµn³õ¡A¯E¹© (4174) ¸³¨Æªø±i©À·Oªí¥Ü¡A¥¼¨Ó10¦~¡A¥xÆW¥Í§Þ·~³Ì«¤jªº¬D¾Ô¬O³W¼Ò¤Ó¤p¡A«ÜÃø¦b°ê»Ú¤W¦³Ävª§¤O¡A§Æ±æ·~¬É¯à¦Û¦æµo®i¦X¨Ö¡A¤]§Æ±æ¬F©²¯àÀ°§U°µ¤@¨Ç±j¨î©Êªº¾ã¦X¡A³o¼Ë¦b°ê»Ú¤W¤~¦³§Q©óÄvª§¡C ±i©À·O»¡¡A¦b·s¦åºÞ¡BÀù¯g©M¤¤¼Ï¯«¸gµ¥¥|¤j»â°ì¡A¥xÆW·Qn©M¥@¬É¥ý¶i¤jÃļtÄvª§ªº¸Ü¡A¦b¬Y¨Ç»â°ìªº½T¥i¥HÄvª§¡A¦ý³oºØ¾÷·|¬O¥i¹J¤£¥i¨D¡A¤£¹L¡AY¬O¦b©t¨àÃĩάO¨È¬w¿W¦³ªº¯e¯f¦p¨xª¢¡B¨xÀù¡A©Î¬O¨ÅÀù¡BªÍ¸¢Àùµ¥¤è¦V¬ãµo·sÃÄ¡A¤´¬O¦³§Q°ò¥i¨¥¡C ±i©À·O»y«¤ßªøªº«ü¥X¡A¥Í§Þ²£·~n¦p¦ó¥h§ä¾÷·|¡A¦³4Ó«ÂI¡A²Ä¤@ӳ̫nªº¬O¤H¤~¡A²{¦b·~¬É¤£¥u¬O¯Ê¥F¤H¤~¡A¨Ã¥B¥¿¦b¬y¥¢·í¤¤¡A¥Í§Þ·~°ª¶¥»â¾É¤H¤~¡A°£¤Fn¯à°µµ¦²¤»â¾É¾ã¦XÁÙn¬O¥i¥H°µ°ê»ÚÄvª§ªº¡A¦p¦óºôù©M°V½m¤Q¤À«n¡C²Ä¤GÓ¬OÃD§÷¡A³o»Ýn«Üªøªº®É¶¡¡A¥xÆW¥Í§Þ·~¤£¥u¦b¥»¤g»â°ìn§ä¨ìÃD§÷¡A¦p¦ó¦b®ü¥~»â°ì§ä¨ì§ó¬O«ÂI¡A¦ý³oÂI¥Ø«e¬Ý¨Ó¦³ÂI§xÃø¡A¥xÆW¸ê¥»¥«³õ¨Ã¤£¬O«Ü¦¨¼ô¡A°ê¥~¸êª÷¤]¤£Ä@·N¶i¨Ó¡A¤]¨Ï±o¥xÆW¥Í§Þ·~·Qn§ä¨ì®ü¥~»â°ìªºÃD§÷§xÃø«×¼W¥[¡C ±i©À·O»¡¡A²Ä¤TÓ«ÂI¬O¸m°]¡A¥xÆW¦b¥þ²yÁöµM¾Ö¦³¦n´X¤dÓ±M§Q¬Ý¦ü¤Q¤Àªº¦h¡A¦ý±M§Q¬O§_¯àµ¥¦P±a¶i°]¤O¬OÓ¥¼ª¾¼Æ¡C·Qn±N±M§QÅܦ¨°]·½¡A³oµ´¤£¬O¾ÇªÌ³Ìªìªº¤@Óµo²{´N¥i¥Hªº¡A¤@ӳ̪쪺µo²{¨ì¦¨¥\°µ¥Xn¨Ó¦Ü¤Ön10¦~(»Ý¸g¹LÁ{§É¸ÕÅçµ¥)¡A«ç»ò¾ã¦X¾ÇªÌ³Ìªìªºµo²{¡A¨ì·~¬É¬ãµo§âÃÄ°µ¥X¨Ó¡A¨Ã±N±M§Q´Á©µªø¡B±N±M§Q³Ì¤j¤Æ¡A³o¤~¥i¥H±N±M§QÂà¤Æ¬°¿ú°]¡C ±i©À·O»¡¡A²Ä¥|Ó«ÂI¿ú°]¡A¥Ø«e¥xÆW¬Ý°_¨Ó¥Í§Þ²£·~¤Q¤À¼öµ¸¡A¥«³õ¤Wªº¼ö¿ú¬Ý°_¨Ó«Ü¦h¡A¦ý¨ä¹ê¨Ã¨S¦³¨º»ò¦h¡A³o¨Ç¿ú©¹©¹³£¬O´²«Èªº§ë¸ê¡A¨Ã«Dªø´Á§ë¸ê¦b¥Í§Þ·~¸Ì±ªº¿ú¡A§Æ±æ©¹¥Í§Þ²£·~§ë¸êªº¿ú¯à§óºë·Ç¡AY¬O°ê»Ú°òª÷±Mªùªº§ë¸ê¡A¹ï¤½¥q¸êª÷¤~¦³¯u¥¿À°§U¡C n§Ú§Ú¬O¬F©²¥xÆW´X®a¾Ç¦WÃÄ·sÃÄÂå§÷ªº§Ú·|¸Õ¹Ï¾ã¦X¦X¨Ö ¨Ò¦p:§ö½÷¥Ã«H°·³ìÑÔ±o³o´X¶¡¥i¥H¨Ö¦¨¤@®a ·sÃij¡¤À:´¼Àº°ò¨È¥H¤Î¥x·LÅé¦w¦¨¥i¥H¨Ö¦¨¤@®a §K¬ÌÀøªkÁÞ¤À¤lªºÁÞ°òÁÞÁp¥H¤Î¯E¹© ¤j®a«ç»ò¬Ý©O?¦pªG¦³¤H¥X¨Ó°µ»âÀY¦Ï§Ú·Q·|«Ü¤£¤@¼Ë |
|
|
·|û¡Gmoncler4710135258 µoªí®É¶¡:2015/9/3 ¤U¤È 09:43:52²Ä 1934 ½g¦^À³
|
«Ü©úÅ㦳¤ß¤H¦b¹B§@¤@¨Ç¨Æ±¡,¤¨À³¸Ó¬O¦³±o¨ì°T®§©Ò¥HºÙ¯f¤Æ¸Ñ |
|
|
·|û¡G¥Ó¥|®ü10139653 µoªí®É¶¡:2015/9/3 ¤U¤È 07:08:12²Ä 1933 ½g¦^À³
|
¤¨x¦b³sx¨Æ¥ó¤U¡A¤S¤£·Q±o¸o¤¤x¡A¤~·|µo¥Í¤µ¤Ñ³oºØ¥©¦X¡A ¤¨x°ª©Û¡C |
|
|
·|û¡Gªü¤å10138375 µoªí®É¶¡:2015/9/3 ¤U¤È 06:23:20²Ä 1932 ½g¦^À³
|
³£¬OÁp¦X³øªº§Ö°T : ¤¨l¼Ù¦b¥_¨Ê¤£¾A ¿Ë¦^°T¡G¥u¬O¦åÀ£°ª |
|
|
·|û¡Gªü¤å10138375 µoªí®É¶¡:2015/9/3 ¤U¤È 06:17:25²Ä 1931 ½g¦^À³
|
¤¨l¼Ù¦b¥_¨Ê¤ßŦ¯fµo °eÂå·m±Ï¤¤ |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2015/9/3 ¤U¤È 04:34:03²Ä 1930 ½g¦^À³
|
³Ìªñ¤w¸g§âªÑ²¼³£¦^¸Éª±¤F.´Nµ¥µÛ¸Ñª¼¤F.¯¬¤j®a¶¶¤ß.¨Åé°·±d. |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2015/9/3 ¤U¤È 04:05:48²Ä 1929 ½g¦^À³
|
¤p©_¥S~~ ¤ÏÂЫä¦Ò±z±ÀºâPFSªºÅÞ¿è¡A°ò©ó±zªº°²³]°ò¦¡A§Ú·Q¨ì¹B¥Î©wÁ㪺±Àºâ¤èªk¡A¥H´î¤Ö®É¶¡®y¼Ð¡u¬Û¥Í¬Û·À¡v¥ª¥k²¾°Ê¡A¤]¥i¥HÁ׶}LR»PCR»~®t¤ñ¨Ò°ÝÃD¡A©Î³\ÁÙ¥i¥H¸ÑÄÀ©µªøÆ[¹î5Ӥ몺¦n³B(10¤ë©³ºI¤î¸ê®Æ)¡A¥H¤U·q½Ð¼·¤¾«ü¥¿¡AÁÂÁ ¥ý±N®É¶¡©wÁã¦b2015¦~5/25¡A¦P®É©wÁã¹ï·Ó²ÕPD¤H¼Æ Generally, no further assessments are available after progression has been declared by the LE, and thepatients may have already moved on to new therapies (based on the investigator¡¦s decision) before the BICR is conducted. This process may lead to a considerable number of patients declared to have progressive disease by the LE but censored by the BICR. ¦p¤W^¤å©Òz¡A¥unLR§P©wPD¡A¥æµ¹CR§P©wY«DPD´N¬O³]¡A¦]¦¹§Ú¥ý§â¹ï·Ó²ÕPD¤H¼Æ©wÁã¤U¨Ó¡A³Ñ¤UªºPD¤H¼Æ¤£¥ÎºÞ¨ì©³n¼0.9©Î0.8¡A¦]¬°¤£ºÞ¦³¦h¤Ö¦ì¦bCR®É±qPD§ï§P¬°³]¡A³o¨Ç¤Hµ´¤j³¡¤À¬OÄÝ©ó«e³]»P«ePD©Ò»Ýnªº180¤H¡AµM«á¦A¦^±À§ä¨å«¬ªºÃöÁäA¬O¦bþÓ¤ë¥÷¡Apºâ¦p¤U¡G ¥h¦~12¤ë©³°h¥X26¤H¡A¤µ¦~5¤ë©³°h¥X37¤H¡A5Ó¤ë·s¼W°h¥X11¤H¡A»P¹L¥h¬Û¤ñ¤ñ¨Ò¤Ó°ª¡A§Ú»{©w³o11¤H³£¬O¹ï·Ó²Õ¡A¦Ó¥B¬Û·í¥i¯à¬O2014¦~6¡B7¡B8¤ë¦¬ªº¡A¦]¬°2014¦~822Á{§Éªºª¾¦W«×¤j¼W¡A§Ú¬Û«H³\¦h°Ñ»P¸ÕÅ窺¿ËªB¦n¤Í·|¦bºô¸ô¤W§ä¸ê®Æ¡A¤@¥¹µo²{¥´¤U¥h´XÓ¤ë¨S¦³¬õ¸~¡A¤£¥Îµ¥Âå®v§PPD´N·|°h¥XÁ{§É´M¨D¨ä¥LªvÀø¡C¦Ü©ó¥h¦~12¤ë©³°h¥X26¤H¡A§Ú¹ï¥b¶}¡A¦U°²³]13¤H¡A©Ò¥H¹ï·Ó²ÕÁ`°h¥X¤H¼Æ¬O11+13=24¤H¡A¤]´N¬O»¡¡A¤µ¦~5¤ë¹ï·Ó²Õ¦³116-24=92¤H§P©wPD¡A¹êÅç²ÕPD+³]=229-92=137¤H¡]¨ä¤¤¦³´X¦ìªø§ÀPD¡A«á±¦A°Q½×¡^¡C¦]¬°PD229¬O©T©wªº¡A¹ï·Ó²ÕPD¤H¼Æ³]©w¶V¦h¡A¹êÅç²ÕPD+³]´N·|¶V¤Ö¡AÃöÁäA¥X²{¤ë¥÷¶V©¹«e©µ¦ù¡Aµ²½×·|¶V¼ÖÆ[¡F¤Ï¤§¡A¹ï·Ó²ÕPD¤H¼Æ³]©w¶V¤Ö¡A¹êÅç²ÕPD+³]´N·|¶V¦h¡AÃöÁäA¥X²{¤ë¥÷¶VÃø©¹«e©µ¦ù¡Aµ²½×·|¶V«O¦u¡C§Ú³]©w¹ï·Ó²ÕPD92¤HÄÝ©ó«O¦u°²³] ¦^±À§ä¨å«¬ªºÃöÁäA¬O¦bþÓ¤ë¥÷¡AÁÙ®t180-137=43¡C2014¦~¹êÅç²Õ¤j·§¦¬61¤H¡A§Ú°²³]Globo³±©Ê»P®z¶§©Ê¦û20%¡]¯Î°|ªø»¡¤£¥Î¿z¯f¤H¡A¦]¬°8¦¨¹À¡I¹ù³Õ¤h»{¬°¨S§@¥Î¤ñ¨Ò¬O25~30%¡^¡A61*0.2=12¡C¤§«e°²³]¹êÅç²Õ¦³13¤H°h¥X¡A«ö¤ñ¨Òpºâ2014¦~¦¬®×61¤H¤¤¡AÀ³¸Ó¦³3¤H°h¥X¡A43+12+3=58¡C137¤H¤¤À³¸Ó¦³´X¦ì¦´Á¦¬®×ªºªø§ÀPD¡A¦¹¼Æ¦r«ÜÃø¹w¦ô¡A«O¦uªº¤H¦ô¤Ö¤@¨Ç¡A¼ÖÆ[ªº¤H¦ô¦h¤@¨Ç¡A¥Ñ©óPFSÆ[¹î´Á¦³24Ó¤ë¤W¡A§Ú¥H«O¦uì«h»P¤è«Kì«h¦ô3¤Hªø§ÀPD¡A³o¼Ë43+12+3+3=61·|§ó¦nÀ´¡C®É¶¡©wÁã¦b2015¦~5/25¡Anº¡¨¬«ePD+«e³]=180¤H¡A«h2014¦~12¤ë¬O¨å«¬ÃöÁäAªº¥X²{¤ë¥÷¡A³o¼ËPFS³Ì¤pȬO17Ó¤ë¡C 2014¦~12¤ë¬O¨å«¬ÃöÁäAªº¥X²{¤ë¥÷¡APFS¬O17Ó¤ë¡A¥Nªí2014¦~1~4¤ë¦³Àø®Äªº¯f±w¡A¦b¤µ¦~5/25¶}ª¼®É·|³Q°O¿ý¬°³]13+¡B14+¡B15+¡B16+¡B16.9+¡C¥Ñ©ó822¸Ñª¼ªº¸ê®ÆºI¤î¤é¥i¯à¦b10¤ë©³¡A³o¨Ç13+¡B14+¡B15+¡B16+¡B16.9+«e³]ªº¤H·|©¹«á²¾¨ìªø§À³]Åܦ¨18+¡B19+¡B20+¡B21+¡B21.9+¡A·íµM¡A¥i¯à¦³´X¦ìÅܦ¨ªø§ÀPD¡A¦ý³o¤£·|¼vÅTPFS¡C¤]´N¬O»¡¡A¦hÆ[¹î5Ó¤ë·|Åý¤j¬ù30¦ì«e³]ªº²¾¨ìªø§À³]¡A«h¨å«¬ÃöÁäAªº¥X²{¤ë¥÷¥i¥H¦A©¹«e²¾3Ó¤ë¡C³o¸Ì·|¥X²{¬Û¥Í¬Û·Àªº°ÝÃD¡A¦]¬°ÃöÁäA©¹«e²¾¡A¥NªíPFS±q17Ó¤ë¼W¥[¨ì18Ó¤ë©Î19Ó¤ë©Î20Ó¤ë¡A±N¾ÉP²¾¬°ªø§À³]ªº18+¡B19+¡B20+¤S¶]¦^«e³]¡A³o³¡¥÷¤£¦n°Q½×¡A¦ý¦h5Ӥ몺Æ[¹î¡AÀ³¥i´£°ªPFS1~2Ó¤ë ¼ÖÆ[ªº¤H¥i¥H1.´£°ª¹ï·Ó²ÕPD¼Æªº°²³]¡A2.´£°ªªø§ÀPD¼Æªº°²³]¡A3.´£°ªGlobo³±©Ê»P®z¶§©Ê¤ñ¨Ò¨ì30%¡A¨Ì¤£¦P¼ÖÆ[µ{«×¥i¥H¼W¥[PFS1~3Ó¤ë¡C¦p¦¹¬Ý¨Ó¡A±i¸³¦b3/3¦^µª²Ä¤@Ó°ÝÃD¡A¤£µL¥i¯à ¥H¤WJ¨¥¶Ã»y¸U¸U¤£¥i·í¦¨§ë¸ê¨Ì¾Ú¡A¤@¤Á¥H¤½¥q¤½§i¬°·Ç |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/9/3 ¤U¤È 03:21:48²Ä 1928 ½g¦^À³
|
8/29~8/30¯E¹©©xºô¤@ª½¶i¤£¥h,8/31¦¤W²×©ó¥i¥H¶i¥h¡A©x¤èªºnews¤W½T¹ê¦³¤@Ó"«e"¦r ©Î³\¬O©È¦U¤è²q´ú¡A¦]¬°©¹«e¦h¤[¤§Ãþªº¡A°®¯Ü®³±¼¤ñ¸û¤£·|¦³ª§Ä³¡C ¥t¥~¤p§Ì©ú¤Ñ·|¥hÅ¥¯Î°|ªø»P±i¸³ªººtÁ¿¡A¦pªG¦³¥ô¦ó¥i¥H"®¶¾Ä"ªº®ø®§ þ©È¬O¤@¤BÂI¤]·|¸ò¦U¦ì¤À¨É¤@¤U~~ ¤µ¤Ñªº¨«¶Õ¦n¼Ëªº¡A¨B¨B°ª¡AÀHµÛ±µªñ©ú¦~3¤ë¡A¦p±i¸³»¡ªº"¦nÀ¸¦b«áÀY"¡A¤d¸U§O¯Ê®u¤F |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/9/3 ¤U¤È 12:14:16²Ä 1927 ½g¦^À³
|
Cleverman¤j¡A ¤p§Ì¬Ý¨ìªº¤½¥q©xºô©M¤½¶}¸ê°TÆ[´ú¯¸¼gªº¤]¬O3¤ë ¦ý¦³ªº´CÅé¼g3¤ë[«e] ¤S¥xÁÞ¤j¥h¹q¤½¥q¨DÃÒ¦³¤@Ó[«e]¦r ¦]¦¹°µ¤F¦p¦¹ªº½×z ¦ý¦³¨S¦³[«e]³oÓ¦r¼vÅT¤£¤j¡A ¦]¬°¥H±M®aªº¥ß³õ¡A¬O«Øij8/28¤§«á¦h¦AÆ[¹î2~3Ӥ몺®É¶¡¡A¥Dn¬OÅý2014/1~2014/8¦¬®×ªº¤j¬ù40~50¦ì¥Ø«e©|¥¼PDªº±wªÌ¡A¦A¦h§e²{¤@ÂIÀø®Äªºª¬ªp¡C·íµM¡A³Ì¦nªº§e²{Àø®Äª¬ªp¬O2015/8/25³Ì±ß¦¬®×ªº¨º¤@¦ì¤]Æ[¹î24Ó¤ë¡A¦ý°µ³o¼Ëªº«Øij´N¤£¥s±M®a¤F¡A©Ò¥H¦Ò¼{®É¶¡©Ê¤Î»°ASCO¦~·|¡A¦]¦¹«Øij¦AÆ[¹î2~3Ó¤ë¡C ³Ì«nªº¥B¥²¶·½T©wªº¤é¤l¬O³Ì²×¸ê®Æ¦¬¶°¤é¡A©Ò¦³ªº±wªÌ¥H³o¤@¤Ñªº¼Æ¾Ú¤Î§PŪµ²ªG·í°µ2016/3¶}ª¼®Éªº¤ÀªR°ò¦¡A¦Ü©ó³Ì²×¸ê®Æ¦¬¶°¤é¬O©w¦b2015/10©Î2015/11´N¤£±o¦Óª¾¡A¦]¬°¤½¥qn¥h¦ôºâ³Ì²×¸ê®Æ¦¬¶°¤é¤§«á©Ò¦³ªºLRÂà´«¦¨CR©Ò»Ýnªº®É¶¡¡A¥H¤Î2016/2¹A¾ä¹L¦~¤u§@¤Ñ¼Æ¤Öµ¥¦]¯À¡A¥un©Ò¦³ªº¼Æ¾Ú³£¦¬»ô¤F¡A¦ÛµM¥i¥H«Å§G¶}ª¼ªº¤é´Á¡A§ì2016/3¸Ñª¼¬O¤½¥q¦ôºâ¹L«á¦³§â´¤ªº¤ë¥÷¡A¦pªG«e¸mªº¼Æ¾Ú¦¬¶°§@·~¥i¥H´£¦§¹¦¨¡A¤½¥q¨S¦³²z¥Ñ¤£ºÉ§Ö¶}ª¼¡A¥HºÉ§Ö¦bCliff¤j©Ò´£¨Ñµ¹§Ú̪ºASCO³Ì«á´Á2016/3/15¤§«e±N¤ÀªRªºµ²ªG°e¥X¥h¡C |
|
|
·|û¡Gkenken10138351 µoªí®É¶¡:2015/9/3 ¤W¤È 11:04:20²Ä 1926 ½g¦^À³
|
§ó¥¿,¬O8¤ë31 |
|
|
·|û¡Gkenken10138351 µoªí®É¶¡:2015/9/3 ¤W¤È 10:56:00²Ä 1925 ½g¦^À³
|
¤£¥Î§n¤F,³£¨S¿ù,¦]¬°³Ì¦ªº©xºô¬O¼g¤T¤ë«e,²{¦b©xºô¬O§ó§ï«áªº¤T¤ë ¦³¿³½ì¥i¥H¥hgoogle ¤@¤U,«ö¤@¤U®w¦sÀɶ,´N¥i¥Hµo²{ì¨Ó8¤ë30¤éªº©xºô¬O¼g3¤ë«e |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/9/3 ¤W¤È 09:03:40²Ä 1924 ½g¦^À³
|
¥xÆW¯E¹©±M®a·|ij«Øij¡G OBI-822II/III´ÁÁ{§É¸ÕÅç ©ú¦~3¤ë¸Ñª¼ ³o¬O©xºôªº·s»D½Z¼ÐÃD. |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/9/3 ¤W¤È 08:52:32²Ä 1923 ½g¦^À³
|
§Ú¬Ýªº¤½¥q©xºô·s»D½Z¥H¤]¬O¼g¤T¤ë.¨S¬Ý¨ì¤T¤ë«e. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/2 ¤U¤È 07:16:13²Ä 1922 ½g¦^À³
|
´¡ªá¤@¤U¡G ¦Ñ¥v¤j»¡¡u822Y¥u°©Âಾ¤£¦¬¡v¡Aªº½T¦p¦¹¡C Why¡H ´¿¸g¬°¦¹·P¨ì§x´b¡A°Ý¹L¤½¥q°ª¼h¡Aµª¡u¶È¦³°©ÂಾªÌ¡v·|¦s¬¡¸û¤[¡A¾ãÓÁ{§É¸ÕÅç®Éµ{¦]¦¹¯Ó®É¤[¤[¡F ¬Û¤Ï¦a¡A¸£ÂಾªÌ·|´c¤Æ«Ü§Ö¡Aµ¥¤£¨ì822µo´§Àø®Ä´N¡K¡A©Ò¥H¤£§Q©óPFS¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2015/9/2 ¤U¤È 05:52:07²Ä 1921 ½g¦^À³
|
¦Ñ¥v¤j ±z¬O¥Î¥\ªº°ª¤â ¬°¤å¤Þ¸g¾Ú¨å ¬O¾Ç´I¤¨®ªº¤~«T «D±`ÁÂÁ±zªº«ü¥¿ èèµy°µ¤F¸Ñ ¤p§Ì¤S¥Ç¡¨·Q·íµMº¸¡¨ªº»~ÂÕ ÁÙ¬O¤Ö¥Îª½Ä±¨Ó§PÂ_ ¤p§Ì¤w¸g¥b¦~¦h¨SŪ®Ñ ¦£©óÅéÀˬÝÂå¥Í ¬°¤FÅý¦Û¤v¥Í¬¡¤Ö¨üÀ£¤O ´X¥G¹LµÛ¶¢¶³³¥Åbªº¥Í¬¡ ²{¦b¥~¶Õ°ÊÀú ªÑ²¼´N¥H¦Û¤v¥i¥H©Ó¨ü±o°_·l¥¢ªº³¡¦ì¨Ó«ù¦³ ¨Ã¯d¨Ç²{ª÷À³ÅÜ ·PÁ±z ¤]·PÁ¤j®a¸sµ¦¸s¤O ¯¬ºÖ¤j®a¦¤é°]´I¦Û¥Ñ ¨É¨ü¥Í¬¡ ÁÂÁ¤j®a! |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2015/9/2 ¤U¤È 03:51:04²Ä 1920 ½g¦^À³
|
²q·Q¤jô PALOMA3 ( palbociclib¡Vfulvestrant vs. placebo¡Vfulvestrant Á{§É¤T´Á ) ¬°½÷·ç¥i¯à¤£·|§â¥¦±À¤W¥«? ¤Þ¥ÎAmy¯d¤Uªº¤å¦r§ó®e©öÀ´ It¡¦s in a second phase 3 which is way late in the game and working well for people who are unsuccessful on endocrine therapy (which is me) Amy 2014/3/24ªA¥Îletrozole¡AªA¥Î¤j¬ù¨âÓ¤ë 2014/6/5Âಾ¨ì¨xªº¸~½F´c¤Æ¡AÀV´Õ²Ä¤¸`ªº¯«¸g³Q¸~½FÀ£¨ì 2014/6/16Âå®v«Øij°Ñ¥[PALOMA3 palbociclib¡Vfulvestrant ªº¥Ø¼Ð¯f±w©Mpalbociclib¡Vletrozole¬O¤£¦Pªº |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/9/2 ¤U¤È 02:34:25²Ä 1919 ½g¦^À³
|
·PÁÂ¥v¥S¡A ¦³¤F±z´£¨Ñªº¸ê®Æ¡A½ü¹ø´N§ó²M·¡¤F¡I |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2015/9/2 ¤U¤È 02:07:12²Ä 1918 ½g¦^À³
|
¤p©_¥S Ibrance¤G¦X¤@¡G20.2Ó¤ë¡A33%¤T´Á¡B67%¥|´Á¡]19%°©Âಾ¡A48%Ŧ¾¹¡^ ¶P¯e§´¤T¦X¤@¡G18.5Ó¤ë¡A78%Ŧ¾¹Âಾ¡A22%«DŦ¾¹Âಾ¡A¥u¦¬HER2±j¶§©Ê¯f±w¡A®z¶§©Ê¤£¦¬ ¶PÀù¥¤G¦X¤@¡G12.4Ó¤ë¡A78%Ŧ¾¹Âಾ¡A22%«DŦ¾¹Âಾ¡A¥u¦¬HER2±j¶§©Ê¯f±w¡A®z¶§©Ê¤£¦¬ letrozole³æ¿WªvÀø1¡G9.4Ó¤ë¡A25%¬O¤T´Á¡B75%¬O¥|´Á¡]32%°©Âಾ¡B43%Ŧ¾¹¡^ letrozole³æ¿WªvÀø2¡G10.2Ó¤ë¡A33%¬O¤T´Á¡B67%¬O¥|´Á¡]19%°©Âಾ¡B48%Ŧ¾¹¡^ letrozole§½³¡´_µoªºPFS12.1Ó¤ë¡A°©ÂಾPFS°¬°9.5¡AŦ¾¹Âಾ°¬°8.3¡AY¬O¨xŦÂಾ¥u¦³3.8Ó¤ë ®õ²ö¦èªâ§½³¡´_µoªºPFS6.4Ó¤ë¡A°©ÂಾPFS°¬°6.2¡AŦ¾¹Âಾ°¬°4.6¡AY¬O¨xŦÂಾ¥u¦³3Ó¤ë 822Y¥u°©Âಾ¤£¦¬ Paloma3¦¬®×¯f±w¡G progressed within 1 month from prior advanced/metastatic endocrine breast cancer therapy |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2015/9/2 ¤U¤È 01:46:59²Ä 1917 ½g¦^À³
|
¨¬·P¤ß ÁÂÁ¤p©_¤jªá¤F³o»ò¤jªº½g´T ¬°¤p§ÌÄÀºÃ ¥B«ä¼{¦p¦¹©P©µ²`¼s §óÅã±o¤p§Ìªº²LÁ¡ ¯à¦³¦¹µ¥¾÷·|¨ü±Ð ¦³°Ý´N¦³¦¬Ã¬ ¤D¤p§Ì¤§©¯¤] ¦A¦¸ÁÂÁ±z ¤]ÁÂÁ¤j®a! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/2 ¤U¤È 01:37:16²Ä 1916 ½g¦^À³
|
¤p©_¤j ÁÂÁ¸ɥR»¡©ú PERJETA® +trastuzumab +docetaxel ¥é³æ¤å¦Û»¡©ú ¥i½T©wªº¬O ¶i¦æ³Ì²× PFS ¤ÀªR®É¡A¦³ 165 ¦W±wªÌ¤w¦º¤`¡A ªvÀø²Õ(17.2%) 402X17.2=69¤H ¹ï·Ó²Õªº¦º¤`²v(23.6%) 406X23.6=96 ¤H Á`¦s¬¡´Á(²Ä 2 ¦¸´Á¤¤¤ÀªR) ªvÀø²Õ¦º¤`²v28.1% 402x28.1= 113¤H ªvÀø²Õ¦º¤`²v37.9% 406x37.9= 154¤H ¥u¬O¤£ª¾¹D¶i¦æ³Ì²× PFS ¤ÀªR »P ²Ä 2 ¦¸´Á¤¤¤ÀªR ¬OÆ[¹î¦h¤[ |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/9/2 ¤U¤È 01:02:54²Ä 1915 ½g¦^À³
|
¥xÁÞ¤j¡A ³øºp¡AÅý±z»~¸Ñ¡A×¥¿¤@¤UÁ¿ªk¡A ¡y§A´£¨ì9 »P4¬O«ü²Ä45Ӥ몺 n at risk¡A´N¬O¨ì45Ó¤ëÁÙ¥¼µo¥Í¦º¤`¨Æ¥óªº¤H¼Æ¡A¡z ¡u´N¬O¨ì45Ó¤ëÁÙ¥¼µo¥Í¦º¤`¨Æ¥óªº¤H¼Æ¡v n§ï¦¨¡u¸g¾úÁ{§É®É¶¡¤j©óµ¥©ó45Ó¤ë¥H¤W¥B¨ì²Ä45Ӥ몺«e¤@¨èÁÙ¥¼µo¥Í¦º¤`ªº¤H¼Æ¡v¡A¦]¦¹¥u¸g¾úÁ{§ÉÆ[¹î44Ó¤ë©Î38Ó¤ë¦ý¥¼¦º¤`ªº±wªÌ(¬°³]¸ê®Æ)¤£¦b9©Î4³o¨âӼƦrùØÀY¡A¥LÌ¥i¯à¦b45Ӥ뤧«e´N¦º¤`¡A¤]¥i¯à¦b50Ó¤ë¥H«á©Î§ó¤[¤~¦º¤`¡AÆ[¹îªº®É¶¡n§ó¤[¤~ª¾¹D¡C ¦]¦¹¡A¡uKaplan-Meier ¦±½u°lÂܨì²Ä30Ó¤ë ¦³143¤HÁÙ¦s¬¡ 259¤H¤w¹L³u¡v¤£¯à³o¼ËÁ¿¡A259¤H¤¤¦³¨Ç¹L³u¡A¦ý¤j³¡¥÷¬OÆ[¹î®É¶¡¤£°÷ªº³]¸ê®Æ¡F¤j©óµ¥©ó30Ӥ몺143¤H¤¤¡A¤]¬O¦³¨Ç¹L³u¡A¦³¨Ç¬O¥¼¹L³uªº³]¸ê®Æ¡A¥u¬O¦bÅu¶}OS§Ç¦C®É¡A¥L̪ºOS¤£ºÞ¬O³]©Î¥¼³]³£¤j©óµ¥©ó30¡C ³ÌÄY«ªºMBC±wªÌ¸gªvÀø«áªºOS¡APERJETA® +trastuzumab +docetaxel¦bHer+ªº±wªÌM OS=56.5Ó¤ë¡A¥Ø«e¤Ñ¤UµL¼Ä¡A³o¤]¬O¬°¦ó822ªºOSÆ[¹î´Á³]©w¬°5¦~ªºì¦]¡A¦]¬°Y¯uªº¦b³ÌÄY«ªºMBC±wªÌ¨¤W¥ÎÃÄ«á¹F¨ìM OS=5¦~¡A¤]¬O¨S¦³Ävª§ªÌ¡A¦Aªá®É¶¡¤H¤Oª÷¿ú¥h°lÂܬO§_¹F¨ì6¦~©Î7¦~¨S¦³¯S§Oªº·N¸q(¦³¾Ç³N¤Wªº·N¸q)¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/2 ¤U¤È 12:23:01²Ä 1914 ½g¦^À³
|
¤p©_¤j §A´£¨ì9 »P4¬O«ü²Ä45Ӥ몺 n at risk¡A´N¬O¨ì45Ó¤ëÁÙ¥¼µo¥Í¦º¤`¨Æ¥óªº¤H¼Æ¡A ©ÎªÌ»¡¹ï¾÷²v¤U°ÁÙ¦³¼vÅTªº¤H¼Æ ·PÁ§A´£¨ÑªºÄ_¶Q¸ê°T PERJETA® +trastuzumab +docetaxel ¹êÅç²Õ n=402¤H ÀH¾÷¤À°t¸ÕÅ礤Á`¦s¬¡´Áªº Kaplan-Meier ¦±½u°lÂܨì²Ä30Ó¤ë ¦³143¤HÁÙ¦s¬¡ 259¤H¤w¹L³u ¨ÅÀù·sÃÄ OBI822 ¹êÅç²Õ n=233¤H °lÂܨì²Ä30Ó¤ë ±qªÑªF·|¸ê°T±oª¾ ¦º¤`¨Æ¥óªº«Ü¤Ö ³o¯u¬O¤@Áû¥O¤H´Á¬ßªºÃÄ |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/9/2 ¤U¤È 12:19:34²Ä 1913 ½g¦^À³
|
²q·Q¤j¡A ±z¤Ó«È®ð¤F¡A½×¦~¬ö¡B½ú¥÷¡B¤H«~¡A¤p§Ì³£¸ÓºÙ©I±z¤@Án¤jô¡A ¯à¦bªO¤W»P±z¤Á½R°Q½×¬O¤p§Ìªººa©¯¡I ¤×¨ä¬O¦bK-M¨ç¼Æ¤W¡A±z©Ò´£¨Ñªº¸ê®Æ¥H¤Î»P±zªº¸£¤O¿E¿º¡A¤p§Ì¨ü¯q¨}¦h¡A·PÁ¤§±¡¤£¨¬¥H¨¥ªí¡A©Ò¥H±z´N¯uªº§O³o»ò«È®ð¤F¡I ÁÙ±æ±z¦b¤p§Ìªº¶K¤å¤¤¡AY¦³¤£¦X²z¤§³B·Ð½Ð¤£§[´£¥X¬Ýªk¡A§K±o¤p§Ì¸¨¤J¿ù»~ªº·Qªk¦Ó¤£¦Ûª¾¡AÁÂÁ¡I ¡yPALOMA-3 ( palbociclib¡Vfulvestrant vs. placebo¡Vfulvestrant Á{§É¤T´Á ) PALOMA-2 ( palbociclib + letrozole vs. letrozoleÁ{§É¤G´Á )¡z ¤p§Ì¬d¤F¤@¤U¡A( palbociclib + letrozole vs. letrozole)Á{§É¤G´ÁºÙ¬°PALOMA-1¡A ( palbociclib + letrozole vs. letrozole)Á{§É¤T´ÁºÙ¬°PALOMA-2¡A¥Ø«eÁÙ¦bÁ{§É¤¤¡C PALOMA-3 ( palbociclib¡Vfulvestrant vs. placebo¡Vfulvestrant Á{§É¤T´Á ) PALOMA-1 ( palbociclib + letrozole vs. letrozoleÁ{§É¤G´Á ) PALOMA-3¡A¹êÅç²Õ»P¹ï·Ó²ÕªºM PFS¤À§O¬O9.2Ó¤ë»P3.8Ó¤ë PALOMA-1¡A¹êÅç²Õ»P¹ï·Ó²ÕªºM PFS¤À§O¬O20.2Ó¤ë»P10.2Ó¤ë¡F¨ä¤¤¤ÀªR61/165=37%ªº±wªÌªºOS¡A¹êÅç²Õ»P¹ï·Ó²ÕªºM OS¤À§O¬O37.5Ó¤ë»P33.3Ó¤ë ³o¨âÓÁ{§Éªº¹ï·Ó²ÕªºM PFS®t²§¹ê¦b¤Ó¤j¡A«eªÌ¬O3.8Ó¤ë¡A«áªÌ¬O10.2Ó¡Afulvestrant©Mletrozole¥Î¦bMBCªº±wªÌ¨¤W¤£À³¦³³o»ò¤jªº®t²§¡A http://www.tma.tw/ltk/101560303.pdf ¹ï©ó°±¸g«áªº°ü¤k¡A²üº¸»XªvÀøªº¿ï¾Ü¥]¬A§Ü°Ê±¡¯À¡]tamoxifen¡Bfulvestrant¡^¡Baromatase inhibitor¡A©Mmegestrol acetate¡C¶Ç²Î¤W¡Atamoxifen¬O¼Ð·Çªº²Ä¤@½uÃĪ«¡A¦Ómegestrol acetate¥i·í§@²Ä¤G½uÃĪ«¨Ï¥Î¡Cªñ¦~¨Óªº¬ã¨sÅã¥Ü¡A¤TºØaromatase inhibitor¥]¬Aanastrozole¡Bletrozole©Mexemestane¡A¦b²Ä¤G½u¨Ï¥Î®É³£¤ñmegestrol acetate¦n¡C¦Ó¦b²Ä¤@½u¨Ï¥Î¤W¡Aanastrozole©Mletrozole¤w³QÃÒ¹ê¤ñtamoxifen¦n¡A¦Ü©óxemestane¥Ø«e¤]¦³²Ä¤G´Á(phase II)Á{§É¬ã¨sªº³ø§i¡CÁÙ¦³¤@Ó·sªºÃĪ«¬Ofulvestrant¡A¥¦¬O¤@ºØ¯Âºéªº§Ü°Ê±¡¯À¡A¨Ã¤£¹³tamoxifen¤@¼Ë¦³¨ó¦P¾¯ªº§@¥Î¡CÁ{§É¹êÅçÅã¥Ü¡A³¡¤À¹ïtamoxifen¦³§ÜÃĩʪº¯f¤H¤´µM¹ïfulvestrant¦³¤ÏÀ³¡C¦Ó¥B¹ï³oÃþ¯f¤H¦Ó¨¥¡Afulvestrantªº®ÄªG©Manastrozole¤@¼Ë¡K. ¤p§Ì±À·Q¦bMBCªºªvÀø¤W¡Aletrozole©Mfulvestrant¬O¥i¥H¤¬¬Û¨ú¥NªºÃĪ«¡AY³o¨âÓÃĪ«±¹ï¦P¤@©â¼Ë¼Ë¥»PKªº¸Ü¡A¨âÓÃĪ«ªºM PFSÀ³¸Ó¤£·|¬O10.2Ó¤ë»P3.8Ó¤ë¦p¦¹¤jªº®t²§¡C¦ý¤Wz¨âÓÁ{§É¤@Ó¬O10.2Ó¤ë¡A¤@Ó¬O3.8Ó¤ë¡A®t²§¤Ó¤j¤F¡AÅý¤p§ÌÃhºÃ³o¨âÓÁ{§Éªº¦¬®×¼Ð·Ç¤£§¹¥þ¤@¼Ë¡C¦P¼Ë¬OMBCªº¦¬®×¡A²O¤ÚÂಾ¡B¦P´úÂê°©¤W²O¤ÚÂಾ¡B°©Âಾ¡B¨x¸£ªÍªºÂಾ¡A¨ä´c©Êµ{«×³£¤£¤@¼Ë¡A¦¬®×±wªÌ¤¤¤£¦P´c©Êµ{«×Âಾ±wªÌªº¤ñ¨Ò±N¼vÅT¤£¦PÁ{§É¹êÅ窺Á{§É¼Æ¾Ú¡C²q´úPALOMA-1 ( palbociclib + letrozole vs. letrozoleÁ{§É¤G´Á )ªº¦¬®×¼Ð·Ç¨S¦³PALOMA-3¨º»òÄYV¡A¦]¦¹¤£ºÞ¹ï·Ó²Õ©Î¹êÅç²ÕªºM PFS©ÎM OSªºÈ³£·|¬Ý°_¨Ó¤ñ¸û°ª(PALOMA-1 ( palbociclib + letrozole vs. letrozoleÁ{§É¤G´Áªº¹ï·Ó²ÕªºM OS=33.3Ó¤ë¡A¤ñ¤@¯ë»{ª¾ªºÂಾ©Ê²Ä¥|´Á¨ÅÀùªºM OS¤j¬ù18~24Ó¤ë¨Ó±o°ª³\¦h)¡C ¦]¦¹¤p§Ìı±oY822ªº¹ï·Ó²ÕªºM FPS¤]¬O3~6Ó¤ë¤W¤U¡A¨º»ò822©Ò©â¼ËªºMBC¼Ë¥»ªº´c©Êµ{«×»PPALOMA-3Á{§É¤T´Á©â¼ËªºMBC¼Ë¥»ªº´c©Êµ{«×·|¤ñ¸û±µªñ¡C¤]´N¬O»¡¡AY³£¬O©Ô¨ì±µªñ®t¤£¦hªºÄYV¼Ð·Çªº©â¼Ë(¥Î¤@¯ë¤ÆÀøÃĩβüº¸»XÃĪº¹ï·Ó²ÕªºM PFS¤j¬ù3~6Ó¤ë¨Ó·íÆ[¹î«ü¼Ð)¡APALOMA-1 ( palbociclib + letrozole vs. letrozoleÁ{§É¤G´Á )ªºM PFS¤£·|¨ì20.2Ó¤ë¡A¨äM OS¦ÛµM¤]¤£·|¨ì3XÓ¤ë¡C PALOMA-3¡A¹êÅç²Õ»P¹ï·Ó²ÕªºM PFS¤À§O¬O9.2Ó¤ë»P3.8Ó¤ë¡A9.2/3.8=2.42 PALOMA-1¡A¹êÅç²Õ»P¹ï·Ó²ÕªºM PFS¤À§O¬O20.2Ó¤ë»P10.2Ó¤ë¡A20.2/10.2=1.98 Y¥Hµû¶qÃÄ®ÄÀ³¸Ó¬Ý¹êÅç²Õ»P¹ï·Ó²Õªº¤ñÈ¡A¤ñ¬Ý¹êÅç²ÕªºM PFSªºµ´¹ïȨӱo¦³°Ñ¦Ò»ùȨӬݡA¤p§Ìı±opalbociclib»Pfulvestrantªº²Õ¦X¥i¯à¤ñpalbociclib + letrozoleªº²Õ¦X¨Ó±o¨Î¡C±q«e±ªº±À´ú¡AY¦P¼Ë±Ä¥Îªñ¦üªºÄYVªº©â¼Ë¼Ë¥»(¥H¹ï·Ó²ÕªºM PFS¤j¬ù3~6Ó¤ë¨Ó·íÆ[¹î«ü¼Ð)¡APALOMA-3¥H¤ÎPALOMA-2ªºM OS¥i¯à¥u¦³2XÓ¤ë¡An¹F¨ì3XӤ몺¾÷²v·¥§C¡C¦]¬°822ºI¦Ü2015/11¡A¦³57% ªº±wªÌªº¸g¾úÁ{§É®É¶¡´¶¹M¦b3X»P4XÓ¤ë¡A¥B¦º¤`¤H¼Æ«Ü¤Ö³o¥y¸Ü¡AÀ³¸Ó¥i¥H½Ķ¦¨¡u2013/6«e¦¬®×ªº57%¹êÅç²Õ¬ù132¦ì±wªÌ¤£¦Ü©ó¦³1/2=66ªº¤H¦º¤`(±i¸³Æ[¹î¨ìªºÁ`¦º¤`¤H¼ÆÁÙ¥]¬A¦³¤j¥bªº¹ï·Ó²Õ±wªÌ¤w¦º¤`)¡v¡A¤@¦¹¤p§Ì±À´ú2016/3¶}ª¼®É¡A822ªºM OS¤j©ó3XÓ¤ë¡AK-M¨ç¼Æ¤´¦Q¦b0.5¤ô¥½u¥H¤W¤@¬q¶ZÂ÷¡C 822ªºM OS¤j©ó3XÓ¤ë¡AY¦b¤@¼Ëªº°ò·Ç¤W¡APALOMA-3©ÎPALOMA-2ªºM OS¥i¯à¬O2XÓ¤ë¡A©Ò¥H¤p§Ì»¡¦bOSªºªí²{¤W¡A822·|§¹³Ópalbociclib¡C·íµM³Ì«nªºÆ[¹î«ü¼Ð´N¬O¡A822ªº¹ê»Ú¦¬®×¼Ë¥»¬O§_»P¤½¥q©Ò³]pªº·Qªk¤@¼Ë¡A¤]´N¬O¹ï·Ó²ÕªºM PFS¤p©óµ¥©ó6Ó¤ë¡A¦]¬°822ì©lÁ{§É³]p¬O¹êÅç²ÕªºM PFS¥un¤ñ6Ó¤ë¦h50%=9Ó¤ëӧﵽ´Nºâ¹LÃö¡A¦pªG822¹ï·Ó²ÕªºM PFS¶W¹L6Ó¤ë¤Ó¦h¡AYK¥i¯à·|³Q±i¸³°á¤@¤U¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/9/2 ¤W¤È 10:14:41²Ä 1912 ½g¦^À³
|
¥xÁÞ¤j¡A ¡y¶P¯e§´¥é³æ¹Ï2 N at risk ¨ì²Ä45Ó¤ë ®É ¹êÅç²Õ9 ¹ï·Ó²Õ4, 9 »P4 ¬O«ü¤°»ò·N«ä? N at risk ? À³¬O«üÁÙ¨Sµo¥Í¨Æ¥ó¼Æ ???¡z 9 »P4¬O«ü²Ä45Ӥ몺 n at risk¡A´N¬O¨ì45Ó¤ëÁÙ¥¼µo¥Í¦º¤`¨Æ¥óªº¤H¼Æ¡A©ÎªÌ»¡¹ï¾÷²v¤U°ÁÙ¦³¼vÅTªº¤H¼Æ¡CY¦b¤ÀªRªº®ÉÂIÅu¶}OS§Ç¦C¡A´N¬O«ü45¡A45+¡A46+¡A47³o¨Ç±wªÌ¡C ¡yÓ¤H±À´ú2016¦~3¤ë«á ¦A¦b¸g¹L2¦~À³ÁÙ¤£·|¨ì¹F 0.5 §A»{¬°?¡z ³æ¾Ì6/3ªÑªF·|±i¸³¤@¥y¡A¦º¤`¤H¼ÆÁ٫ܤ֡A¤p§Ì±À·Q2016/3¶}ª¼®ÉOSªºK-M¨ç¼Æ¹Ï«¬¤WM OS·|¤j©ó3XÓ¤ë¡A¤w¸g¬O¸õÅD¦¡±À´ú¡A2~3¦~«á¹êÅç²Õ±wªÌªºOS¸ê®Æ·|«ç»òÅܤơA¹ê«D¤p§Ì©Ò¯à²q±o¨ì¡A©Ò¥H¡A´N«Ý¨ì2016/3¬Ý¨ìK-M¨ç¼Æªº¾÷²v¨ì©³°¨ì0.9©Î0.8©Î0.7¦A¨Ó²q§a¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/1 ¤U¤È 10:50:56²Ä 1911 ½g¦^À³
|
¤p©_¤j Ó¤H«D¬ì¾Çªº²q´ú ¦³¨º¸Ì¿ù»~ ½Ð«ü¥¿ A PERJETA + Herceptin + docetaxel at the final analysis1 µo²{ MOS ¦s¬¡¦±½u ±q 1 ¤U°¨ì0.5 ¸g¾ú¤F56.5Ó¤ë ±q0.9¤U°¨ì0.5¸g¾ú¤F 41.5Ó¤ë(56.5-15)¹êÅç²Õ¦º¤`ªº¯f±w¼Æ113¤H ±q1¤U°¦Ü0.5 ¦@5ӰϬq °²³]«Ü¥§¡¤À§G ¨CӰϬq¬ù23¤H B §A´£¨ì 2013¦~1¤ë¨ì2013¦~6¤ë¦¬®×ªº¹êÅç²ÕºI¦Ü2015/11¤ë¤w¸g¾ú29~35Ó¤ë¡A2012/12¥H«e ¦¬®×ªº±wªÌ¤w¸g¾ä¶W¹L35Ó¤ë¥H¤W C Ó¤H±Àºâ 2013¦~4¤ë ¦¬®×¹L¥b ¦Ü2015¦~11¤ë ¸g¾ú¤F 31Ó¤ë D °²³]822¹êÅç²Õ¦º¤`ªº¯f±w¼Æ«Ü¤Ö(°²³]¦b23¤H¥H¤º)MOS ¦s¬¡¦±½uÀ³ÁÙ°±¦b0.9(¸g¾ú¤F31Ӥ백¦b0.9¦ì¸m) Ó¤H«D¬ì¾Çªº²q´ú MOS ¦s¬¡¦±½u ¶P¯e§´+¶PÀù¥+¼Ú¬wµµ§ü¾J±q0.9¤U°¨ì0.5¸g¾ú¤F41.5Ó¤ë +31Ó¤ë=72.5Ó¤ë E PERJETA + Herceptin + docetaxel M OS 56.5 /M PFS 18.5 = 3 72.5 /3 = 24 F ¥H¤W¬O¤ÈºÎ¤¤ÆF·P¨Ó³X®É«D¬ì¾Çªº²q´ú ¥i¯à¦³»~ ¤£n¤Ó¬Û«H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2015/9/1 ¤U¤È 06:19:13²Ä 1910 ½g¦^À³
|
ÁÂÁ¤p©_¤jºëªöªº¤ÀªR ¤£¹L±z¤U¦Cªº³o¬q½×z ¤p§Ì¦³¨Ç¤£¸Ñ ¡§ °Ñ¦Òµ½¤H¤j¤À¨ÉªºIbrance¦b¤ñ¸ûÄYVªº¦¬®×±ø¥óªºÁ{§É¤T´ÁPALOMA3(http://www.breastcancer.org/research-news/ibrance-offers-benefits-as-second-line-tx¡A2015¦~ªºASCO©Òµoªí¡A The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib¡Vfulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo¡Vfulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001).¡A ¹êÅç²ÕªºM PFS=9.2Ó¤ë¡A¦b¤£¦Pªº¦¬®×±ø¥ó¤U¡AM PFS¨Ã¨S¦³PALOMAÁ{§É¤G´ÁªºM PFS=20.2Ó¤ë³o»ò°ª¡A·Ó²z±À½×¡APALOMA3ªº¹êÅç²ÕªºM OSn¹F¨ìPALOMAÁ{§É¤G´Áªº¤j¬ù38Ӥ몺¥i¯à©Ê¤£°ª ¡¨ ¤p§Ìªº·Pı 822©Î³\¤£¥Î¸ò PALOMA3 ( palbociclib¡Vfulvestrant vs. placebo¡Vfulvestrant Á{§É¤T´Á ) ªºÃĮĤñ¸û ¦]¬°½÷·ç¥i¯à¤£·|§â¥¦±À¤W¥«? 822n PK ªº¹ï¶HÀ³¸Ó¬O¤wÀòFDA¤W¥«³\¥i ¦ý¤´³B©óÁ{§É¤T´Áªº PALOMA-2 ( palbociclib + letrozole vs. letrozole ) ³o¼Ë©Î³\¤ñ¸û¦X²z ? ÁÙ¬O±z¤w¸g»{¬° ¥¼¨Ó PALOMA-2 ¥XÄlªº ¤¤¦ìOS À³«D822¹ï¤â ¹ï©óPALOMA3¦Ó¨¥ ·íµM§ó¤£¬O¹ï¤â ? ¤p©_¤jÁo©ú¹L¤H ¤p§ÌÃø±æ¶µI ¦³©Ò¾q¶w¥¢Â§¤§³B ©|½Ð¨£½Ì ÁÂÁ¤j®a! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/1 ¤U¤È 04:51:00²Ä 1909 ½g¦^À³
|
§ó¥¿ «á¨Ó¦AÆ[¹î12Ó¤ë Á`¦@Æ[¹î60Ó¤ë(5¦~) ¤~¹º¥X¨Ó¤¤¦ì¼ÆÁ`¦s¬¡´Á¬O56.5Ó¤ë http://www.perjeta.com/hcp/clinical/efficacy/overall |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/9/1 ¤U¤È 04:34:29²Ä 1908 ½g¦^À³
|
¤p©_¤j ¤Óºë±mªº¶K¤å¤À¨É »áªR¯à¤O²z©Ê«ÈÆ[ ¤S¯à«e«á©IÀ³ ¨ü¯q¨}¦h ¥t¥~§Ú̱`°Q½×³o¤@±i ¶P¯e§´¥é³æ http://www.roche.com.tw/home/products/products01/perjeta.html ¹Ï 2 ³o¤@±i ÀH¾÷¤À°t¸ÕÅ礤Á`¦s¬¡´ÁªºKaplan-Meier ¦±½u ³o±i¹Ï¬OÆ[¹î48Ó¤ë ¦]M¡@¢÷¢ûÁÙµLªk¹º¥X¨Ó ¹êÅç²Õ¦º¤`ªº¯f±w¼Æ113 (28.1%) ¦¬®×402¤H ¶P¯e§´¥é³æªí2 ÀH¾÷¤À°t¸ÕÅ窺Àø®ÄºKn «á¨Ó¦AÆ[¹î12Ó¤ë Á`¦@Æ[¹î60Ó¤ë¤~¹º¥X¨Ó¤¤¦ì¼ÆÁ`¦s¬¡´Á¬O57.5Ó¤ë http://www.perjeta.com/hcp/clinical/efficacy/overall 822Á`¦s¬¡´Á¨ì2015¦~3¤ëÁ`¦@Æ[¹î51Ó¤ë °²³]¦º¤`¤H¼Æ¯uªº«Ü¤Ö ¤¤¦ì¼ÆÁ`¦s¬¡´ÁªºKaplan-Meier ¦±½u ¦]§K¬ÌÀøªkéw«á·|ºû«ùªø¤[éw Ó¤H±À´ú2016¦~3¤ë«á ¦A¦b¸g¹L2¦~À³ÁÙ¤£·|¨ì¹F 0.5 §A»{¬°? ¶P¯e§´¥é³æ¹Ï2 N at risk ¨ì²Ä45Ó¤ë ®É ¹êÅç²Õ9 ¹ï·Ó²Õ4, 9 »P4 ¬O«ü¤°»ò·N«ä? N at risk ? À³¬O«üÁÙ¨Sµo¥Í¨Æ¥ó¼Æ ??? http://www.perjeta.com/hcp/clinical/efficacy/progression-free ¶P¯e§´ PFS |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/9/1 ¤U¤È 02:56:00²Ä 1907 ½g¦^À³
|
822ªºÀø®Ä½T»{¤wªñ§ÀÁn¡A¤½¥q¦b3/3ªk»¡¤w¸g¤j¬ù¥i¥H²q¨ì¸Ñª¼®É¶¡ÂI¡A´N¬O¤µ¦~12¤ë¨ì2016¦~²Ä¤@©u¡A¦]¬°3/3®É¤wª¾2015/12¦³187¦ìLR ªºPD¡A¦]¦¹±M®a·|ij¿ï¾Ü¦b8¤ë©³¥l¶}¡A³oӮɶ¡³Ì«á¤@¦ì¦¬®×ªº±wªÌ¤]¤w¸g¦³12Ӥ몺Æ[¹î´Á¡A¥B187¦ìPD¨ì2015/8¤@©w·|¦³200¦h¦ìªºLRªºPD¡ALRªºM PFS½T»{¥i¹F0.5¤ô¥½u¡A¦ýÁÙ¤£¯à§¹¥þ´x´¤ªº´N¬OCRªºPD¬O§_¦¬ÀĨì¥i¥H¦w¥þ¶W¶V0.5ªº¤ô¥½u¡A©Ò¥H3/3»¡³Ì§Ö12¤ë¸Ñª¼¡A·í®É¤½¥q±À´úY±M®a¦P·N¶}§¹·|´N¶}©l²M¼Æ¾Ú¡Aµ¥«Ý²M¼Æ¾Ú¥H¤Îµ¥«ÝLRÂনCRªº®É¶¡¤j¬ùn3Ó¤ë¡A¦]¦¹³Ì§Ö¬O12¤ë¸Ñª¼¨Ã¤½¶}¼Æ¾Ú¤ÀªRµ²ªG¡A¦ý±M®a³q±`¤ñ¸ûÂÔ·V«O¦u¡A¤£§Æ±æ¦Û¤v°µ¥Xªº«Øij¥X¤F°ÝÃD¡A¦]¦¹«Øij¦Aµ¥«Ý3Ó¤ë¡A¨ä¹ê¥¼¨Ó3Ó¤ë©Ò¶·nÆ[¹îªº±wªÌ¥Dn´N¬O2014¦~©Ò¦¬®×ªºÁÙ¨S¦³PDªº40~50¦ì¹êÅç²Õ±wªÌ¡A¤@¤è±Åý³o¨Ç±wªÌ§e²{¥L̯u¹êªºÀø®Ä(ºI¦Ü2015/11¡A2014/8/25¦¬®×ªº³Ì«á¤@¦ì±wªÌÆ[¹î¤F15Ó¤ë¡A2014/1¦¬®×ªº±wªÌÆ[¹î¤F23Ó¤ë¡APD©Î¨SPD·|§ó¥[½T©w )¡A¤@¤è±¤]µ¥CRªºPD³vº¥»PLRªºPD¦¬ÀÄ¡A©Î³\¹F¨ì220©Î230¤H¥H¤W¬O¬Û·í¦w¥þ¦¨¼ôªº¶V¹L0.5¤ô¥½uªº¼Æ¦r¡C¤½¥qÀ³¸Ó¦³ªí¹F·Q°Ñ¥[ASCO¦~·|ªº¥ß³õ¡A±M®a«Øijµ¥¨ì2015/11¬°³Ì²×¸ê®Æ¦¬¶°¤é¡A¦Aµ¥«Ý²M¼Æ¾Ú¥H¤Îµ¥«ÝLRÂনCRªº®É¶¡¤j¬ùn3Ó¤ë¡A¦]¦¹¤½§i3¤ë«e¸Ñª¼¡A¥[¤@Ó¡y«e¡z¦r¥i¯à¬O¦pªG²M¼Æ¾Ú¤Îµ¥«ÝLRÂনCRªº°Ê§@§Ö¤@ÂI¡A´N¥i¥H¦´X¤Ñ¶}ª¼¡A¦ý»Ýn¤j¬ù3Ӥ몺®É¶¡¶]¤£±¼¡C ¥xÁÞ¤j¡A ¡y¤µ¤Ñ¶K¤å´£¨ìPFSªº¦s¬¡¦±½u¥i¯àn¨ì0.5ÁÙ¦³¤@¬q¶ZÂ÷¡A³o»P·íªì±À´ú¤¤ë ¥÷¥i¯à¤w¨ì0.5¦³¤Ó¤ë®t¶Z¡A³o¼Ëªº±¡ªp¤U¨Ì¾Ú§Aªº±À¦ô¤j¬ù¥i¼W¥[´XӤ몺PFS¡H¡z §Úªº·N«ä¬O¡AY¥H2015/5ªºLRªºPD=229¤H¡A½T©w¦¤w¹L¤F0.5ªº¤ô¥½u¡ALRªºM PFS¤w¸g¦¨¼ô¤F¡C¦ý2015/8/28Y¦¬¨ìCRªºPD¼Æ¾Ú¡A¥i¥H·í§@¬Û·í©ó©ó2015/5/25ªºCRªºPDªºªñ¦üÈ(¤w¸g¹L¤F3Ó¤ë)¡AY¥HCR/LR=0.8¤ñȦôp¡A¬Û·í©ó2015/5/25ªºCRªºPD¬ù¬O183¤H¡AY¦b2015/8/31´N©w¬°³Ì²×¸ê®Æ¦¬¶°¤é¡A¦¹®Éµ¥¨ì3Ó¤ë«á®³¨ìªºCRªºPD¥i¯à¬O200¤H¦h¤@ÂI¡A¦p¦¹¦³¼Æ¾Ú¤£°÷¦¨¼ôªº·ÀI¡A©w11¤ë¬°³Ì²×¸ê®Æ¦¬¶°¤é¥i¥HÅýCRªº¼Æ¾Ú§ó¿²©ó¦¨¼ô¡A¤]ÝÅU»°¤WASCO¦~·|ªº»Ý¨D(822¯à¤£¯à»°±o¤WASCO¦~·|¡A½Ð¦Û¦æ·r°u)¡C¦]¦¹§Ú»¡PFSªº¦s¬¡¦±½u¥i¯àn¨ì0.5ÁÙ¦³¤@ÂI¶ZÂ÷¡A¬O«ü2015/8/28±M®a¬Ý¨ìªºCRªºPD¥u¦³183¤H¡A¶ZÂ÷0.5¤ô¥¥i¯àÁÙ¦³¤@ÂI¶ZÂ÷¡A¤£°÷¦w¥þ¡A©Ò¥H¨S¦³«Øij§Y¤é°_¶i¦æ¸Ñª¼ªº«e¸m°µ·~¡C ¤§«e¤w°Q½×¹L¡ACR·|¤p©óLR¡ACRªºM PFS·|Àu©óLRªºM PFS¡A¦ý¦n¦h¤Ö¡A¦]¬°¨S¦³¥ô¦ó®ÉÂIªºCRªº¼Æ¾Ú¡A®Ú¥»µLªkµû¦ô¡A©Ò¥H³ø«ù¤¤©Êªº¤H´N¥[Ó0%~10%§a¡A¼ÖÆ[ªº´N¥[Ó10%~20%¡AY¦³Åå³ßªº¼Æ¦r¡A´N·í°µ¬O¤Ñ¤W±¼¤U¨ÓªºÂ§ª« ¡y¤å¤¤´£¨ìÁ`¦s¬¡´Á2013¦~6¤ë¦¬®×¤w¶W¹L29Ó¤ë¡A¦s¬¡¦±½uÀ³ÁÙ°ª°ª±¾¦b0.9¥H¤W¤U¤£¨Ó¡A§A±À¦ô¯à§_¥´±Ñ¶P¯e§´+¶PÀù¥+¼Ú¬wµµ§üªºÁ`¦s¬¡¬¡´Á?¡z 2013¦~1¤ë¨ì2013¦~6¤ë¦¬®×ªº¹êÅç²ÕºI¦Ü2015/11¤ë¤w¸g¾ú29~35Ó¤ë¡A2012/12¥H«e¦¬®×ªº±wªÌ¤w¸g¾ä¶W¹L35Ó¤ë¥H¤W¡A³o57%ªº¹êÅç²Õ±wªÌ¤]¥i¥H¶]¼È®ÉªºM OSªº²Îp¡A¦]¬°±i¸³¦b6/3®É»¡¹L¦º¤`¤H¼ÆÁ٫ܤ֡A¦]¦¹³o57%±wªÌªºM OSªº0.5¤ô¥½u¤@©wÁÙ¨S¹F¨ì¡A¦ý¹Ï«¬¤W¥i¥H½T»{¥L̪ºM OS¤j©ó3XÓ¤ë¥BÁÙ¦b«ùÄò±À¶i¤¤¡A¦bOS ªº¤ñ¸û¤W§¹³ÓIbrance¦bÁ{§É¤G´Áªº¤j¬ù38Ó¤ë¡C °Ñ¦Òµ½¤H¤j¤À¨ÉªºIbrance¦b¤ñ¸ûÄYVªº¦¬®×±ø¥óªºÁ{§É¤T´ÁPALOMA3(http://www.breastcancer.org/research-news/ibrance-offers-benefits-as-second-line-tx¡A2015¦~ªºASCO©Òµoªí¡A The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib¡Vfulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo¡Vfulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001).¡A¹êÅç²ÕªºM PFS=9.2Ó¤ë¡A¦b¤£¦Pªº¦¬®×±ø¥ó¤U¡AM PFS¨Ã¨S¦³PALOMAÁ{§É¤G´ÁªºM PFS=20.2Ó¤ë³o»ò°ª¡A·Ó²z±À½×¡APALOMA3ªº¹êÅç²ÕªºM OSn¹F¨ìPALOMAÁ{§É¤G´Áªº¤j¬ù38Ӥ몺¥i¯à©Ê¤£°ª¡CY822ªº¹ï·Ó²ÕªºM PFS¸Ñª¼«á½T»{¬O3~6Ó¤ë¤W¤U¡A«h822ªº57%ªº¹êÅç²Õªº¼È®ÉM OS ±N»·Àu©óIbrance¡A822¦bOSªºªí²{§¹³ÓIbrance¡C ¥Ø«e¦bMBCªºOSªí²{¤W¡A¨S¦³ÃĪ«¥i¥H¥´±Ñ¶P¯e§´+¶PÀù¥+¼Ú¬wµµ§ü¾Jªº²Õ¦X¡A2016/3¸Ñª¼¤]¥u¯àª¾¹D822ªºM OSÀ³¸Ó¦³3XÓ¤ë¡AOS¯à§_±À¨ì5¦~¡AÁÙ»Ýn2~3¦~ªº°lÂÜ´Á¤~¯à½T»{¡C ¥H¤W¬°Ó¤H±À·Q¡A¶È¨Ñ°Ñ¦Ò¡C |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2015/9/1 ¤U¤È 12:59:00²Ä 1906 ½g¦^À³
|
»{¦P¤p³ì¤j¡A¥u»Ý¦^À³°ò¥»±°Q½×¡C¥ý«e¤w¦³¨¥©ú¡A2Q¤Î3Q³£¬O¥Í§Þ¶Â·t´Á¡A¤£n¦³¹L«×´Á«Ý¡C³Ìªñ¬Ýªº®Ñ¡A¤À¨É¨ä¤¤«Ü¨ü¥Îªº¤@¬q:¬ã¨s¤HÃþ¦¨¥\¾Çªº©l¯ª®³¯}±[.§Æº¸¦b¸g¾ú¤@¥Íªº¾D¹J«á¡A©ó¤K¤Q¥|·³®É¡A¼g¤U¤H¥Í³Ì«nªº¤@¥»µÛ§@(¤ßÀRP´I:§l¤Þ°]´I³Ì±j¤jªº¤O¶q¡A±q§x¹Ò¨ì¹Ú·Q¦¨¯uªº¯¦®|)¡AÁ`µ²¤@¥Íªº¬ã¨sµ×µØ¤Îºëªöªº¤ß¸ô¾úµ{¡A¨Ã´¦ÅS(´I¨¬)ªº³Ì«á¤@¶ô«÷¹Ï¡C ¥L¦b®Ñ¤¤¼g¹D:[ÂA¤Ö¦³¤H¯à¤£¸g¾ú¤@®Éªº¥¢±Ñ©M¥Rº¡ªq³àªº¶¥¬q¡A´Nª½±µÁÚ¤J¦¨¥\¡C¥i¬O¥un§A¯à´x´¤¤º¦bªº¦Û§Ú¡A´N¤£·|¦³¤@Ãݤ£®¶³oºØ¨Æ¡C§A©Î³\·|³Q¥´Ë¡A¦ý°¨¤W´N¯à¤ÏÀ»;§A©Î³\·|¶¨ì±T¹òªº¹D¸ô¤W¡A¦ýÁ`¯à§ä¨ì¤è¦¡¦^¨ì¥©Zªº¤j¹D¤W¡C]¦b¬ÝºÉ¤H¥ÍªººØºØWµh«á¡A¥L¤À¨É¤F¤@¥y¦Ü²z¦W¨¥:¿iÃø¬O¸ÉÃĦӫD²Ì¸}¥Û¡A¨CÓ¿iÃø³£®IÂõۦPµ¥©Î§ó¤jºÖ®ðªººØ¤l¡I |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2015/9/1 ¤U¤È 12:32:53²Ä 1905 ½g¦^À³
|
«D±`»{¦P¤p³ì¤j»¡ªk¡A 8/28¨´¤µ¯S§O·PÁªü®¶¤j |
|
|
·|û¡G¤p³ì10135960 µoªí®É¶¡:2015/9/1 ¤U¤È 12:17:48²Ä 1904 ½g¦^À³
|
«Øij¦U¦ì¤j¤j¤£¥Î¦A°w¹ï¬Y¨Ç¤H·²D¸Ü¨¥½×¦^À³,¶È¹ï¯A¤Î±M·~¦^À³§Y¥i, ¦^À³³o¨Ç¤H¤]¥u¬O®ö¶O¤j®a®É¶¡¦Ó¥BªÑ»ù¤@¶^©T©w³o¨Ç¤H¤S¶]¥X¨Ó, ¾Ç¾Ç«¼C©ÎCliff/¤p©_/¦Ñ¥v¤j,¥u¹ï°ò¥»±¬Ýªk¦^À³,¨Ñ¦U¦ì¤j¤j°Ñ¦Ò |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2015/9/1 ¤W¤È 11:13:23²Ä 1903 ½g¦^À³
|
³o¤äªÑ²¼¤Wº¦¶qÁY¤U¶^¶q¼W¡A´X¥G¨C¤Ñ¶}°ª¦¬§C ªp¥B¥@¬É¤W¨S¦³¤°»ò¬Oµ´¹ïªº¡AÂ÷¶}µP®É¶¡ÁÙ¦³ ¥b¦~¦h¨ì®ÉªÑ»ù·|¬O¦h¤Ö¨S¦³¤H·|ª¾¹D¡A§Ú¥uª¾¹D ³o¤äªÑ²¼®M¨c¤@°ï¤H¡C |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/9/1 ¤W¤È 10:54:36²Ä 1902 ½g¦^À³
|
¤p¶§¤j,¤j¤á¤H®a¤j¡G ³oÓª©±cliff/¥xÁÞ/¤p©_/«¼C³\¦h¤j¤j³£¬O°ª¤â¡A«Ü¦h¤j¤j«Ü¦´N»¡¹L¦pªG¬Ý¦nnªø©ê¤£µMºÉ¦¨« ªÑ¥«³Ì©Èµ¥¡A¤@µ¥¦bµ¥¡A¦]¬°¤j®a³£¥u·Qn°¨¤W´NÁÈ¡A¦ý¬Onµ¥¨ì©ú¦~3¤ëÁÙ¦³7Ó¤ë¡A³£·|@¤£¦í©Ê¤l 1.ªÑ¥«º¦·|¥h°l¥D¬yªÑ¡A¥Í§Þ²{¦b¬O¸¨¤ôª¯¡A©Ò¥H¤£·|º¦ 2.ªÑ¥«¶^·|¥h°¦a·ÀI¡A¯E¹©¤Ó°ª»ù·|³Q°l±þ¤]¦X±¡¦X²z °ò¥»±¦b¨ºùØ¡AªÑ»ù³Ì«á´N·|¬O¦b¨ºùØ¡A¦pªG»¡©ú¦~¤T¤ë§A¦³¥i¯à¤¤¼Ö³z§A·|¤£·|¶R? ¦Ò¼{¦]¯À¬O: 1.§ë¤J¦¨¥»¦h¤Ö? 2.¤¤¼ú¾÷²v¦h°ª? ¼Ö³z¤~50,100§A¶R¤F¦ÛµM¤£·|¤ßµh¡A¯E¹©²{¦b¤@±i¤]ÁÙn26¸U¡A¶R¤£¶R? ¨£¤¯¨£´¼ ¤¤¼ú¾÷²v¦ÛµM¬O¤ñ¼Ö³z°ª«Ü¦h¡A¤£µM´N¤£·|¤@¸s¶Ì¤l¥]§t§ÚÁٶ̶̪º©êµÛ ¦pªG»¡¥ú³s±ÂÅvª÷³£¨CªÑ¥i¥H®³¨ì388¤¸ªº¸Ü¡A¤S¦ó¥²½æ¦b§CÂI? ¦]¬°°ò¨Èªºì¦]³\¦h¤H¤£¬Û«H¥Í§ÞªÑ¡A©È¦A«×¨ü¶Ë¡A¥i¯E¹©¤£·|¬O°ò¨È²Ä¤G ©Î³\«Ü¦h¤H³£¤Ó¼ÖÆ[ªÑ»ù¡A¨º¬O¦]¬°Àø®ÄÁÙ¬O¬Û·í¤£¿ù¡A±qS¤p©j¸òªü¬Â¤jªº¹Ú¹Ò¨Ó¬Ý ¥i¥H±Ï¤Hªº¤jÃħr ¤£·Qµ¥ªº¤H³ÌºC¤]·|¦b¸Ñª¼3Ó¤ë«e¡A¤]´N¬O©ú¦~1¤ë¤U¥h½ä¤@§â ¥ú¬O³oªÑ¤O¶qÀ³¸Ó´N¥i¥H«·sÅýªÑ»ù¯¸¤W400, ¤ÏÃҮɶ¡·|»¡¸Ü¡A¨CÓ¤H³£¥Î¿ú¦b§ë¯E¹©¤@²¼ ³Ó¿ï´NÁÈ¿ú¡A±Ñ¿ï´N½ß¿ú¦Ó¤w |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/9/1 ¤W¤È 10:21:02²Ä 1901 ½g¦^À³
|
«¢«¢,¤p¶§¤j¤µ¤Ñ³o¤@¦^¦X§A¤SŤF.®¥³ß±z.»¡¯uªº¦³®ÉÔ§Ú¦b³oÓª©¬Ý¨ì¤@¨Ç¤j¤j¨ººØ·¥«×¼ÖÆ[¤ßºA,¤°»ò³£¥i¥H©¹³Ì¼ÖÆ[ªº¨Ó¸ÑŪ.°ß®£©Ò¦³ªº¤H¬Ý¨ì´N·Q°¨¤W¸õ¶i¥h¶Rªº¤ßºA,§Ú¬O¹ê¦b¤£²z¸Ñ.§Ú¤]¥u¯à©¹¦nªº¤è±·Q,¥i¯à³o¨Ç¤H§ë¸êªÑ¥«ªº¦~¸êÁÙ²L§a.¬ÝªºÁÙ¤£°÷¦h. |
|
|
|